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AraC family transcriptional activators are defined by a 100-amino acid DNA-binding 
domain (DBD) containing two DNA binding helix-turn-helix (HTH) motifs.  My research 
focused on three AraC family proteins: RhaR (activator of the E. coli L-rhamnose catabolic 
regulon), VirF (activator of expression of the Shigella flexneri type three secretion system), and 
ToxT (activator of Vibrio cholera virulence gene).   
By using fluorescence-based thermal shift assay, and intrinsic tryptophan fluorescence 
assay, I have shown that small molecule inhibitor SE-1 directly binds to VirF and RhaS-DBD.  
Mutagenesis studies of residues in RhaS support the prediction of docking that SE-1 is likely 
bound to a small pocket between the two HTH motifs.  With a final goal to provide direct 
evidence of the position on the ToxT protein that serves as the SE-1 binding site, ToxT was 
crystalized under solution conditions different than the previously published ones, and the 
structure of ToxT was determined to a higher resolution than the published structure.  A region 
that was missing from the previously determined structure now can be traced entirely.  Using 
Electrophoretic Mobility Shift Assay (EMSA), SE-1 was found to inhibit DNA binding by ToxT.  
Co-crystallization trials of SE-1 and ToxT were carried out.  Unfortunately, I was not able to 
obtain any crystals of ToxT-SE-1. 
 In collaboration with Dr. Jeff Aubé, I have tested SE-1 analogues with the ultimate goal 
of optimizing the potency and specificity of SE-1.  Unfortunately, no analogs were found with 
increased VirF inhibition potency relative to SE-1.  In the process of synthesizing analogs, we 
found that SE-1 and its analogues converted to corresponding quaternary salts in aqueous 
solution, and the quinolinium salt was responsible for the observed inhibition by SE-1.   
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In this study, I also investigated the mechanism by which RhaR responds to L-rhamnose.  
During these studies, I discovered that the RhaR start codon was previously annotated 30 codons 
upstream of the true start codon.  The equilibrium binding affinity of RhaR to its full and half 
DNA binding sites, of the isolated RhaR-DBD to the half-site, and the rhamnose dependence of 
DNA bending by RhaR were measured.  The findings support a model in which RhaR NTD 
increases the DNA binding affinity of each RhaR protomer DBD, independent of rhamnose; and 
that rhamnose signalling primarily increases the positive cooperativity of DNA binding by the 
two DBDs in a RhaR dimer.  These findings suggest a model for the mechanism of allosteric 
rhamnose signalling in RhaR. 
To provide more structural information about RhaR protein, the structures of RhaR-NTD 
were determined in the presence and absence of L-rhamnose.  The 2.05Å rhamnose-bound 
RhaR-NTD structure showed that the protein forms an antiparallel dimer, and shared a fold that 
was similar to the AraC-NTD, binding its respective sugar L-rhamnose within a β-barrel.  In 
addition, a Ni2+ ion, which has not been seen in other AraC family protein structures, was present 
in the sugar-binding, cupin superfamily, motif of RhaR.  A rhamnose-free structure was also 
solved to 1.73 Å, and in this structure, a loop region that is involved in rhamnose binding was 
completely disordered.  A second loop region also has minor structural changes.  Each of the two 
regions with rhamnose-dependent structural changes is predicted to be at the interface between 
the RhaR NTD and DNA-binding domain, suggesting their potential involvement in rhamnose 
allosteric signaling.  No differences were observed in the RhaR N-terminal arm region in the 
fully and partially rhamnose-occupied structures, suggesting that RhaR rhamnose-dependent 
allosteric signaling shares some features with the ‘light switch’ model of AraC, but differs in 
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AraC Family of Transcriptional Activators 
The AraC family is a large family of bacterial transcriptional activator proteins that have 
been identified in over 70% of sequenced bacterial genomes [1].  The defining feature of 
members of the AraC family is a 100 amino acid stretch comprising a DNA binding domain 
(DBD) with two helix-turn-helix (HTH) motifs [2-6]; these HTH motifs bind in consecutive 
major grooves of specific DNA sequences that are unique for each AraC family paralog [7, 8].  
Although some family members such as MarA and SoxS consist of a single domain, most AraC 
family members also have a domain that we refer to as the regulatory domain.  The regulatory 
domain is typically directly responsible for dimerization and/or effector binding, and if protein 
activity responds to an effector, allosterically regulates DBD activity [3, 4, 8].  A large subset of 
homologs share sufficient sequence similarity with the regulatory domain of AraC [3, 4] that 
they are expected to share structural similarity.  This subset includes the activators of the E. coli 
L-rhamnose regulon, RhaS and RhaR; VirF, the master regulator of the type three secretion 
system (T3SS) in Shigella flexneri; and ToxT, a transcriptional activator of virulence gene 
expression in Vibrio cholera. 
 AraC family proteins regulate expression of genes that are involved in carbon metabolism, 
stress responses, and virulence [1-4, 9].  Proteins that regulate expression of genes involved in 
carbon metabolism include RhaS and RhaR (catabolism of L-rhamnose in E.coli) [10], AraC 
(catabolism of L-arabinose in E.coli) [11], XylR (catabolism of xylose in E. coli) [4], XylS 
(catabolism of benzene derivatives in Pseudomonas putida) [12], MelR (catabolism of melibiose 
in E.coli) [13].  The second group of AraC family regulators controls stress responses, for 
instance Ada (response to alkylating agents in E. coli, Salmonella typhimurium and Bacillus 
subtilis) [14-16], SoxS (response to oxidative stress in E.coli) [17], MarA (response to antibiotics 
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in E. coli) [18].  The third group of AraC family regulators regulates expression of genes related 
to virulence, for example ToxT (regulates expression of cholera toxin, the toxin-coregulated 
pilus, and its own expression in Vibrio cholerae) [19-23], Rns (regulates expression of CS1 and 
CS2 pili from Enterotoxigenic E. coli) [24], VirF (master regulator of T3SS gene expression 
from Shigella flexneri) [25], and ExsA (regulates expression of T3SS related genes in 
Pseudomonas aeruginosa) [26].  
Mechanism of transcription activation by AraC 
AraC is the founding member of the AraC family proteins and responds to its effector 
arabinose to regulate expression of the L-arabinose regulon using a well-characterized molecular 
mechanism known as the “light switch” mechanism (Fig. 1) [27-31].  In addition, although no 
full-length structure is yet available, high-resolution structures are available for both domains of 
AraC, including structures of the N-terminal regulatory domain (NTD) in the absence and 
presence of the effector arabinose [32-34].  In the “light switch” model of AraC, residues at the 
N-terminus of AraC, a region known as the “arm”, play an important role in transmitting the 
arabinose-binding signal from the AraC NTD to its DBD.  In the absence of arabinose, the arm is 
required to constrain the AraC dimer such that it forms a DNA loop between two well-separated 
protomer-binding (half) DNA sites in its repressing state.  When arabinose binds to the AraC 
NTD, the conformation of the arm changes, releasing the constraint on the AraC dimer such that 
AraC can to bind to adjacent half-sites and activate transcription from the araBAD promoter 
[35].  Recent studies provide evidence that arabinose binding may affect the flexibility of the 
AraC inter-domain linker, which in turn could alter the conformation and DNA binding 





Fig. 1.  The AraC “Light switch” Mechanism.  (A) The domain structure of one protomer of 
AraC protein.  (B)  In the absence of the arabinose, the N-terminal arm of AraC contacts the 
DNA binding Domain (DBD), constraining the conformation of the protein such that one 
protomer contacts the distal O2 half-site, resulting in DNA looping and inhibition of araBAD 
transcription.  (C).  In the presence of arabinose, the arm folds over the arabinose-binding 
pocket, allowing the protein to contact the adjacent I1 and I2 half-sites, thus activating 
transcription. From Schleif (2000) [37].   
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AraC is hypothesized to reposition the two DBDs in a dimer relative to the N-terminal effector-
binding domains, which for AraC results in an increased affinity for adjacent half sites.  Most 
characterized AraC family proteins do not use DNA looping as part of their allosteric signalling 
mechanisms.  However, analogous effector-dependent rigid body movement of DBDs could, in 
principle, toggle proteins between states with greater (activating state) or lesser (non-activating 
state) capability to activate transcription; with transcription activation increasing with DNA 
binding affinity and/or ability to contact RNA polymerase. 
Mechanism of transcription activation by ToxT 
ToxT is an AraC family transcriptional activator of Vibrio cholera virulence gene 
expression with a C-terminal DNA binding domain and an N-terminal domain involved in 
dimerization and effector binding [38].  ToxT directly activates the expression of the genes 
encoding the toxin-coregulated pilus, which is essential for colonization of the human intestine, 
and the cholera toxin, the cause of the diarrheal disease that is characteristic of cholera [19-21].  
ToxT has also been shown to positively auto-regulate its own expression from the tcp promoter 
[22, 23].  In V. cholera, ToxT-dependent gene activation was inhibited by both bile and 
individual unsaturated fatty acids found in bile, such as arachidonic acid, linoleic acid, oleic acid, 
and plamitoleic acid (PAM) [39-41].  Unlike AraC, ToxT is in its non-activating state in the 
presence of its effector [38, 40].  The crystal structure of the full-length ToxT protein in its non-
activating state with effector bound has been solved [38] (Fig. 2a).  A model for the mechanism 
of transcription activation by ToxT has been proposed based on structural and genetic analysis 
[38, 41] (Fig. 2b).  According to this model, the presence of the effector fatty acid keeps ToxT in 






Fig. 2.  The Structure and model for the regulation of ToxT.  (A) Structure of ToxT (PDB 
code: 3GBG) [38]. Ribbon diagram of the ToxT with the effector palmitoleic acid (PAM) bound 
in the NTD. The N-terminal domain is in cyan, the DNA binding domain is in grey, the PAM is 
in yellow sphere.  (B) Model for the regulation of ToxT by monounsaturated fatty acids. ToxT is 
in a “closed” conformation in the presence of fatty acid, which cannot bind to DNA. In the 
absence of fatty acid, ToxT is in an “open” conformation that can bind to DNA. In the “open” 
conformation the N-terminal domain is free to move in relation to the C-terminal domain, and is 
able to dimerize with another ToxT at an adjacent toxbox. The linker is sufficiently flexible to 




residue Lys31 from NTD and Lys230 from DBD through the carboxylate head group of the fatty 
acid.  The inter-domain interaction mediated by effector in this “closed” form, is likely a 
mechanism for transmitting the effector binding signal from the NTD to the DBD [38].  In the 
absence of the effector, Lys31 and Lys230 no longer can be bridged by the effector, therefore the 
inter-domain interaction is lost and the protein is converted to an “open conformation” which 
dimerizes and is capable of binding DNA and activating transcription [38].  Alternatively, given 
the large ToxT inter-domain interface (~2000 Å2)[38], and the presence of inter-domain contacts 
in AraC in both its (+) and (-) arabinose states [42], we propose that the ToxT inter-domain 
contacts may be altered and/or rearranged, but not eliminated, in its activating state.   
The L-Rhamnose Regulon 
The L-rhamnose regulon of E. coli consists of six genes that are grouped into three 
operons: rhaSR, rhaBAD and rhaT (Fig. 3) [10, 43-46].  The rhaSR operon encodes the 
activators RhaS and RhaR, which are both AraC family members [2, 4, 6, 46].  The rhaBAD 
operon encodes three enzymes required for L-rhamnose catabolism - rhamnulokinase, L-
rhamnose isomerase and rhamnulose-1-phosphate aldolase, respectively [44, 47].  The rhaT 
operon encodes the L-rhamnose -proton symporter that transports L-rhamnose into the bacterial 
cell [45].  RhaS activates transcription of both the rhaBAD and the rhaT operons in response to 
L-rhamnose [10, 45], and RhaR activates the expression of the rhaSR operon, also in the 
presence of L-rhamnose.  RhaS and RhaR activate transcription to maximal levels (above basal 
levels) only in the presence of their common effector, L-rhamnose.  In the absence of L-
rhamnose, all three of the L-rhamnose-regulated operons in E. coli are expressed at basal levels 
[10, 48, 49].  When L-rhamnose becomes available, basal levels of RhaR protein activate 







Fig. 3.  Schematic Representation of the Escherichia coli L-rhamnose Regulon.  Thick 
horizontal black lines represent DNA.  Top: Expanded view of the regulatory region between the 
rhaSR and rhaBAD operons with the approximate positions of the known proteins bound to DNA 
at rhaBAD and rhaSR.  Bent arrows indicate transcription start sites.  RhaR is in orange, RhaS in 
pink, CRP in green, and RNAP in teal.  Letters “S” and “B” at the ends of the top line represent 
the beginning of the rhaS and rhaB genes, respectively.  Bottom: Representation of the 
orientation and direction of transcription for the genes in the L-rhamnose regulon.  Courtesy of 
Dr. Susan Egan.   
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transcription of the rhaBAD and rhaT operons [10, 44, 45, 50].  The full transcription activation 
of all three operons within the L-rhamnose regulon requires a second protein, CRP [10, 49, 51].  
CRP binds upstream of the RhaS and RhaR DNA binding sites, at positions centered at -92.5 and 
-93.5 at rhaBAD and rhaT [10, 49], respectively, and at -111.5 at rhaSR [10].   
Transcriptional Activators RhaS and RhaR 
RhaS and RhaR are predicted to have similar structures due to their relatively high levels 
of sequence identity (35%) and similarity (67%) with each other.  RhaS is 278 amino acids in 
length and RhaR is longer with 312 amino acids [46].  Previous study has shown that the extra 
length of RhaR is mostly due to a 33 amino acid extension at the N-terminal end.  The function 
of this 33 amino acid extension is unknown since deletion of the extension did not change 
transcription activation in vivo [52].  Both RhaS and RhaR function as homodimers, and contain 
two domains.  One domain is a C-terminal, AraC family DNA-binding domain (DBD).  The 
DBDs bind two 17-bp inverted repeat DNA half sites, which are separated by 16 bp (for RhaS) 
or 17 bp (for RhaR), and contacts RNA polymerase[50, 51, 53, 54].  The other domain is an N-
terminal regulatory domain (NTD) that contains an L-rhamnose binding site and a dimerization 
interface [50, 53, 55]. 
In the absence of L-rhamnose, RhaS is in a conformation that is unfavorable to bind 
DNA; however RhaS DBD can bind DNA and activate transcription [10, 55].  This suggests that 
the NTD in the absence of L-rhamnose limits (inhibits) RhaS binding to DNA; however in the 
presence of L-rhamnose, inhibition of DNA binding is relieved through allosteric signaling.  In 
contrast, although both RhaR and RhaR DBD can detectably bind DNA in the absence of L-
rhamnose, only full-length RhaR can fully activate transcription when L-rhamnose is present [48, 
53, 55].  This suggests that the RhaR NTD in the absence of L-rhamnose does not inhibit the 
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binding of RhaR to DNA.  Previous mutagenesis study showed that RhaS and RhaR both make 
protein-protein interactions with the σ70 subunit of RNA polymerase to activate transcription [54, 
56]. 
Previous work leads us to propose a model that the binding of L-rhamnose to RhaR 
increases both DNA binding and transcription activation [48, 53, 55], and this increase is likely 
due to structural and/or dynamics changes in RhaR upon L-rhamnose binding; the signal of L-
rhamnose binding must be transmitted from NTD to DBD of RhaR to toggle RhaR between its 
non-activating and activating states.  Previously, our lab has constructed single alanine 
substitutions in the RhaR linker region connecting the NTD and DBD, and found that all the 
variants activated transcription to the same extent as the wild-type RhaR in the presence of L-
rhamnose and no variants has shown an increase in transcription activation over 1.5-fold [57].  
The results suggested that none of the residues tested in the linker region is crucial for the L-
rhamnose response or transcription activation, thus may not play an important role in activation 
[57].  However, recent study of AraC protein indicated that the linker region is possibly 
transition from a unstructured loop to α-helix in response to L-arabinose [36].  Recently, the 
structure of the regulatory domain of ExsA, an AraC family protein from P. aeruginosa, was 
solved, and the structure was expected to represent the activating conformation of ExsA [58].  
Analysis of the ExsA regulatory domain revealed that the linker region is in a helical 
conformation instead of unstructured.  Therefore, it is likely that the allosteric signal that 
converts RhaR from its non-activating state to its activating state involves L-rhamnose-dependent 




AraC family virulence regulator VirF  
VirF is an AraC family transcriptional activator from Shigella, the causative agent of 
bacillary dysentery, or shigellosis [59].  Various pathogenic species of Shigella, such as S. 
flexneri,  S. dysenteriae, S. sonnei and S. boydii are responsible for 165 million illnesses and over 
1.1 million deaths worldwide each year, with 70% of the deaths occurring in children under the 
age of five [60, 61].  All of these species harbor a 230 kb virulence plasmid, of which a 31 kb 
region named the “entry region” encodes proteins required for the invasion of the bacteria into 
colonic and rectal epithelial cells, the formation of the type 3 secretion system (T3SS) 
machinery, invasion of Shigella into host epithelial cells, and cell-to-cell spread [62-66].   
The regulation of Shigella virulence gene expression is largely controlled by the activity 
of VirF in response to many environmental signals, including temperature, osmolality, and pH 
[59, 67-69].  The primary regulator VirF positively activates the transcription of two virulence-
associated genes, virB and icsA (Fig. 4).  VirB protein then activates transcription of several 
virulence-associated genes, including icsB which is important for intercellular spread [70],  ipaB 
which is required for epithelial cell entry and phagosome escape [64], and mixE which regulates 
the expression of many other virulence-associated genes [71].  IcsA encodes a Shigella adhesin 
that facilitates intracellular spread through actin-based motility [72, 73].  Given that VirF 
controls the regulation and gene expression of the entire T3SS, any factor that could influence the 
activity of VirF would affect the expression of virB and icsA, and consequently impact Shigella 
virulence.  Therefore, small molecules that target VirF have the potential to be developed into 





Fig. 4.   VirF activates transcription of the virB and icsA operons [69]. VirB in turn activates 
expression of genes in mxi, spa and ipa operons that are required for the formation of T3SS 
machinery, invasion and cell-cell spread of Shigella into host epithelial cells [62-66]. (Figure 
courtesy of Dr. Susan Egan).  
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Small molecule inhibitor SE-1 
Antibiotic resistance has become a worldwide problem that threatens the treatment and 
prevention of bacterial infections.  Each year in the United States, at least 2 million people 
infected with antibiotic-resistant bacteria, and at least 23,000 people die each year as a direct 
result of these antibiotic-resistance infections [74].  Traditional antibiotics target bacterial 
processes essential for the growth, including cell wall synthesis, protein synthesis, DNA 
replication, and RNA transcription.  One alternative strategy that targets virulence factors has 
been reported in recent literature [75-82].  As mentioned earlier, members of the AraC family 
proteins regulate bacterial virulence and stress response [1-4, 9], which makes them ideal targets 
for this unique strategy.  Since a structurally conserved DNA-binding domain is present in all of 
the AraC family proteins, it is expected that a small molecule inhibitor affecting this domain 
would impact the activity of the proteins and thus act as an effective microbial agent for 
preventing diseases.  In fact, several studies have identified small molecule inhibitors that target 
specific AraC family proteins [76-79, 82-84].   
Using high-throughput screening, our lab has identified a small molecule compound, SE-
1 (previously called OSSL_051168) (Fig.5), as an inhibitor of the AraC family protein RhaS 
[81].  Further study has also shown that SE-1 inhibited several other AraC family regulators, 
including RhaR, ToxT, and VirF [80, 81]; however, SE-1 does not block DNA binding by the 
non-AraC family proteins LacI and CRP [81], which suggested that SE-1 has specificity towards 
AraC family proteins.  It was found that SE-1 inhibited DNA binding by the DNA-binding-
domain (DBD) of RhaS to the same extent as the full-length RhaS, which indicated that the DBD 




Fig. 5.  Structure of SE-1.  Chemical structure of SE-1, 1-butyl-4-nitromethyl-3-quinolin-2-yl-
4H-quinoline.  From [81].    
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binding by VirF, it also has been demonstrated that SE-1 reduced the expression of many 
virulence genes regulated by VirF, including icsA, virB, icsB, and ipaB in Shigella, and the 
invasion to the host cell by Shigella [80].  Therefore, SE-1 has the potential to be developed into 
a novel antibacterial agent since it exhibits selectivity toward AraC family protein. 
Research goals 
The overall goals of my research are to identify small molecule inhibitor SE-1 binding 
site of AraC family regulators, to optimize SE-1, and to better understand the transcriptional 
activation mechanisms by RhaR.  The overall goals can be divided into the following sub-goals. 
Identify the binding site of the small molecule inhibitor SE-1 on AraC family regulators.  
The first goal of my research was to test whether SE-1 directly binds to purified VirF and RhaS 
proteins, and identify where SE-1 may bind to the protein RhaS.  Using fluorescence-based 
thermal shift assay, I found that the addition of 80 μM SE-1 increased the Tm of purified VirF 
protein (1 μM) by 0.61°C (±0.09), which support the hypothesis that SE-1 directly binds to VirF.  
Using an intrinsic tryptophan fluorescence assay, I found that there was a concentration 
dependent quenching of purified RhaS DBD protein fluorescence upon addition of SE-1 that 
saturated at ~7% reduction in the fluorescence peak signal.  This result supports the hypothesis 
that SE-1 directly binds to RhaS, specifically RhaS DBD.  Mutagenesis study of residues in 
RhaS that were predicted in the SE-1 binding pocket by computational docking suggested that 
residues D191, S249, and L257 were at or near the SE-1 binding site on RhaS-DBD, which 





Crystallization of of ToxT from Vibrio cholera.  The second goal of my research was to test 
whether SE-1 inhibited in vitro DNA binding by ToxT, and set up crystallization trials to co-
crystalize SE-1 with ToxT to provide direct evidence of the position on the ToxT protein that 
serves as the SE-1 binding site.  Using Electrophoretic Mobility Shift Assay (EMSA), I found 
that SE-1 inhibited DNA binding by ToxT.  I further crystallized ToxT using solution conditions 
that were different than the published conditions, and solved the structure of ToxT to a higher 
resolution than the published structure.  A region that was missing from the previously 
determined structure now can be traced entirely.  Then I started to crystalized SE-1 and ToxT.  
Unfortunately, I wasn’t able to obtain any crystals of ToxT-SE-1 due to many reasons.  
SE-1 Optimization.  The third goal of my research is to optimize small molecule inhibitor SE-1.  
Despite the fact that SE-1 has been shown to block DNA binding by many AraC family proteins, 
SE-1 showed some nonspecific inhibition at higher concentrations against non-AraC family 
proteins CRP and LacI.  In addition, the concentration of SE-1 required to inhibit AraC family 
activators would need to be decreased for SE-1 to be useful as a novel antimicrobial agent.  In 
collaboration with Dr. Jeff Aubé, I assayed both commercially purchased analogs of SE-1 and 
analogs synthesized by the Aubé group in the whole cell based in vivo inhibitor assay.  
Unfortunately, no analogs were found increased VirF inhibition potency relative to SE-1.  
However, in the process of synthesizing analogs, we found that SE-1 and its analogues converted 
to corresponding quaternary salts in aqueous solution, and the quinolinium salt was responsible 
for the observed inhibition by SE-1.  In addition, by testing the inhibition of SE-1 and its 
analogues in EMSA with purified RhaR protein, we found that some uncharged analogues show 
more inhibition in vitro than in vivo, suggesting that the uptake of the analogues into bacterial 
cells may be a reason why some analogues did not show inhibition in the whole cell-based assay.  
17 
 
Purification of RhaR and Identification of RhaR annotation error.  To better understand the 
properties of RhaR, and the mechanism of transcription activation by RhaR, the fourth goal of 
my research was to purify RhaR protein to perform biochemical assays.  In initial purifications of 
RhaR, I found that there were two different sized RhaR proteins being purified, and DNA-
binding assays suggested that the smaller sized RhaR was the active form.  Protein peptide 
mapping and N-terminal sequencing indicated that the smaller sized RhaR was missing the 30 
amino acids relative to the larger sized RhaR.  Further examination of the sequence of the rhaR 
open reading frame showed that immediately upstream of the sequence encoding the N-terminal 
protein sequence was a GTG codon, which can also be used as a start codon in E. coli.  To test 
the hypothesis that the GTG codon served as the true rhaR start codon, I constructed a new 
plasmid to test the putative GTG start codon and its associated Shine-Dalgarno (SD) sequence, 
and tested the ability of the encoded RhaR to activate transcription in a reporter gene assay.  The 
results support the hypothesis that wild-type RhaR translation initiates at the GTG codon, not the 
upstream ATG codon, and that the previously annotated RhaR protein sequence had 30 extra 
amino acids at its N-terminal end relative to the native 282 residue RhaR protein sequence.  
High Resolution Structures of the Regulatory Domain of RhaR.  To provide more structural 
information about RhaR protein, the fifth goal of my research is to crystalize RhaR-NTD and 
solve the structure of RhaR-NTD.  After crystallization screening and condition optimization, I 
was able to obtain RhaR-NTD crystals, and the structures of RhaR-NTD were determined.  The 
rhamnose-bound RhaR-NTD structure showed that the protein forms an antiparallel dimer, and 
shared a fold that was similar to the AraC-NTD, binding its respective sugar L-rhamnose within a 
β-barrel.  In addition, a Ni2+ ion, which has not been seen in other AraC family protein structures, 
was present in the sugar-binding, cupin superfamily, motif of RhaR.  A rhamnose-free structure 
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was also solved, and in this structure, a loop region that is involved in rhamnose binding was 
completely disordered.  A second loop region also has minor structural changes.  Each of the two 
regions with rhamnose-dependent structural changes is predicted to be at the interface between 
the RhaR NTD and DNA-binding domain, suggesting their potential involvement in rhamnose 
allosteric signaling.  No differences were observed in the RhaR N-terminal arm region in the 
fully and partially rhamnose-occupied structures, suggesting that RhaR rhamnose-dependent 
allosteric signaling shares some features with the ‘light switch’ model of AraC, but differs in 
other features. 
DNA binding and allosteric signaling by RhaR.  The last goal of my research was to further 
characterize the mechanism by which RhaR responds to L-rhamnose.  I have measured the 
effects of rhamnose on the equilibrium binding affinity of RhaR to the RhaR protomer (half) and 
dimer (full) DNA binding sites, and determined the rhamnose dependence of DNA bending by 
RhaR.  The equilibrium binding affinity of the isolated RhaR-DBD for the half DNA binding site 
was also measured.  RhaR binding affinity to the half site DNA was independent of rhamnose 
and 300-fold tighter than for the DBD alone.  In contrast, rhamnose increased the strength and 
angle of bending of RhaR bound to full site DNA.  The findings support the hypothesis that 
RhaR NTD increased the DNA binding affinity of each RhaR protomer, independent of 
rhamnose; and that rhamnose signalling primarily increased the cooperativity of binding to the 
full site DNA by the two DBDs in a RhaR dimer.  These findings enable development of a 









MATERIALS AND METHODS  
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Growth conditions.  Escherichia coli strains were grown in tryptone-yeast extract (TY) broth 
(0.8% Difco tryptone, 0.5% Difco yeast extract, and 0.5% NaCl, [pH 7.0]) unless otherwise 
indicated.  Difco nutrient agar (1.5% agar) (BD, Cockeysville, MD) was used routinely to grow 
E. coli strains on solid medium. To test for lacZ expression by RhaS and RhaR on solid media, 
Difco nutrient agar was supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside, 
40 µg/ml) and X-gal with L-rhamnose (0.2%), respectively. All cultures were grown at 37°C, 
and liquid cultures were grown with shaking.  
General Methods. Primers used in this study were synthesized by Eurofins MWG Operon 
(Huntsville, AL). PCR was performed using Phusion High-Fidelity DNA Polymerase (Thermo 
Fisher Scientific).  Amplified DNA fragments were cleaned up using either E.Z.N.A. Cycle Pure 
(Omega Bio-tek, Norcross, GA) or IBI Gel/PCR products extraction kits (IBI Scientific, Peosta, 
IA).  Standard methods were followed for restriction endonuclease digestion, ligation, and 
transformation. Restriction endonucleases and T4 DNA ligase were purchased from New 
England Biolabs (Beverly, MA).  Plasmid isolation from bacteria was performed using the IBI 
High-Speed Plasmid Mini kit (MIDSCI, St. Louis, MO). DNA sequencing was performed to 
obtain sequences of for both strands of the entire cloned region for all cloned and mutagenized 
DNA fragments at the Northwestern University Genomics Core (Chicago, IL). 
Bacterial strains, plasmids and oligos. Bacterial strains, plasmids and oligos used in this study 
are shown in Tables 1, 2, 3 respectively.  All strains used in β-galactosidase assays were derived 





Table 1.  Bacterial strains used in this study.   
Strain Genotype Source or Reference 
SME1088 ECL 116 ΔS recA::cat λΦ 772 rhaB-lacZ Δ84 Laboratory collection 
SME1222 ECL 116 ΔrhaS/ λBS 742 (rhaB-lacZ Δ110) Laboratory collection 
SME1773 SME1222 + pALTER-1-mut rhaS F248A This study 
SME1774 SME1222 + pALTER-1-mut rhaS H253A This study 
SME2525 ECL116 λΦ(rhaS-lacZ) Δ128 ΔrhaSR::kan recA::cat Laboratory collection 
SME3160 ECL116 λΦ( rhaS-lacZ) Δ85 ΔrhaSR::kan recA::cat Laboratory collection 
SME3358 SME1085(ΔrhaS recA::cat) / λHTS1-lacZ [81] 
SME3632 
SME3600 recA::cat, final genotype = λΦ(rhaB-
lacZ)∆84 ∆(rhaSR)::kan malP::lacIq zhc-511::Tn10 
recA::cat 
[81] 
SME3359 SME3358 + pHG165 lacI This study 
SME3634 SME3632 + pHG165 rhaS This study 
SME4259 
ECL116 λMAD102Φ[(virB-lacZ)] malP::lacIq zhc-
511::Tn10 recA::cat 
[81] 
SME4384 SME1088+ pHG165 rhaS V188A (AmpR) This study 
SME4385 SME1088+ pHG165 rhaS W190A (AmpR) This study 
SME4386 SME1088+ pHG165 rhaS D191A (AmpR) This study 
SME4387 SME1088+ pHG165 rhaS D191R (AmpR) This study 
SME4388 SME1088+ pHG165 rhaS L220A (AmpR) This study 
SME4389 SME1088+ pHG165 rhaS L220R (AmpR) This study 
SME4390 SME1088+ pHG165 rhaS H253A/ (AmpR) This study 
SME4395 SME1088+ pHG165 rhaS V188R (AmpR) This study 
SME4396 SME1088+ pHG165 rhaS N221A (AmpR) This study 
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SME4397 SME1088+ pHG165 rhaS N221R (AmpR) This study 
SME4398 SME1088+ pHG165 rhaS S249R (AmpR) This study 
SME4399 SME1088+ pHG165 rhaS L257A (AmpR) This study 
SME4400 SME1088+ pHG165 rhaS L257R (AmpR) This study 
SME4414 SME1088+ pHG165 rhaS R224A (AmpR) This study 
SME4415 SME1088+ pHG165 rhaS F248A (AmpR) This study 
SME3564 SME3160 + pHG165 rhaR  This study 
SME4601 BL21 (DE3) + pSE308 (pET24b rhaR-his6) (Kan
R) This study 
SME2483 
BL21 (DE3) + pSE326 (pET24b +30 rhaR-his6) 
(KanR) 
This study 
SME4608 SME3160 + pHG165 rhaR (AmpR) This study 
SME4612 SME3160 + pSE312(pHG165 rhaR) This study 
SME4614 SME3160 + pSE313 (pHG165 rhaR) This study 
SME4666 








B834(DE3) + pSE327 (pET24b rhaR-NTD-his6) 
(KanR) 
This study 
SME3565 SME2525 + pHG165 rhaR (AmpR) This study 
SME4677 SME2525 + pHG165 rhaR V20A (AmpR) This study 
SME4678 SME2525 + pHG165 rhaR Q28A (AmpR) This study 
SME4679  SME2525 + pHG165 rhaR H34A (AmpR) This study 
SME4680  SME2525 + pHG165 rhaR H74A (AmpR)  This study 
SME4681 SME2525 + pHG165 rhaR Y76A (AmpR) This study 
SME4687 SME2525 + pHG165 rhaR R25A (AmpR) This study 
SME4688 SEM2525 + pHG165 rhaR F31A (AmpR) This study 
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SME4689 SEM2525 + pHG165 rhaR N86A (AmpR)  This study 
SME4382  SME4259 + pHG165 virF This study 
SME4706 SME3632 + pHG165 rhaS V188A (AmpR) This study 
SME4707 SME3632 + pHG165 rhaS D191A (AmpR) This study 
SME4708 SME3632+ pHG165 rhaS D191R (AmpR) This study 
SME4709 SME3632+ pHG165 rhaS L220A (AmpR) This study 
SME4710 SME3632+ pHG165 rhaS L220R (AmpR) This study 
SME4711 SME3632+ pHG165 rhaS N221A (AmpR) This study 
SME4712 SME3632+ pHG165 rhaS N221R (AmpR) This study 
SME4713 SME3632+ pHG165 rhaS S249R (AmpR) This study 
SME4714 SME3632+ pHG165 rhaS H253A (AmpR) This study 
SME4715 SME3632+ pHG165 rhaS L257A (AmpR) This study 
SME4716 SME3632+ pHG165 rhaS L257R (AmpR) This study 
SME 2923 BL21 (DE3) + pSE230 (pET15b His6-rhaS CTD) This study 
SME4618 BL21 (DE3) + pSE328 (pET24b rhaS-his6) (Kan
R) This study  
SME4631 
BL21 (DE3) + pSE329 (pET24b rhaSL201R-his6) 
(KanR) 
This study 
SME4037 SME1088 + pHG165 rhaS L208M This study 
SME4038 SME1088 + pHG165 rhaS L208I This study 
SME4039 SME1088 + pHG165 rhaS Q210R This study 
SME4040 SME1088 + pHG165 rhaS Q210S This study 
SME4041 SME1088 + pHG165 rhaS Q210G This study 
SME4042 SME1088 + pHG165 rhaS Q210N This study 
SME4043 SME1088 + pHG165 rhaS Q210K This study 
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SME4044 SME1088 + pHG165 rhaS Q210G This study 
SME4045 SME1088 + pHG165 rhaS Q210V This study 
SME4046 SME1088 + pHG165 rhaS Q210I This study 
SME4047 SME1088 + pHG165 rhaS T212C This study 
SME4048 SME1088 + pHG165 rhaS T212M This study 
SME4049 SME1088 + pHG165 rhaS T212A This study 
SME4050 SME1088 + pHG165 rhaS L214V This study 
SME4051 SME1088 + pHG165 rhaS L214I This study 
SME4052 SME1088 + pHG165 rhaS L214M This study 
SME4053 SME1088 + pHG165 rhaS L214G This study 
SME4054 SME1088 + pHG165 rhaS R218V This study 
SME4055 SME1088 + pHG165 rhaS R218L This study 
SME4056 SME1088 + pHG165 rhaS R218G This study 
SME4057 SME1088 + pHG165 rhaS Y219F This study 
SME4058 SME1088 + pHG165 rhaS Y219L This study 
SME4059 SME1088 + pHG165 rhaS Y219F This study 
SME4060 SME1088 + pHG165 rhaS M226L This study 
SME4061 SME1088 + pHG165 rhaS M226E This study 
SME4062 SME1088 + pHG165 rhaS M226R This study 
SME4063 SME1088 + pHG165 rhaS M226V This study 
SME4064 SME1088 + pHG165 rhaS M226G This study 
SME4065 SME1088 + pHG165 rhaS M226D This study 
SME4066 SME1088 + pHG165 rhaS K227Y This study 
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SME4067 SME1088 + pHG165 rhaS K227F This study 
SME4068 SME1088 + pHG165 rhaS K227D This study 
SME4069 SME1088 + pHG165 rhaS K227L This study 
SME4070 SME1088 + pHG165 rhaS K227S This study 
SME4071 SME1088 + pHG165 rhaS K227S This study 
SME4072 SME1088 + pHG165 rhaS R229I This study 
SME4073 SME1088 + pHG165 rhaS R229G This study 
SME4074 SME1088 + pHG165 rhaS R229D This study 
SME4075 SME1088 + pHG165 rhaS R229T This study 
SME4076 SME1088 + pHG165 rhaS R229P This study 
SME4077 SME1088 + pHG165 rhaS H230E This study 
SME4078 SME1088 + pHG165 rhaS H230V This study 
SME4079 SME1088 + pHG165 rhaS H230I This study 
SME4080 SME1088 + pHG165 rhaS H230Q This study 
SME4081 SME1088 + pHG165 rhaS H230L This study 
SME4082 SME1088 + pHG165 rhaS H230G This study 
SME4083 SME1088 + pHG165 rhaS H230R This study 
SME4084 SME1088 + pHG165 rhaS L232M This study 
SME4085 SME1088 + pHG165 rhaS L232V This study 
SME4086 SME1088 + pHG165 rhaS L232I This study 
SME4087 SME1088 + pHG165 rhaS R233L This study 
SME4088 SME1088 + pHG165 rhaS R233P This study 
SME4089 SME1088 + pHG165 rhaS R233A This study 
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SME4090 SME1088 + pHG165 rhaS R233W This study 
SME4091 SME1088 + pHG165 rhaS R233D This study 
SME4092 SME1088 + pHG165 rhaS R233G This study 
SME4093 SME1088 + pHG165 rhaS H234T This study 
SME4094 SME1088 + pHG165 rhaS H234I This study 
SME4095 SME1088 + pHG165 rhaS H234K This study 
SME4096 SME1088 + pHG165 rhaS H234G This study 
SME4097 SME1088 + pHG165 rhaS H234Y This study 
SME4098 SME1088 + pHG165 rhaS H234V This study 
SME4099 SME1088 + pHG165 rhaS H234D This study 
SME4100 SME1088 + pHG165 rhaS H234E This study 
SME4101 SME1088 + pHG165 rhaS E261N This study 
SME4102 SME1088 + pHG165 rhaS E261G This study 
SME4103 SME1088 + pHG165 rhaS E261S This study 
SME4104 SME1088 + pHG165 rhaS E261M This study 
SME4105 SME1088 + pHG165 rhaS E261F This study 
SME4106 SME1088 + pHG165 rhaS F262Y This study 
SME4107 SME1088 + pHG165 rhaS F262L This study 
SME4108 SME1088 + pHG165 rhaS N263Y This study 
SME4109 SME1088 + pHG165 rhaS N263E This study 
SME4110 SME1088 + pHG165 rhaS N263R This study 
SME4111 SME1088 + pHG165 rhaS N263L This study 
SME4112 SME1088 + pHG165 rhaS N263W This study 
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SME4113 SME1088 + pHG165 rhaS W264H This study 
SME4114 SME1088 + pHG165 rhaS W264M This study 




Table 2.  Plasmids used in this study.   
Plasmid Relevant characteristics Source or Reference 
pHG165 lacZα rop AmpR (ColE1 origin from pBR322) [86] 
pET15b lacI AmpR (ColE1 origin from pBR322) Novogen 
pET24b lacI KanR (ColE1 origin from pBR322) Novogen 
pTYB11 lacI rop AmpR (pMB1 origin) New England BioLabs 
pTXB1 lacI rop AmpR (pMB1 origin) New England BioLabs 
pSE325 pTYB11 +30rhaR  This study 
pSE326 pET24b +30rhaR-his6 This study 
pSE230 pET15b his6-rhaS 163-278 (DBD) This study 
pSE308 pET24b rhaR-his6 This study 
pSE327 pET24b rhaR 1-172 (NTD) -his6 This study 
pSE228 pET24b rhaR 166-282 (DBD) -his6 This study 
pRT pTXB1 toxT R. Taylor 
pSE302 pHG165 +30rhaR  This study 
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pSE312 pHG165 rhaR (GTG start codon) This study 
pSE313 
pHG165 +30rhaR-his6 (extra 30-residue at N-
terminus, extra nucleotide after ATG, out of frame 
expression) 
This study 
pHG165 lacI lacI expressed from pHG165 lac promoter, Amp
R [81] 
pSE328 pET24b rhaS-his6 This study 




Table 3. Oligonucleotides used in this study. 
Oligo 
No. 
Oligonucleotide sequence 5’-3’ Use 
2082 GTGAAGCTTTTAATCTTTCTGCGAATTGAG 
Clone rhaR into pHG165 
(Downstream) 




Clone rhaR NTD into pET24b 
(Downstream) 
2345 GCGCCGCGCATATGAGTGATTCGTTGCCGCCA 
Clone rhaR DBD into pET24b 
(Upstream) 
2349 GCGCCGCGCATATGCAGGAGAACCTGGAAAACAGC 
Clone rhaS and rhaSL201R into 
pET24b (Upstream) 
2349 GCGCCGCGCATATGCAGGAGAACCTGGAAAACAGC 










Clone rhaS and rhaSL201R into 
pET24b (Downstream) 
2714 TGAGTAAAGCTTTTATTGCAGAAAGCCATCCCG 
Clone rhaS into pHG165 
(Downstream) 
2967 CGGGATCCTTATTGCAGAAAGCCATCCC 





Construct rhaS V188A, V188R, 



























Construct rhaS L220A, L220R, 





















Construct rhaS R224A (Upstream) 
3367 GGGCTCTTCTCCACAGCGATAGGCGATGTCAGTAAC 













Construct rhaS L257R (Upstream) 
3415 GCGCCGCGCATATGGCGCATCAGTTAAAACTTCTC 
Clone rhaR into pET24b, pET15b, 
and pTYB1 (Upstream) 
3416 CTGGCGGCTCTTCCAACGCGCATCAGTTAAAACTTCTC 









Clone rhaR into pHG165 (to test a 





Clone rhaR into pHG165 (to 






IRD700 labeled (MWG) top strand 





IRD700 labeled (MWG) bottom 
strand with full RhaR DNA binding 




IR682 labeled (MWG) top strand 
with RhaR half site (rhaI4) for 
EMSA
3459 TCTTACCTTAAATTTTCGACGGAAA 
Bottom strand with RhaR half site 




IRD700 labeled (MWG) top strand 





Bottom stand with full RhaS DNA 




IR682 labeled (MWG) top strand 
with rhaI1 DNA binding site for 
EMSA
3461 CATTGGCAACCAGGGAAAGATGAAC 
Bottom strand with rhaI1 DNA 




Top strand of ToxT binding site 





Bottom strand of ToxT binding 
site on tcp promoter for EMSA. 
From [38] 
3371 [aminoC6+DY682]GTGCCCTGGTCTGG 
IR700 labeled oligo for LUEGO 


























































Construct rhaR N86A 
(Downstream) 
3433 ATCACAGTGAGACTGACAGT 
Downstream primer to amplify 
DNA for bending experiment 
3101 GTGCTCTTCACATCGGCAGNNNAAGCAGCAAACG 
Construct rhaS L208X 
(Upstream) 
3102 GTGCTCTTCGATGTAGCGTACGCAGTGAAAG 
Construct rhaS L208X 
(Downstream) 
3103 GTGCTCTTCTAAGCAGNNNACGGGACTGACG 
Construct rhaS Q211X 
(Upstream) 
3104 GTGCTCTTCTAAGCAGCAANNNGGACTGACGCCTCAG 










Construct rhaS Q211X, T212X, 
L214X (Downstream) 
3107 GTGCTCTTCGCCTCAGNNNTACCTGAACCGCCTG 
Construct rhaS R218X 
(Upstream) 
3108 GTGCTCTTCGCCTCAGCGANNNCTGAACCGCCTGCG 
Construct rhaS Y219X 
(Upstream) 
3109 GTGCTCTTCGAGGCGTCAGTCCCGTTTG 
Construct rhaS R218X, Y219X 
(Downstream) 
3190 AGTCTCTTCTCGCAGGCGGTTCAGGTATCGC 





Construct rhaS M226X 
(Upstream) 
3192 AGTCTCTTCGCAGCTTAAGNNNCAAACGGGACTGACG 
Construct rhaS Q210X 
(Upstream) 
3193 AGTCTCTTCGCTGCCGATGTAGCGTACGCAG 





































Construct rhaS H230X 
(Upstream) 
2949 AGTCTCTTCATAGCAGATGTCGGGCTTTC 
Construct rhaS R233X, H234X 
(Downstream) 
2950 AGTCTCTTCACTANNNCACAGCGAGGCCAG 
Construct rhaS R233X 
(Upstream) 
2951 AGTCTCTTCACTACGCNNNAGCGAGGCCAGCG 
Construct rhaS H234X 
(Upstream) 
2850 AGTTCACTCTTCGGGCTTTCATCAGTCGCAGG 
Construct rhaS L232X 
(Downstream) 
2851 AGCTCACTCTTCAGCCCGACATCTGNNNCGCCACAGCG 





Construct rhaS R229X 
(Upstream) 
Underlined sequences are primer-template mismatches that include restriction endonuclease 
cleavage sites and random nucleotides. 
For oligonucleotides with NNN, N= A, G, C, T  
36 
 
DNAs for RhaR DNA bending experiments.  To measure the angle of RhaR DNA bending, we 
designed five fragments of DNA with RhaR full binding site at various positons.  The DNA 
fragments were subsequently synthesized and cloned to plasmid pCR2.1by Eurofins MWG 
Operon (Huntsville, AL).  PCR was used to amplify and label each DNA fragment.  The set of 
oligos used was 3371 -3433, and the DNA sequences of each fragment are listed below.  The 
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designed five fragments of DNA with RhaS full binding site at various positons.  The DNA 
fragments were subsequently synthesized and cloned to plasmid pCR2.1by Eurofins MWG 
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Construction of RhaS variants to identify SE-1 binding site.  Wild-type rhaS and all variants 
were cloned into and expressed from the plasmid pHG165 [86] using the restriction enzymes 
EcoRI and HindIII.  Wild type rhaS, rhaS F248A, and rhaS H253A were PCR amplified using 
oligos 2098 and 2714.  Site-specific mutagenesis of rhaS was performed using PCR to make 
oligonucleotide-directed mutations at each of the desired positions.  Wild type rhaS was used as 
template for all PCR amplifications.  The specific oligo sets used to create each set of mutants 
are described in Table 4.  Plasmids carrying mutations were then transformed into strain 
SME1088 for initial evaluation of the transcription activity, and then were transformed into 
SME3632 for testing SE-1 analogues in vivo dose-dependent assay.  
Table 4.  Oligonucleotides to Amplify Fragments to Generate RhaS Variants 
Variant 
Oligos to amplify 
upstream DNA fragment
Oligos to amplify 
downstream DNA fragment 
V188A 2098-3355 3356-2714 
V188R 2098-3355 3359-2714 
W190A 2098-3355 3357-2714 
D191A 2098-3355 3358-2714 
D191R 2098-3355 3360-2714 
L220A 2098-3361 3362-2714 
L220R 2098-3361 3363-2714 
N221A 2098-3361 3364-2714 
N221R 2098-3361 3365-2714 
R224A 2098-3361 3366-2714 
S249R 2098-3367 3368-2714 
L25RA 2098-3367 3369-2714 
L257R 2098-3367 3370-2714 
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Construction of RhaR L-rhamnose binding variants.  Variants were cloned using standard 
techniques as described above.  The specific oligo sets used to create each variant are described 
in Table 5.  Plasmids carrying mutations were transformed into strain SME2525 for β-
galactosidase assay.  
Table 5.  Oligonucleotides to Amplify Fragments to Generate RhaR Variants 
Variant 
Oligos to amplify 
upstream DNA fragment
Oligos to amplify 
downstream DNA fragment 
V20A 3430-3482 3481-2082 
Q28A 3430-3485 3483-2082 
F31A 3430-3485 3491-2082 
H34A 3430-3485 3484-2082 
H74A 3430-3488 3486-2082 
Y76A 3430-3488 3487-2082 
N86A 3430-3493 3492-2082 
 
Construction of RhaS variants to elucidate RhaS rhamnose allosteric signaling.  Wild-type 
rhaS and all variants were cloned into and expressed from the plasmid pHG165 [86] using the 
restriction enzymes EcoRI and HindIII.  Random mutations were introduced by amplifying rhaS 
using a pair of oligonucleotides with the downstream oligonucleotide carrying a randomized 
codon (NNN) at the desired position with wild type template.  Wild type rhaS was used as 
template for all PCR amplifications.  The specific oligo sets used to create each set of mutants 
are described in Table 6.  Plasmids carrying mutations were then transformed into strain 
SME1088 for evaluation of the transcription activity using β-galactosidase assays. 
Table 6.  Oligonucleotides to Amplify Fragments to Generate RhaS Variants 
Variant 
Oligos to amplify 
upstream DNA fragment
Oligos to amplify 
downstream DNA fragment 
L208X 2098-3102 3101-2714 
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Q210X 2098-3193 3192-2714 
Q211X 2098-3106 3103-2714 
T212X 2098-3106 3104-2714 
L214X 2098-3106 3105-2714 
R218X 2098-3109 3107-2714 
Y219X 2098-3109 3108-2714 
M226X 2098-3190 3191-2714 
K227X 2098-2946 2947-2714 
R229X 2098-2946 3100-2714 
H230X 2098-2946 2948-2714 
L232X 2098-2850 2851-2714 
R233X 2098-2949 2950-2714 
H234X 2098-2949 2951-2714 
E261X 2098-3198 3194-2714 
F262X 2098-3198 3195-2714 
N263X 2098-3198 3196-2714 
W264X 2098-3198 3197-2714 
 
Construction of RhaR expression plasmids to test upstream start codons and Shine-
Dalgarno (SD) sequences for in vivo experiment.  In order to test the native RhaR start codon 
GTG, rhaR (282 residues) with associated SD sequence was cloned into pHG165 to make 
plasmid pSE312 using oligos 3430 and 2082.  To introduce a frame shift at the upstream ATG 
start codon of rhaR (312 residues), oligos 3031 and 2082 were used to create plasmid pSE313.  
The cloning method consisted of PCR amplification of the gene encoding different size of RhaR 
and their corresponding SD.  The PCR fragments and plamid pHG165 were both digested with 
restriction endonucleases EcoRI and HindIII, and then ligated with T4 ligase.   
Construction of plasmids for overexpression of RhaR-His6, RhaR-NTD-His6, and RhaR-
DBD-His6 proteins.  Plasmids were constructed for overexpression of RhaR-His6, RhaR-NTD 
(residue 1-172)-His6 RhaR-DBD (residue 166-282)-His6.  The inserts encoding RhaR were 
generated by PCR with oligos 2352 and 3415.  The RhaR-NTD insert was generated by PCR 
with oligos 3451 and 2344.  The RhaR-DBD fragment was amplified by PCR with oligos 2345 
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and 2352.  For all the inserts, a thrombin cleavage site was primer encoded at the C-terminal end 
of the protein.  All the inserts were digested with restriction endonucleases NdeI and XhoI, and 
then ligated with similarly digested plasmid pET24b to make pSE308 (encodes RhaR-His6), 
pSE327 (encodes RhaR-NTD-His6), and pSE226 (encodes RhaR-DBD-His6). 
Construction of plasmid for overexpression of RhaS-His6, and RhaS
L201R-His6.  Plasmids 
were constructed for overexpression of RhaS-His6 and RhaS
L201R-His6.  The inserts encoding 
RhaS and RhaSL201R was generated by PCR with oligos 2349 and 2353.  A thrombin cleavage 
site was primer encoded at the C-terminal end of the protein.  The inserts were digested with 
restriction endonucleases NdeI and XhoI, and then ligated with similarly digested plasmid 
pET24b to make pSE328 (encodes RhsS-His6) and pSE329 (encodes RhaS
L201R-His6). 
β-galactosidase assays. β-galactosidase assays were performed as described previously [87],  
using the growth protocol of Neidhardt [88]and the assay method of Miller [89].  Briefly, all 
strains for β-galactosidase assays were grown in three serial steps:  tryptone-yeast extract culture 
with ampicillin; overnight culture (MOPS-buffered minimal medium containing 0.04% glycerol 
as a limiting carbon source and ampicillin); and growth culture (MOPS-buffered minimal 
medium with 0.4% glycerol, 200 µg/ml ampicillin, and with or without 0.4% L-rhamnose).  
Specific activities were averaged from three independent experiments with two replicates in each 
experiment.  Standard deviation of the mean was calculated for all the variants.   
Western blot.  Cultures of the strains used in β-galactosidase assays were lysed by boiling at 
100°C for 20 minutes, loaded onto a 12% sodium dodecyl sulfate -polyacrylamide gel, 
electrophoresed, blotted onto a nitrocellulose membrane, blocked with Odyssey® blocking 
buffer (LICOR, Lincoln, NE), and incubated with primary and secondary antibodies using 
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standard procedures.  The rabbit anti-RhaR and anti-RhaS primary antibodies were custom-made 
from Cocalico Biologicals (Reamstown, PA).  The mouse anti-DnaK primary antibody was 
purchased from Abcam (Cambridge, MA ).  The Alexa Fluor® 680-labled anti-rabbit secondary 
antibody and IRDye® 800-labled anti-mouse secondary antibody were obtained from Life 
Technologies (Carlsbad, CA) and LI-COR (Lincoln, NE), respectively.  The blot was imaged 
using an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). 
In vivo dose-response experiments.  In vivo dose-response assays were performed as previously 
described [81].  For all the assays performed, SE-1 was dissolved in 100% dimethyl sulfoxide 
(DMSO).  To test the effect of SE-1 on RhaS and RhaS variants, cell cultures of RhaS and its 
variants were grown to an optical density at 600 nm (OD600) of ~0.1 and then mixed with 
various concentrations of analogues (final concentration of DMSO, 6.2%), induced with 1 mM 
isopropyl 1-thio-β-D-galactopyranoside (IPTG) (final concentration) and 0.2% L-rhamnose (final 
concentration) for 3 hours at 37°C, lysed, and β-galactosidase activity was measured.  Uninduced 
(no IPTG and no analogues) and uninhibited (1 mM IPTG, 0.2% L-rhamnose and no analogues) 
controls were included for each of the rhaB-lacZ and control strain, and used to normalize β-
galactosidase activity, as described previously [81].   
To assay the effects of SE-1 analogues, similar in vivo dose-response assay was carried 
out with some exceptions.  Twenty-four commercially available compounds were obtained from 
Sigma Aldrich (St. Louis, MO), and other analogues were synthetized by Dr. Jeff Aube’s group.  
Bacterial cultures of SME4382 which was a virB-lacZ reporter fusion and contained a plasmid 
expressing VirF, and SME3359 which was a control strain carrying a lacZ reporter fusion (hts-
lacZ) with a synthetic promotor that was repressed by LacI and did not require VirF for 
activation,  were used to test all analogues.  Cells were grown the same way as mentioned above, 
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and then induced with 1 mM IPTG (final concentration).   For all the assays, fifty percent 
inhibitory concentrations (IC50) were calculated and graphs were drawn using Graphpad Prism 
(GraphPad, La Jolla, CA).  All data plotted were from three independent experiments with two 
replicates in each experiment.   
E. coli growth rate experiments.  To test whether the SE-1 and its analogues had any impact on 
the growth of the bacterial strains used for in vivo dose-response assays (SME4382 and 
SME3359), the growth rate in the presence and absence of the compounds were compared using 
a procedure described previously[81], except the bacterial cultures were grown in TY broth.  
Briefly, the cells were grown at 37°C in TY broth plus 1 mM IPTG (final concentration), in 24-
well microtiter plate, either with compounds (44 µM, 6.2% DMSO) or with DMSO (6.2%) 
alone, in a PowerWave XS plate reader (BioTek Instruments).  
Overexpression of RhaR-NTD-His6, RhaR-His6, and RhaR-DBD-His6.  The C-terminal His6 
tagged RhaR-NTD (residue 1 to 172) was first overexpressed and purified from E. coli BL21 
(DE3) cells (Novagen) for crystallization screen.  Cells were first grown in TY with 50 µg/ml 
kanamycin at 37°C until cells reached an OD600 of 0.6, and then induced with 0.5 mM IPTG 
(final concentration) and incubated at 15°C overnight.  Once crystal condition was found, the 
RhaR-NTD-His6 protein was overexpressed in E. coli B834 (DE3) cells (Novagen) to 
incorporate seleno-methionine, to allow solution of the phase problem.  To overexpress seleno-
methionine incorporated RhaR-NTD-His6 protein, cells were grown using a protocol modified 
from New England Biolabs.  Briefly, cells were first grown in minimal media supplemented with 
50 µg/ml L-methionine and kanamycin at 37°C to an OD600 of 0.6, and then pelleted and 
resuspended in a fresh minimal media containing 50 µg/ml kanamycin but without methionine or 
seleno-methionine.  The cells were grown for 4 hours at 37°C to deplete methionine, and then 
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incubated with 50 µg/ml seleno-methionine for 30 minutes. The cells were induced with 0.5 mM 
IPTG (final concentration) and incubated at 25°C overnight.   
RhaR-His6 was overexpressed in the strain BL21 (DE3) (Novagen).  The overall 
overexpression procedure was similar to the procedure overexpressing RhaR-NTD-His6, except 
that no L-methionine or seleno-methionine was added, and cells were induced with 0.5 mM 
IPTG once the OD600 reached 0.6. 
Overexpression of RhaR-DBD-His6, and His6-RhaS-DBD.  Both of the proteins were 
overexpressed in the strain BL21 (DE3) (Novagen) using the following procedure.  Cells were 
first grown in TY with 50 µg/ml kanamycin for RhaR-DBD-His6 and 100 µg/ml ampicillin for 
His6-RhaS-DBD at 37°C until cells reached an OD600 of 0.6.  The cells were then induced with 
0.5 mM IPTG (final concentration) and incubated at 15°C overnight. 
Overexpression of RhaS-His6 and RhaS
L201R-His6 with rhamnose.  C-terminal His6 tagged 
RhaS and RhaSL201R was overexpressed in strain BL21 (DE3) (Novagen) using the following 
procedure.  Cells were first grown in TY with 100100 µg/ml ampicillin at 37°C until cells 
reached an OD600 of 0.6.  The cells were then incubated on ice for 15 minutes.  0.2% rhamnose 
(finial concentration) and 0.5 mM IPTG (final concentration) were then added to the cells.  The 
cells were then incubated at 15°C overnight. 
Overexpression of RhaR fusion protein with chintin-binding domain(CBD) and intein 
domain at the N-terminus.  RhaR was overexpressed as a CBD-intein fusion protein from 
plasmid pTYB11 (New England Biolabs) in E.coli strain ER2566 (New England Biolabs).  The 
protein was overexpressed by using an lactose-driven (instead of IPTG-driven) auto-induction 
protocol [90].  Briefly, cells were grown in ZYM-5052 media [1% tryptone (w/v), 0.5% yeast 
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extract (w/v), 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 0.5% glycerol 
(v/v), 0.05% glucose (w/v), α-lactose (w/v), 2 mM MgSO4, 10 µM FeCl3, 4 µM CaCl2, 2 µM 
MnCl2, 2 µM ZnSO4, 0.4 µM CoCl2, 0.4 µM CuCl2, 0.4 µM NiCl2, 0.4 µM Na2MoO4, 0.4 µM 
Na2SeO3, 0.4 µM H3BO3] with 200 µg/mL ampicillin at 37°C until cells reached an OD600 of 0.6.  
The cells were then moved to 25°C until the following morning for induction.   
Purification of RhaR-NTD-His6, RhaR-His6, RhaR-DBD-His6, and His6-RhaS-DBD.  The 
purification of all four proteins follows the procedure described below.  Cells were harvested by 
centrifugation.  The cell pellets were re-suspended in binding buffer containing 20 mM Na 
phosphate pH 7.6, 500 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), 5 mM 
imidazole, 5% (v/v) glycerol, and then lysed by French press.  The lysate was centrifuged at 
11000 rpm for 30 minutes.  Nickel agarose resin (Glodbio) was equilibrated with binding buffer, 
mixed with the supernatant for an hour with shaking at 4 °C, and then loaded onto a gravity flow 
column. The nickel resins were washed with 5 column volumes of binding buffer, 10 column 
volumes of wash buffer (binding buffer but containing 60 mM imidazole).  The proteins were 
eluted with 5 column volumes of elution buffer (binding buffer but containing 500 mM 
imidazole). The elution fractions with most concentrated proteins were then pooled and loaded 
onto a HiPrep 16/60 Sephacryl S-300 HR column (GE healthcare), and eluted with buffer 
containing 10 mM tris-acetate pH7.4, 500mM NaCl, 1mM EDTA, 0.5 mM TCEP, 1 mM 
dithiothreitol (DTT), 5% glycerol.  Protein fractions were pooled and concentrated using 
Amicon® ultra centrifugal filter unit (Millipore) with a molecular mass cutoff 10 kDa.  The final 
concentrations of RhaR-NTD-His6, RhaR-His6, and RhaR-DBD-His6 were at 6 mg/ml, 2 mg/ml, 
and 2.5 mg/ml, respectively.  His6-RhaS-DBD protein fractions were also combined, loaded onto 
HiPrep 26/10 Desalting column, and eluted with buffer containing 100mM K2HPO4 pH 6.6, 200 
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mM KCl, 1 mM DTT, 5% glycerol.  Protein fractions with most concentrated proteins were 
combined and used for further analysis, and the protein final concentration was at 1 mg/ml.   
Purification of CBD-intein-RhaR.  Cells were harvested by centrifugation.  The cell pellets 
were re-suspended in column buffer with 20 mM HEPES pH 8.0, 500 mM NaCl, 1 mM EDTA, 
0.5 mM TCEP, and then lysed by French Press.  The lysate was centrifuged at 11000 rpm for 30 
minutes.  1 ml of chitin resin (New England Biolabs) was equilibrated with column buffer, 
mixed with the supernatant for an hour with shaking at 4°C, loaded onto a gravity flow column, 
and then washed with 20 column volumes of column buffer.  10 column volume of cleavage 
buffer (column buffer with 100 mM DTT) was added, and then column was gently agitated by 
shaking for at least 16 hours to promote the intein-mediated cleavage of RhaR from the fusion 
protein.  The untagged RhaR was eluted, and then concentrated with a 4 ml Amicon® ultra 
centrifugal filter unit (Millipore) with a molecular mass cutoff of 10 kDa. 
Purification of RhaS-His6 and RhaS
L201R-His6 with rhamnose.  Cells were harvested by 
centrifugation.  The cell pellets were re-suspended in binding buffer containing 20 mM Na 
phosphate pH 7.6, 500 mM NaCl, 0.2% rhamnose, 0.5 mM TCEP, 5 mM imidazole, 5% (v/v) 
glycerol, and then lysed by French press.  The lysate was centrifuged at 11000 rpm for 30 
minutes.  Nickel agarose resin (Glodbio) was equilibrated with binding buffer, mixed with the 
supernatant for an hour with shaking at 4 °C, and then loaded onto a gravity flow column. The 
nickel resins were washed with 5 column volumes of binding buffer, 10 column volumes of wash 
buffer (binding buffer but containing 60 mM imidazole).  The proteins was eluted with 5 column 
volumes of elution buffer (binding buffer but containing 500 mM imidazole). The elution 
fractions with most concentrated proteins were then pooled and loaded onto a HiPrep 16/60 
Sephacryl S-300 HR column (GE healthcare), and eluted with buffer containing 10 mM tris-
48 
 
acetate pH7.4, 500mM NaCl, 1mM EDTA, 0.5 mM TCEP, 1 mM dithiothreitol (DTT), 5% 
glycerol.  Protein fractions were pooled and concentrated using Amicon® ultra centrifugal filter 
unit (Millipore) with a molecular mass cutoff 10 kDa.  The final concentration of RhaS- His6 and 
RhaSL201R-His6 were at 2 mg/ml.  
Purification and crystallization of ToxT.  The expression and purification of ToxT was 
performed as described previously [38], with a few exceptions.  Briefly, ToxT was 
overexpressed as a ToxT-intein-CBD fusion from plasmid pTXB1 (New England Biolabs), by 
auto-induction in ZYM-5052 media [90] with 200 µg/mL ampicillin using strain BL21 (DE3) 
(Novogen) instead of strain BL21-CodonPlus® (DE3)-RIL (Stratagene) as previously described 
[38].  The initial purification was carried out using a chitin affinity column (New England 
Biolabs) with gravity flow.  The CBD tag was on column removed by 100 mM DTT.  The eluent 
from the chitin column, which contained untagged ToxT, was loaded onto a HiTrap SP 
Sepharose Fast Flow cation exchange column (GE healthcare) in buffer containing 20 mM Tris-
HCl pH 6.8, 33.3 mM DTT, and 50 mM NaCl.  Buffer A and B contained 0.05 M and 1 M NaCl, 
respectively, and the protein was eluted using a gradient from 0 to 100% buffer B and protein 
peak was found at 88% buffer B.  The fractions containing purified ToxT protein were combined 
and then concentrated to 1.65 mg/mL for crystallization screening using a 4 ml Amicon® ultra 
centrifugal filter unit (Millipore) with a molecular mass cutoff of 10 kDa.  All crystallization 
screening was conducted in Compact Jr. or Clover Jr. (Rigaku Reagents) sitting drop vapor 
diffusion plates incubated at 293 K using 0.75 µl of protein and 0.75 µl crystallization solution 
equilibrated against 75 µl of the latter.  Crystals displaying needle (~100 µm × 10 µm) or plate 
(~60 µm × 20 µm) morphology formed overnight from various screens.  Plate shaped crystals, 
used for data collection, were obtained from the Proplex HT screen (Molecular Dimensions Inc.) 
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condition H10 [5% (w/v) PEG 4000, 10% (v/v) 2-propanol, 0.1 M MES pH 6.5, 200 mM 
MgCl2], a condition that shared no components with the crystallization solution used by Lowden 
et al [38].  Crystals were transferred to a fresh drop composed of 80% crystallization solution 
and 20% ethylene glycol and stored in liquid nitrogen.   
Data collection and structure refinement of ToxT.  X-ray diffraction data were collected by 
Kevin Battaile at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M pixel 
array detector, and solution of the structure was performed by Scott Lovell.  Intensities were 
integrated using XDS [91], the Laue class analysis and data scaling were performed with 
Aimless[92] which suggested that the highest probability Laue class was 2/m and space group 
P21.  The Matthew’s coefficient [93] (Vm=2.3 Å3/Da, % solvent=46.8) suggested that 
asymmetric unit contained a single molecule.  Structure solution was conducted by molecular 
replacement with Phaser [94] via the Phenix [95] interface using a previously determined non-
isomorphous structure of ToxT (PDB code 3GBG [38]) as the search model.  All space groups 
with 2-point symmetry were tested and the top solution was obtained for a single molecule in the 
asymmetric unit in the space group P21.  Structure refinement and manual model building were 
conducted with Phenix and Coot [96] respectively.  TLS refinement [97] [98]was incorporated in 
the latter stages to model anisotropic atomic displacement parameters.  Structure validation was 
conducted with Molprobity [99] and figures were prepared using the CCP4MG package [100].  
Refined atomic coordinates and experimental structure factors have been deposited to the Protein 
Data Bank (PDB code 4MLO). 
Crystallization of RhaR-NTD-His6.  The rhamnose-bound RhaR-NTD-His6 was crystallized in 
hanging drops using 1 µl of protein and 1 µl well solution which contains 100 mM MES pH 6.0, 
50 mM Ca(OAc)2, 12 % PEG 3350.  The crystals were soaked in well solution with 50 mM 
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rhamnose for 10 minutes.  After transferring to a fresh drop containing 70% crystallization 
solution and 30% ethylene glycol (V/V), crystals were flash frozen with liquid nitrogen.  The 
rhamnose-free RhaR-NTD-His6 was also crystallized in hanging drops with 1 µl of protein and 1 
µl well solution which contains 100 mM MES pH 6.0, 50 mM Ca(OAc)2, 6 % PEG 3350.  
Crystals were transferred to a fresh drop composed of 80% crystallization solution and 20% (v/v) 
ethylene glycol (RhaR-NTD-EG), glycerol (RhaR-NTD-GLY), PEG 200 or PEG 400 for 1 
minute and stored in liquid nitrogen. 
X-ray data collection and structure determination of rhamnose-bound RhaR-NTD. X-ray 
data for the full rhamnose-occupied Met-RhaR-NTD were collected remotely at the Stanford 
Synchrotron Radiation Lightsource (SSRL), and data for the partial rhamnose-occupied native 
RhaR-ND were collected remotely at Advanced Photon Source (APS).  All data were processed 
by Haiyan Zhao with the program HKL2000 [101].  The structure was determined at 2.05 Å 
resolution using the single-wavelength anomalous dispersion method with the program 
SOLVE/RESOLVE [102].  Automated model building with the program PHENIX [95] resulted 
in a model covering ∼80% of the protein (205 out of 258 residues).  This model was used in 
further model building and refinement with the program COOT [96] and PHENIX.   
X-ray data collection and structure determination of rhamnose-free RhaR-NTD.  X-ray 
data for the rhamnose-free RhaR-NTD were collected at the Advanced Photon Source (APS) 
beamline 17-ID using a Dectris Pilatus 6M pixel array detector by Kevin Battaile.  Structures 
were determined by Scott Lovell.  Structure solution was conducted by molecular replacement 
with Phaser [94] using a previously determined isomorphous structure of RhaR-NTD as the 
search model.  Structure refinement and manual model building were conducted with Phenix 
[95] and Coot [96] respectively.  Disordered side chains were truncated to the point for which 
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electron density could be observed.  TLS refinement [97, 98] was carried out in the latter stages 
of refinement to model anisotropic atomic displacement parameters.  Structure validation was 
conducted with Molprobity [99] and figures were prepared using the CCP4MG package [100] 
Electrophoretic mobility shift assays (EMSA) for RhaR and RhaR-DBD.  To determine the 
active protein concentrations and the dissociation constants (Kd) for RhaR and RhaR-DBD, 
EMSAs were performed in which either RhaR or RhaR-DBD was mixed with fluorescently 
labelled DNA in reaction buffer consisting of 10 mM Tris-acetate, pH 7.4, 50 mM KCl, 50 mM 
L-rhamnose (when present), 1 mM EDTA, 0.05% NP40, 1 mM DTT, and 5% glycerol.  The 
reactions were incubated until the system reached equilibrium, and then loaded onto 6% 
polyacrylamide gel.  The gels (6% acrylamide, polyacrylamide to bis-acrylamide ratio, 60:1, 
w/w) were soaked in running buffer (22 mM Tris-borate, 5 mM EDTA), and pre-run at 150V for 
at least 15 minutes prior to loading samples.   
Electrophoretic mobility shift assays (EMSA) for RhaS and RhaS-DBD.  To determine the 
active protein concentrations and the dissociation constants (Kd) for RhaS and RhaS-DBD, 
EMSAs were performed in which either RhaS or RhaS-DBD was mixed with fluorescently 
labelled DNA in reaction buffer consisting of 10 mM Tris-acetate, pH 7.4, 50 mM KCl, 50 mM 
L-rhamnose (when present), 1 mM EDTA, 1 mM DTT, and 5% glycerol.  The reactions were 
incubated until the system reached equilibrium, and then loaded onto 6% polyacrylamide gel.  
The gels (6% acrylamide, polyacrylamide to bis-acrylamide ratio, 60:1, w/w) were soaked in 
running buffer (22 mM Tris-borate, 5 mM EDTA), and pre-run at 150V for at least 15 minutes 
prior to loading samples.  The gels used to measure full length RhaS DNA binding also 
contained 0.2% rhamnose during gel casting.   
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RhaR and RhaS DNA bending detected by EMSA.  To determine the angle of RhaR DNA 
bending in the presence and absence of L-rhamnose, the DNA bending assay was performed as 
described by Wu & Crothers (1984) [103].  Briefly, RhaR protein was mixed and incubated with 
each DNA fragment, loaded onto the gels, and electrophoresed for approximately 3 hours.  The 
five 292 bp DNA fragments with the 51 bp RhaR DNA binding site at different positions were 
amplified and labeled with IR700 fluorescence tag via PCR.  To calculate the bend angle, 
method developed by Thompson & Landy (1988) [104] was used.  T-test [105] was performed to 
analyze the significance of the bend angles measured in the presence and in the absence of L-
rhamnose.   
 To determine the angle of RhaS DNA bending in the presence of L-rhamnose, the DNA 
bending assay was performed as described above.  Briefly, RhaS protein was mixed and 
incubated with each DNA fragment, loaded onto the gels, and electrophoresed for about 3 hours.  
Each of the 291 bp DNA fragments with the 51bp RhaS DNA binding site at various positions 
was amplified and labeled with IR700 fluorescence tag via PCR.   
Active protein concentration assay.  Total protein concentration was determined by Bradford 
assays. The concentration of active protein in each protein sample was determined using EMSA 
assays under stoichiometric conditions – with the DNA concentration in great excess over the 
protein concentration - as previously described [53].  DNA was mixed with serial dilutions of the 
protein of interest and an EMSA was performed.  A linear relationship between protein 
concentration and the amount of DNA bound was determined.  This linear trend line was used to 
determine the protein concentration necessary to bind all of the DNA, and the percent active 
protein was calculated as a function of the total DNA concentration divided by the total 
concentration of RhaR or RhaS protein, as described previously [106, 107].  Measurements of 
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active protein concentration were performed very close in time and with the same protein 
aliquots as the final equilibrium dissociation constant assays to ensure accurate active protein 
concentration values were used in the dissociation constant calculations.  
Electrophoretic mobility shift assays (EMSA) to detect DNA-binding by ToxT.  To 
determine whether purified ToxT protein was active and responsive to effector fatty acid, 
EMSAs were performed.  The 54-bp double stranded DNA for ToxT binding was annealed 
including the ToxT binding site sequence from the tcp promoter region.  Fatty acid oleic acid 
was dissolved in 100% methanol.  To carry out binding assay, 1.8 µM of ToxT was mixed with 
DNA in reaction buffer consisting of 10 mM Tris-acetate, pH 7.4, 50 mM KCl, 0.008% oleic 
acid (when present), 1 mM EDTA, 1 mM DTT, and 5% glycerol..  The reactions were incubated 
at 30 °C for 30 minutes, and then loaded onto 6% polyacrylamide gel.  The gels (6% acrylamide, 
polyacrylamide to bis-acrylamide ratio, 60:1, w/w) were soaked in running buffer (22 mM Tris-
borate, 5 mM EDTA), and pre-run at 150V for at least 15 minutes prior to loading samples.  
EMSAs were also performed to test whether SE-1 inhibits DNA-binding by ToxT.  SE-1 was 
dissolved in 100% DMSO.  1.8 µM of ToxT was mixed with SE-1(or DMSO only) first and 
incubated on ice for 30 minutes; DNA was then added and incubated at 30°C for 30 minutes 
before loading onto the gel. 
Fluorescence-based thermal shift assay.  Binding of SE-1 to purified VirF was performed 
using a thermal shift assay with the fluorescent dye Sypro Orange [108, 109] (Molecular Probes). 
A protocol of Ericsson et al. [109] was used with the following minor modifications.  The 
binding of SE-1 to an unrelated purified protein MBP-NS1-NTD (more than 95% pure) was also 
assayed as a control.  Each reaction mixtures contained 1 μM protein, 20× Sypro Orange, 0.76× 
EMSA buffer (7.6 mM Tris-acetate [pH 7.4], 0.76 mM K-EDTA, 38 mM KCl, and 0.76 mM 
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DTT), 80 μM SE-1 with 4% DMSO or 4% DMSO only.  Low-profile 0.1-ml PCR 8-tube strips 
with optically clear flat caps (USA Scientific) were used to carry each reaction.  Each reaction 
was then put in a StepOnePlus real-time PCR thermocycler (Applied Biosystems), with heating 
from 25 to 99°C in increments of 0.8°C.  Boltzmann sigmoidal model was used to analyze all the 
data collected and to calculate the Tm with GraphPad Prism software (GraphPad).  Data points 
before and after the fluorescence intensity minimum and maximum, respectively, were excluded 
from fitting.  The values for ΔTm (Tm changes) are averages for three independent experiments 
with two replicates in each experiment.   
Intrinsic tryptophan fluorescence assay.  Serial dilutions of SE-1 were prepared with protein 
buffer containing 100 mM K2HPO4 pH 6.6, 200 mM KCl, 1 mM DTT, 5% glycerol.  His6-RhaS-
DBD protein was diluted to a final concentration of 0.9 μM with the aforementioned buffer.  
Reactions were set up by mixing 1 µl of SE-1 dilutions and 2 ml of protein, and kept on ice 
before using.  SE-1-only controls were also set up by mixing 1 µl of SE-1 dilutions and 2 ml of 
buffer.  Each reaction was placed in a 2 ml cuvette, and the fluorescence was monitored using 
Varian Cary Eclipse Fluorescence Spectrophotometer (Varian Medical Systems, Palo Alto, CA) .  
Excitation was at 295nm, and the slit width was 5nm for both excitation and emission.  
Preliminary experiments indicated that SE-1 has significant absorption at the wavelength at 
which the tryptophan emits photon; therefore this inner filter effect needs to be corrected.  To do 
so, a 1 ml cuvette was filled with SE-1 only controls, and the UV absorption was scanned and 
recorded from 280 to 380 nm using Beckman UV/Vis spectrophotometer (Beckman Coulter).  
The corrected fluorescence intensity was calculated as described previously [110]. 
Protein peptides mapping by LC/MS.  The protein peptides mapping by LC/MS experiments 
were performed by Dr. Nadya Galeva of the University of Kansas Mass Spectrometry/Analytical 
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Proteomics Laboratory as described previously [111].  Briefly, NanoAcquity chromatographic 
system (Waters Corp., Milford, MA) and Binary Solvent Manager were used to develop gradient 
with solvents of highest purity (Optima LC-MS grade, Fisher Scientific) and to deliver analytes 
through a reverse-phase column (Thermo Scientific Acclaim PepMap300) to an electrospray 
source of an LTQ-FT mass spectrometer (ThermoFinnigan, Bremen, Germany).  A linear 
gradient was developed in 50 minutes with a flow rate of 10 µl/min.  The LTQ-FT mass 
spectrometer was operated in a data-dependent acquisition mode.  Thermo Scientific™ 
Xcalibur™ software (Waltham, MA) was used to acquire the data.  Mascot software [112, 113] 
was used for database search and protein mapping, setup to search SwissProt or custom protein 
sequence with the digestion enzyme trypsin.  Mass tolerance was 20 ppm for precursor ions and 
0.5 u for fragment ions.  Carbamidomethyl was set as a fixed modification of cysteine residues, 
oxidation of methionine residues and acetylation of protein N-terminus were specified as 
variable modifications.  The results were exported into Scaffold software (Proteome, Portland, 











Identifying Small Molecule Inhibitor Binding Site in RhaS  
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Previously, using high-throughput screening, the Egan lab has identified a small molecule 
inhibitor SE-1 that inhibited the activity of many AraC family activators, including RhaS, RhaR, 
and VirF [80, 81].  It was also found that SE-1 inhibited RhaS-DBD with an IC50 of 10 µM.  
The inhibition of SE-1 to the RhaS-DBD was to the same extent as full-length RhaR, which 
suggested that the RhaS N-terminal domain was not required for SE-1 to inhibit RhaS, and the 
DBD was the target for SE-1 [81].  However, it was unclear where the binding site of SE-1 was 
in the RhaS DBD, and what the mechanism of action of SE-1 was.  In an effort to identify the 
binding site of SE-1, the Egan lab has performed a computational docking study by using online 
docking servers SwissDock [114], and BSP-SLIM [115].  Both of the servers require 3-D 
structure of target protein to calculate the possible binding of small molecule ligand [114, 115].  
Therefore,  AraC-DBD (PDB:2K9S) [34], MarA (PDB: 1BL0) [8] whose structures have been 
solved were first used to carry out the docking study.  Although crystallization attempts of RhaS, 
Rns and VirF have not yet been successful, by utilizing online structure prediction server 
ITASSER, we also obtained the modeled structures of RhaS-DBD, Rns-DBD, and VirF-DBD, 
and used them to perform docking studies.  Both SwissDock and BSP-SLIM have predicted 
several binding site of SE-1 in each of the protein, and different poses of SE-1 were also 
predicted at each predicted SE-1 binding site.  The top model with the most favorable energy 
score predicted the binding site of SE-1 was located at a small pocket between the two HTH 
motifs in all of the protein structures tested (Fig. 6).   
Here, I have used fluorescence-based thermal shift assay and intrinsic tryptophan 





Fig. 6.  Top model of SE-1 docked to the RhaS-DBD.  The I-TASSER [116] predicted 
structure of RhaS-DBD is in gray and SE-1 is in red.  Only one pose of SE-1 is shown.  The 





also have used site-directed mutagenesis to test the predicted SE-1 binding site on the RhaS 
protein. 
SE-1 binds directly to VirF.  The finding that SE-1 blocked DNA binding by VirF but not by 
the non-AraC family proteins LacI and CRP, suggested that SE-1 might bind directly to VirF.  
To test the hypothesis that SE-1 binds to VirF, I performed thermal shift assays [108, 109] using 
the dye Sypro Orange (Molecular Probes, Invitrogen).  In this assay, as the temperature increases 
and the protein begins to unfold, an increased fluorescence signal will be observed upon the 
binding of Sypro Orange to the exposed hydrophobic residues of the protein.  Therefore, the Tm 
of the protein in the absence and presence of a ligand can be measured, and any melting 
temperature changes (ΔTm) of the protein due to the increased protein stability caused by ligand 
binding can be calculated.   Using the thermal shift assay, It was found that the addition of 80 
μM SE-1 increased the Tm of MBP-VirF (1 μM) by 0.61°C (±0.09) (Fig. 7A).  Although this Tm 
change seems to be a relatively small, the following evidence supports the conclusion that this 
likely indicates binding of SE-1 to VirF.  Pantoliano et al. [108] has tested over 100 different 
proteins and used a ΔTm cutoff of 0.5°C or higher to determine the binding of the small molecule 
ligands to the target proteins.  Furthermore, the ΔTm for VirF with 80 μM SE-1 is much higher 
than that found with 40 μM SE-1 (0.15°C ± 0.04 [data not shown]).  SE-1 is quite hydrophobic 
and dissolves poorly in water (~1.4 mM).  Preliminary tests suggested that fluorescence dye 
Sypro orange could bind to SE-1 and increase the base level of the fluorescence during the assay.  
When mixing 160 μM of SE-1 (or higher) with the protein, the fluorescence signal of the protein 




Fig. 7.  Thermal shift assay showing that SE-1 binds to VirF protein. Melting curve of MBP-
VirF (A) and MBP-NS1-NTD (B).  Binding assays were performed in the absence (DMSO only) 
or presence of 80 mM SE-1.  Results of a single experiment (representative of three independent 




Therefore, only 80 μM of SE-1 was tested in the assay.  It is likely that the binding saturation of 
SE-1 to VirF was not achieved at 80 μM, and that a higher ΔTm would be observed if higher 
concentrations of SE-1 was tested.  Lastly, multiple reports with small Tm changes have been 
shown to represent true binding of small molecules to proteins [108, 117-119]. Overall, the 
finding that the binding of 80 μM SE-1 causes Tm changes of VirF by 0.61°C (±0.09) suggested 
that SE-1 directly binds to VirF.  
In order to rule out the possibility that SE-1 bound to MBP since the VirF protein tested 
was fused with MBP at the N-terminus, I also tested an unrelated MBP fusion protein (MBP-
NS1-NTD).  NS1 is a poxvirus protein that does not belong to the AraC family.  MBP-NS1-NTD 
protein showed only a 0.15°C (±0.06) change in the Tm (Fig. 7B), and the melting curve of SE-1 
binding to the protein almost overlapped with the DMSO only control, suggesting that SE-1 did 
not bind to MBP.  Therefore, we concluded that SE-1 binds directly to VirF. 
SE-1 binds directly to RhaS DBD.  The finding that SE-1 blocked DNA binding by RhaS-DBD 
suggested that SE-1 might bind directly to RhaS-DBD.  To test the hypothesis that SE-1 binds to 
RhaS-DBD, I performed intrinsic tryptophan fluorescence assay using purified RhaS-DBD 
protein.  An important feature of intrinsic tryptophan fluorescence is the high sensitivity of 
tryptophan to its local environment.  Changes in the emission spectra of tryptophan often occur 
in response to protein conformational changes.  If SE-1 directly binds to RhaS-DBD, the binding 
would change the conformation of the protein and thus change the local environment of 
tryptophans, and I would expect to see a quench in the fluorescence signal upon SE-1 addition.  
Using this assay, I found that there was a concentration dependent quenching of RhaS 
fluorescence upon addition of SE-1 (after inner filter correction [110] ) that saturates at ~7% 
reduction in the fluorescence peak (Fig. 8).  Both structural and biochemical studies have shown 
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that L-arabinose binds to AraC [33, 42, 120], despite that the binding of L-arabinose to the AraC-
NTD only induced 5 - 10% reduction in the total fluorescence emission [120].  The small change 
in fluorescence of arabinose binding to AraC was similar to that of the binding of SE-1 to RhaS-
DBD, supporting that SE-1 directly binds to RhaS-DBD.   
Mutagenesis to identify SE-1 binding site in RhaS.  Computational programs SwissDock and 
BSP-SLIM predicted that SE-1 bound to a small pocket between the two HTH motifs.  To test 
this prediction, I made substitutions at each of the positions in RhaS that were predicted to be at 
the pocket, and these position included residues V188, W190, D191, L220, N221, R224, F248, 
S249, H253, and L257.  For each of the positons, I constructed both alanine and arginine 
substitutions (for positon W190, R224, F248, S249, and H253, only alanine substitution was 
made) and the rationale for making both substitutions is outlined below.  Alanine substitution 
eliminates the side-chain beyond the β carbon and its non-bulk nature does not change the main-
chain conformation nor does it impose any electrostatic or steric effects [121].  If one residue is 
involved in interacting with SE-1, an alanine substitution will no longer be able to make contact 
with SE-1 and thus will disrupt SE-1 binding.  If several residues are involved in contacting SE-
1, making alanine substitution at one position may not have enough impact to disrupt the binding 
of SE-1.  While making an arginine substitution will introduce a large side-chain potentially 
occupying the space for SE-1 to bind.  Since all the variants that I constructed are at the DNA-
binding interface, it is expected that some of them would be defective for DNA binding.  
Therefore, I started by measuring the in vivo transcription activation activity of all the variants 
relative to the wild-type RhaS by β-galactosidase assay.  These assays did not involve the 




Fig. 8.  Quenching of intrinsic RhaS-DBD tryptophan fluorescence by SE-1.  Protein was at 
0.9 μM.  SE-1 concentrations were from 1.8 mM  to 14.4 μM, with serial 2-fold dilutions.  
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D191R, L220A, L220R, N221A, N221R, S249R, H253A, L257A, and L257R was high enough 
(at least 3% of the wild-type activity) to be further tested in the whole cell based assay with SE-
1, and few of the variants including V188R, W190A, R224A, and F248A had very low activity 
so they would not be assayed in the whole cell based dose-response assay (Table 7).  Therefore, I 
assayed variants V188A, D191A, D191R, L220A, L220R, N221A, N221R, S249R, H253A, 
L257A, and L257R in the RhaS-activated rhaB-lacZ fusion assay in vivo in E. coli (Fig. 9a), and 
found that SE-1 inhibited variants V188A, L220A, L220R, N221A, N221R, and H253A to 
approximate the same extent as WT RhaS, which suggested that these variants did not affect the 
inhibitory effect of SE-1 to RhaS.  The IC50 of SE-1 to the wild-type RhaS was about 20 µM, and 
the IC50 values of SE-1 for these variants were approximately 20-30 µM.  the IC50s of SE-1 to 
variants D191A, D191R, S249R, L257A, and L257R were in the range of 60-90 µM (Fig. 9B), 
which suggested that these variants were less sensitive than wild-type RhaS to inhibition by SE-1 
in the dose-response assay.  Thus, it was likely that residues D191, S249, and L257 were at or 
near the SE-1 binding site on RhaS-DBD, which supports the prediction of docking that SE-1 is 
likely bound to a small pocket between the two HTH motifs.  Sequence alignment showed that 
residue D191 shared sequence identity with RhaR and residue S249 shared sequence identify 
with Rns and VirF (Fig. 10); however, these two residue do not share any sequence identity with 
other proteins we analyzed, and moreover, residue L257 does not share any sequence identify 
with any of the proteins tested, which might contribute to the IC50 differences in SE-1 binding to 
RhaS, RhaR, VirF, Rns and ToxT.  The in vivo transcription activities of variants W190A, 
R224A, F248A are too low to be assayed with SE-1 in the whole cell based dose-response assay, 
therefore an assay that does not rely on DNA binding would be needed to assess the effect of SE-





% WT Activation  
(-)L-rhamnose (+) L-rhamnose 
V188A 11 3 
V188R 0.3 1 
W190A 1 1 
D191A 69 244 
D191R 103 453 
L220A 9 3 
L220R 5 3 
N221A 31 9 
N221R 44 39 
R224A 0.01 1 
F248A 0.1 1 
S249R 21 80 
H253A 10 4 
L257A 97 301 
L257R 89 124 
 
Table 7.  Activation activities of variants relative to wild-type RhaS by β-galactosidase 
assay.  β-galactosidase activity was assayed from a single-copy Φ(rhaB-lacZ)Δ84 fusion, in a 
strain with ΔrhaS::kan recA::cat (SME1088) and wt or RhaS variants expressed from a plasmid.  
Cultures were grown with or without L-rhamnose.  Variants were assayed in groups with a wild 
type RhaS activity range of 0.61-0.72 Miller Units (-) L-rhamnose and 171-180 Miller Units (+) 
L-rhamnose.  Percent of wild-type activation was calculated by dividing the activity of each 
variant, either (-) or (+) L-rhamnose, by the wild-type value (-) or (+) L-rhamnose, respectively, 




Fig. 9.  Reporter fusion to test the effect of SE-1 in vivo and inhibition of in vivo RhaS 
variants in E. coli.   (A) RhaS-activated rhaB-lacZ fusion, shown in uninduced, (-) rhamnose 
state (left) and induced (+) rhamnose state (right).  (B) In vivo inhibition by SE-1 of β-
galactosidase expression from the rhaB-lacZ fusion by wild-type RhaS or RhaS variants.  
Activity in the absence of SE-1was set to 100% for the reporter fusion.  Results are the average 







Fig. 10. Sequence alignments of predicted SE-1 binding site in RhaS, RhaR VirF, Rns, and 
ToxT.  Residues predicted to contact SE-1 are highlighted in gray.  
RhaS   188  VNWDAVADQFSLSLRTLHRQLKQQTGLTPQRYLNRLRLMKARHLLRHSEASVTDIAYRCGFSDSNHFSTLF   258
RhaR   193  FALDKFCDEASCSERVLRQQFRQQTGMTINQYLRQVRVCHAQYLLQHSRLLISDISTECGFEDSNYFSVVF   263
VirF   175  WRLSDISNNLNLSEIAVRKRLE-SEKLTFQQILLDIRMHHAAKLLLNSQSYINDVSRLIGISSPSYFIRKF   244
Rns    178  WTLGIIADAFNASEITIRKRLE-SENTNFNQILMQLRMSKAALLLLENSYQISQISNMIGISSASYFIRIF   247
ToxT   186  WRWADICGELRTNRMILKKELE-SRGVKFRELINSIRISYSISLMKTGEFKIKQIAYQSGFASVSYFSTVF   255
                 ..     .   :::.:. .   . .. :  :*:  :  *:      :.:::   *: . .:*   * 
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SE-1, and intrinsic fluorescence assay measures binding by the fluorescence signal quenching 
upon SE-1 addition.  Therefore both assays could serve alternate methods to test the effect of SE-













 ToxT is an AraC family transcriptional activator of Vibrio cholera virulence gene 
expression.  ToxT contains a C-terminal DNA binding domain and an N-terminal domain 
responsible for dimerization and effector binding [38].  As a master virulence regulator, ToxT 
directly activates the expression of the genes encoding the toxin-coregulated pilus (TCP) and the 
cholera toxin (CT), and auto-regulate its own expression from the tcp promoter [19-23].  TCP is 
essential for colonization of the human intestine, and CT is the cause of the diarrheal disease that 
is characteristic of cholera [19-21].  In V. cholera, both bile and individual unsaturated fatty 
acids found in bile has been shown to inhibit ToxT-dependent gene activation [39, 40].  The full-
length structure of ToxT determined by Lowden et al. had the fatty acid cis-palmitoleic acid 
(PAM) bound to the N-terminal domain [38].  Although oleic acid is likely the physiological 
effector of ToxT given its high concentration in bile, both PAM and oleic acid were shown to 
reduce activation of tcp and ctx in vivo, and to reduce DNA binding by ToxT in vitro [40].   
 The small molecule inhibitor SE-1 has been previously shown to effectively inhibit 
transcription activation by several AraC family proteins, including RhaS, RhaR, and VirF [80, 
81].   Given that AraC family proteins have a structurally conserved DNA binding domain, we 
hypothesized that SE-1 might inhibit DNA binding by AraC family proteins in addition to RhaS, 
RhaR, and VirF, for instance, ToxT.  If this was true, we could set up crystallization trials to co-
crystalize SE-1 with ToxT since ToxT was stable and the structure of ToxT has been solved by 
Lowden et al. [38], and therefore the chance of getting SE-1 crystalized with ToxT was higher 
than with the proteins that had never been successfully crystalized.  This would provide direct and 
detailed information about the binding site of SE-1 on AraC family proteins.  Here, I have tested 
whether SE-1 inhibited in vitro DNA binding by ToxT, and set up crystallization trials to co-
crystalize SE-1 with ToxT.   
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SE-1 inhibition of in vitro DNA binding by ToxT.  Electrophoretic Mobility Shift Assays 
(EMSAs) were performed to investigate whether SE-1 inhibited DNA binding by purified ToxT 
protein.  Protein was purified using methods described previously [38].  Briefly, the ToxT 
protein was first expressed as a chitin-binding domain -intein fusion protein, and purified 
through chitin affinity chromatography.  The chitin binding-domain was removed by DTT 
without any extra amino acids at the C-terminus (Fig. 11A).  Before testing whether SE-1 
inhibited DNA binding by ToxT protein, it was important to know that whether the purified 
ToxT was active.  Therefore EMSAs were carried out to test if purified ToxT can bind to DNA.  
Since in the presence of fatty acid, ToxT protein is in its inactive form and cannot bind DNA, we 
also would want to know if purified ToxT protein is responsive to fatty acid.  ToxT protein was 
mixed with 0.008% oleic acid and DNA (or mixed only with methanol and DNA).  The results 
suggested that 0.008% oleic acid was able to fully inhibited DNA binding by ToxT, which was 
consistent with what Lowden et al. has demonstrated [38], and adding methanol to the protein 
did not affect DNA-binding by ToxT (Fig. 11B).  To test if SE-1 inhibits DNA binding by ToxT, 
protein was mixed with SE-1 (when present) and DNA.  Our results indicate that SE-1 was able 
to inhibit ~90% DNA binding by ToxT at a concentration of 1.34 mM (Fig. 11C).  Previously we 
have shown that SE-1was able to fully inhibit DNA binding by RhaS and VirF at 0.67 mM [80, 
81].  However, at 0.67 mM, SE-1 was only able to inhibit ~80% DNA binding by ToxT, and 
~90% DNA binding even at 1.34 mM.  The concentration of SE-1 required to fully inhibit DNA 
binding by ToxT would be much higher than the concentration tested to fully inhibit DNA 
binding by RhaS and VirF, suggesting that although SE-1 could block DNA binding by ToxT, 
the binding affinity of SE-1 to ToxT may be much weaker than to other proteins tested including 




Fig. 11. Purified ToxT protein tested with oleic acid and SE-1 in DNA binding assay, and 
cystals of ToxT.  (A) Purified ToxT protein (12% SDS-PAGE gel).  Pre-stained protein ladder 
(Thermo Fisher Scientific) is in the first lane.  ToxT protein was expressed as chitin-binding 
domain-intein fusion protein (molecular mass: ~ 55 kDa), the chitin-binding domain was then 
cleaved off by DTT on column, and ToxT protein was eluted without any extra amino acid at C-
terminal.  (B) EMSA showing ToxT effector oleic acid (in methanol, MeOH) inhibited in vitro 
DNA binding by ToxT.  MeOH control was including showing that it did not affect DNA 
bingind by ToxT. (C) EMSA showing SE-1 inhibited (in DMSO) in vitro DNA binding by 
ToxT. DMSO only control was included showing that it did not affect DNA binding by ToxT. 
(D) Crystals of ToxT forming either needles (~100 µm x 10 µm) or plates (~60 µm x 20 µm ).
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Crystallization of ToxT.  Once we had shown that SE-1 inhibited in vitro DNA binding by 
ToxT, we set up crystallization trials in hopes of obtaining co-crystals of SE-1 with ToxT, with 
the goal of obtaining a detailed model of the positon of SE-1 binding to ToxT.  As the first 
attempt to achieve this goal, I initially set up crystallization trials of ToxT using the 
crystallization condition that Lowden et al. (2010) used to successfully crystalize ToxT.  
However, we weren’t able to obtain any crystal of ToxT.  Therefore, we screened over 480 
different crystallization conditions, and eventually obtained crystals of ToxT with a condition 
containing 5% (w/v) PEG 4000, 10% (v/v) 2-propanol, 0.1 M MES pH 6.5, 200 mM MgCl2, a 
solution that is completely different from the published one.  The structure was solved to 1.65Å 
resolution (Fig. 11D).   
1.65 Å resolution structure of ToxT.  The final refinement and model statistics of ToxT are 
given in Table 8.  The final model of ToxT could be traced in the electron density maps from 
residues K5 to G272, except for a single disordered residue, G133, which is located in a loop 
connecting helix α2 to α3 (Fig. 12A).  Electron density consistent with PAM was also present 
(Fig. 12B), as was observed in the original ToxT structure (PDB code 3GBG [38]), although 
PAM was not added in either case but was acquired from the expression host.  Interestingly, 
residues D101 to E110 could be modelled in this structure, which included helix α1 and a loop 
region that connects this helix to the β9 sheet.  This helix can be thought of as containing two 
segments which we refer to as α1 and α1’ to be consistent with the prior secondary structure 
assignment for 3GBG [38](Fig. 12C).  In addition, three chloride ions were modelled in the C-
terminal region of ToxT, which were assigned based on the coordination distances (~3.1-3.3 Å) 




Table 8   Data collection and refinement statistics for ToxT structure  
Data Collection  
Unit-cell parameters (Å, o) a=47.34, b=39.41, c=80.24, =97.94 
Space group P21 
Resolution (Å)1 39.73-1.65 (1.68-1.65) 
Wavelength (Å) 1.0000 
Temperature (K) 100 
Observed reflections 117,532 
Unique reflections 35,493 
<I/(I)>1 10.3 (1.9) 
Completeness (%)1 99.6 (99.8) 
Multiplicity1 3.3 (3.4) 
Rmerge (%)
1, 2 8.1 (68.0) 
Rmeas (%)
1, 4 9.7 (82.6) 
Rpim (%)
1, 4 5.2 (43.1) 
CC1/2 
1, 5 0.997 (0.714) 
Refinement  
Resolution (Å) 39.74-1.65 
Reflections (working/test) 33,700/1,777 
Rfactor / Rfree (%)
3 16.8/19.4 
No. of atoms  
(Protein/Chloride/PAM/Water) 
2,181/3/18/179 
Model Quality  
R.m.s deviations   
Bond lengths (Å) 0.009 
Bond angles (o) 0.947 
Average B-factor (Å2)  








Ramachandran Plot   
Most favored (%) 99.6 
Additionally allowed (%) 0.4 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = hkli |Ii(hkl) - <I(hkl)>| / hkli Ii(hkl), where Ii(hkl) is the intensity 
measured for the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = hkl ||Fobs (hkl) | - |Fcalc (hkl) || / hkl |Fobs (hkl)|; Rfree is calculated in an  
identical manner using 5% of randomly selected reflections that were not included in the refinement. 






Fig. 12.  (A) Asymmetric unit of ToxT (PDB code 4MLO) colored by secondary structure.  The 
N- and C-terminal residues (K5 and G272) for the model are indicated along with the disordered 
region between AsnN132-F134.  The 310 helix spanning L99-D101 is coloured blue.  The PAM 
molecule and chloride ions are drawn as cylinders and gold spheres respectively.  (B) Fo-Fc omit 
map contoured at 3σ (green mesh) for PAM and associated hydrogen bonds (dashed lines) to 
ToxT.  (C) Zoomed in view of the region from S87 to E110.  Helix α1 spans S87 to I98 and 
contains a kink at L94. This is followed by a 310 helix spanning L99-D101 and shorter helix from 
L102 to L107 referred to as α1’.    
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chloride sites, positive electron density was observed following refinement indicating an 
underestimation of electrons.  Therefore, the modelling of chloride ions at these sites was 
consistent with the observed electron density and coordination. 
The overall structure is similar to PDB code 3GBG reported by Lowden et al. (2010) 
with an RMSD between Cα atoms of 1.00 Å (Lys5 to Gly272) as determined using a Secondary 
Structure Matching (SSM) [127] algorithm with Superpose via the CCP4 [128] interface.  
However, there are also differences between the two structures as shown in the per-residue 
RMSD plot in Fig. 13A and the superimposed structures in Fig. 13B.  Specifically, the region 
between α1 and β9, which was disordered in 3GBG [38] from residues D101 to E110, could be 
fully traced in the current structure (Fig. 14A).  In this region, helix α1 spans S87 to I98 and 
contains a kink at L94.  This is followed by a 310 helix spanning L99-D101 that continues into a 
shorter helix from L102 to L107 (α1’).  Residues T108 to D113 form a connecting loop between 
α1’ and β9.  This region appears to be stabilized by residues E156, N160 and I162 from helix α3, 
which form hydrogen bonding interactions with residues R105 and S109 of the loop region (Fig. 
14B).  The loop region connecting helices α3-α4 also shows conformational differences relative 
to 3GBG [38], as depicted in Fig 15A, potentially due to the interactions between residues in the 
previously disordered region and residues in helix α3.  Interestingly, the residue D101 to E110 
region is folded over the loop that connects helices α3-α4, spanning K158 to A170, and thus is 
located sequentially after it.  A very similar arrangement can be observed in the structure of the 
regulatory domain of ExsA where the loop connecting α1 and β9 folds over helix α4 (PDB code 
4ZUA [58]).  ExsA is an AraC family transcriptional activator that regulates type three secretion 
system genes in Pseudomonas aeruginosa [58, 129].  Residue G133 in 3GBG [38] was ordered, 
and stabilized by residue K4 through hydrogen bonding interaction.  However, both G133 and 
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K4 were missing from current structure.  It is likely that the slight conformational change in the 
connecting loop region (N132 to D141) disrupted the hydrogen bonding interaction between 
G133 and K4, causing both residues to become flexible and untraceable in the current structure.   
Further analysis was conducted to gauge the quality of fit of the models to the electron 
density.  Analysis of the map-model correlation coefficients via Phenix revealed several regions 
in 3GBG [38] that display low correlation to the 2Fo-Fc map, including the α3-α4 (K158 to 
A170) loop as shown in Fig. 15B.  Although the K158 to A170 loop region was modelled in the 
3GBG [38] structure, it is poorly defined, making it difficult to discern the exact position of the 
residues in this region.  By contrast, the electron density in the current structure was clearly 
traceable in this region, which is reflected in the high correlation coefficient.  It should be noted 
that none of the residues in this loop form hydrogen bond contacts with symmetry related 
molecules, which suggests that crystal packing is not a factor in the conformational differences 
relative to 3GBG [38].  Additional differences between the two structures were observed in the 
loop connecting helices α2-α3 (Asn132 to Asp141) and in part of helix α2 (E122 to V126) (Fig. 
15B). 
SE-1-ToxT crystallization trials.  Co-crystallization trials were set up in attempt to 
obtain crystals of ToxT in complex with SE-1, and two methods of co-crystallization were used.  
With the first methods, ToxT protein was mixed with 1.2-fold molar excess of SE-1, and set up 
crystal screening looking for new conditions that could yield crystals of ToxT with SE-1.  I was 
able to obtain several crystals under new conditions; however, after the X-ray diffraction and 
structure solving, we found that SE-1 was not in the structure.  The second method utilized ToxT 




Fig. 13.  (A) Plot of RMSD deviations per residue between Cα atoms for ToxT (PDB code 
4MLO) and previously determined structure (PDB code 3GBG [38]).  (B) Superpostion of (PDB 
code 4MLO, blue) with the previously determined structure (PDB code 3GBG [38], magenta).  




Fig. 14.  Loop region between α1’ and β9.  (A) 2Fo-Fc map contoured at 1σ (blue mesh) for 
residues G100 to N111 which were disordered in PDB code 3GBG [38].  (B). Interactions 
between α1’ and α3.  Residues within the α1’ (R105) and α3 (E156) helices are coloured cyan. 




Fig. 15.  (A) Comparison of the regions connecting helices α2-α3 and α3-α4 for ToxT (PDB code 
4MLO, magenta) with the previously determined structure (PDB code 3GBG [38], green).  (B) 
Comparison of map correlation coefficients (2Fo-Fc) for ToxT PDB   
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stock for 20 minutes.  Unfortunately, after the X-ray diffraction and structure solving, again, SE-








Optimization of the activity of the SE-1 inhibitor  
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As mentioned in the previous chapters, the small molecule inhibitor SE-1 has been shown 
to effectively inhibit transcription activation by several AraC family proteins including RhaS, 
RhaR, VirF, and ToxT [80, 81].  Therefore, SE-1 has the potential to be developed into a novel 
antibacterial agent.  However, SE-1 has shown ~30% inhibition of the control strain at higher 
concentration, suggesting nonspecific inhibition at higher concentrations, and its potency (IC50 in 
µM range) was not high enough for therapeutic applications.  Thus, optimization of SE-1 would 
be needed to improve both its potency and its specificity so that it might be further developed 
into a lead compound.   
In collaboration with Dr. Jeff Aubé and his group, I have tested both commercially 
purchased analogs of SE-1 (Fig. 16) and SE-1 analogs synthesized by the Aubé group for 
inhibition of the AraC family activator VirF from Shigella.   To do this, I used a whole cell based 
VirF-activated virB-lacZ fusion in vivo.  Various parts of SE-1 were substituted to explore the 
structure–activity relationship (SAR) (Fig. 17).  All the analogues were tested at various 
concentrations in the VirF reporter strain, as well as in a control strain.  The control strain carries 
a LacI-repressed fusion and LacI-expressing plasmid.  This fusion contains lacZ under the 
control of a synthetic promoter (Phts) with an induction level similar to that of the virB fusion 
[81].  Of all the analogues tested, we would screen for analogues that show greater inhibition 
(lower IC50) value) than SE-1, which would suggest that these analogues have a much higher 
potency than SE-1.  In addition, to consider an analogue to be a true positive hit, the analogues 
with greater inhibition also would need to have little or no inhibition against the control strain 
and does not inhibit bacterial cell growth, which would suggest that the hit analogue does not 











Fig. 17. Illustration showing that various parts of SE-1 were substituted with different 
chemical groups.    
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First, I have tested 24 commercially purchased analogues selected by the Aubé group to 
explore the initial SAR (Fig. 16), and found that analogues E1, and A2 inhibited VirF to 
approximately the same extent as SE-1, with IC50 values of 7 µM and 10 µM respectively; while 
analogues C4 and D3 exhibited less inhibition relative to SE-1, with IC50 values of 30 µM and 45 
µM, respectively (Fig. 18 top).  Other analogues with substitutions, such as an indole, a phenyl 
ring, a benzimidazole and a napthyl ring, exhibited no detectable inhibition of VirF in this assay 
(Fig. 18 bottom).   
Next, seven 3,4-disubstitued dihydroquinolines, three quinolinium synthetic precursors 
were synthesized by the Aubé group, and tested in the whole cell based inhibition assay (entry 5-
11, Table 9).  It was found that replacing the n-butyl group with a 4-chlorobenzyl (entry 5, Table 
9) caused a decreased inhibitory activity against VirF with IC50 of 80 µM.  Analogues with the 
quinolone replaced by 5-methyl pyridine (entry 6, Table 9), 3-chlorophenyl (entry 7, Table 9)) 
also showed a significant loss of inhibition against VirF with IC50 > 100 µM.  Analogues with 
the nitro-methyl group of the 1,4-dihydroquinoline replaced with phenyl (entry 8, Table 9), 
methyl (entry 11, Table 9) were found inactive, as well as analogues with the same substitution 
of a 1,2-dihydroquinolines (entries 9 &10, Table 9).  Analogues with the quinoline core replaced 
were also synthesized and tested.  The results showed that replacing the quinolone core with an 
indole (entries 12 and 13, Table 9), 9-acridone (entry 15 Table 9) and 4-quinolone (entry16, 
Table 9) resulted in no inhibitory activity against VirF.   
Surprisingly, it was found by the Aubé group that SE-1 and many of the tested analogues 





Fig. 18.  In vivo inhibition of SE-1 and its analogues on β-galactosidase expression from the 
virB-lacZ fusion by VirF.  Activity in the absence of SE-1was set to 100% for the reporter 
fusion.  Results are the average of three independent experiments with two replicates each.  
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decomposed during their synthesis.  In addition, it was observed that various dihydroquinoline 
analogues dissolved in DMSO at room temperature had reversed to the quinolinium precursor 
form after two days.  Further analysis of the aqueous stability of the 3,4-disubsititued 
dihydroquinoline analogues was carried out.  Analogues were dissolved in 100% DMSO first 
and then diluted to 10 µM in phosphate-buffered saline (PBS).  Analogues samples were then 
analyzed every hour through an auto-sampler by RP HPLC/UV/HRMS for a time course of 48 
hours at room temperature.  It was found that SE-1 and many analogues converted completely to 
the corresponding quinoliumium salt upon immediate dissolving in the aqueous solution (Fig. 
19).   Given that there wasn’t any detectable SE-1 in aqueous solution that had not converted to 
the quaternary salt, it was likely that the observed inhibitory effects of SE-1 and its analogues 
were caused by the quinolinium salt since the reporter assays were performed with SE-1 
dissolved in aqueous buffer solution.  To test this hypothesis, three quinolinium salts analogues 
(Table 9, entries 2–4) were tested, and the result showed that these quinolinium salts inhibited 
VirF activity to the same level as compared to their non-quinolinium salt form (Table 9, entries 2 
to SE-1, entries 3 to 5, and entries 4 to E1).  This result supported the hypothesis that the 
quinolinium salt is responsible for the observed inhibitory activity.   
Given that many synthesized analogues converted completely to the corresponding 
quinoliumium salts form in aqueous solution, we want to be certain that the observed inhibitory 
activity by the quinolinium analogues was not caused by detergent effect.  Some antibiotics, for 
instance, cetylpyridinium chloride (CPC) - a cationic quaternary ammonium salt, act as 







Fig. 19. In situ decomposition of SE-1 to quinolinium salt. From [130].   
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The nonpolar regions of CPC, which has similar characteristics to the cell membrane lipids, 
penetrate the cell membrane and thus alter the osmolality of the cell ultimately resulting cell 
death [131, 132].  Three analogues that behave similarly to CPC were synthesized and tested.  
The triethylammonium (entry 18, Table 9) analogue showed no inhibitory activity, the 
acridinium (entry 17, Table) and pyridinium (entry 18, Table 9) showed non-specific activity 
against both the VirF (8 µM and >50 µM, respectively) and control strain (15 µM and >50 µM, 
respectively), suggesting that the inhibitory activity of SE-1 and its analogues is not due to the 
detergent effect.   
Further optimization of the quinolinium core was carried out by synthesizing and testing 
various N-substituted and 3-aryl analogues.  It was found that analogues including i-propyl 
(entry 19, Table 9), n-propyl (entry 20, Table 9), n-hexyl (entry 21 Table 9) and pent-4-en-1-yl 
(entry 24, Table 9) all showed inhibitory activity similar to SE-1 with IC50 values of 12 µM, 16 
µM, 11 µM and 11 µM respectively; the exception was the methyl substitution (entry 4, Table 9) 
which exhibited a decreased inhibitory activity with a IC50 value of 90 µM.  In addition, 
analogue with 3-quinoline substituent replaced by naphthalene group (entry 23, Table 9) also 
showed similar inhibitory activity to SE-1against VirF (9 µM of IC50).  However, analogue with 
n-nonyl (entry 22, Table 9) showed increased inhibition with an IC50 value of 3 µM against VirF 
and an IC50 value of 25 µM against the control strain, which suggested that this analogue may 
have non-specifically bound to the cellular proteins and interfered with normal cell functions.  
Therefore, E. coli cell growth study was carried out to further analyze the cell toxicity of this n-




Table 9.  IC50 of synthesized analogues tested in the strain with VirF-activated lacZ fusion and a 
control strain with a synthetic promoter driving the expression of lacZ.  Results are the average 
of three independent experiments with two replicates each.  
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of both the VirF and control strains as compared to other analogues (both synthetized and 
purchased), suggesting the cell toxicity of this analogue.  
Given that the quinolinium salts are electrophilic in nature, and can accept an electron 
pair in order to bond to a nucleophile [133]. Once the quinolinium salts bonded with a 
nucleophile species forming new compounds, their chemical property may be altered.  This 
could result in losing selectivity towards the target protein (for instance, VirF or RhaS) since the 
new compound may not be able to bind to the target protein or function differently.  However, 
recent research shows that Gram negative antibiotics tend to be positively charged, and the 
charge is required for uptake of many known Gram negative antibiotics, for example the 
aminoglycosides including streptomycin and gentamicin [134, 135].  The positive charge helps 
this class of antibiotics entering the Gram negative bacteria cell, and primary inhibiting protein 
synthesis [134, 135].  Since all the analogues were initially tested in whole cell based assays, it is 
likely that some analogues without charges may not show inhibition in this assay due to lack of 
uptake into the bacterial cells.  Therefore, I have tested uncharged analogues synthesized by 
Aubé group using a cell-free assay – an in vitro DNA-binding EMSA assay using purified RhaR 
protein (Fig. 20).  This assay directly assays the inhibitory effect of each analogue on protein, 
and does not require the uptake of the analogue.  I quantified each gel using ImageJ [136], to 
determine the percentage decrease in DNA binding by RhaR in the presence of 82.5 mM final 
concentration of each analog.  Using this assay, I identified thirteen analogues showing at least 
20% inhibition of DNA-binding by RhaR (Table 10).  Some analogues showed more inhibition 
in vitro than in vivo, including analogues A1, C5, E4, A17, and A23, which suggested that 
uptake of uncharged analogues may be a reason why some analogues showed no or little 





Fig. 20.  SE-1 and its analogues inhibited DNA-binding by RhaR in vitro.  A set of 
representative EMSA gel images were shown.  Analogue concentrations were in large excess as 




Table 10  IC50 of analogues tested in the in vitro DNA-binding by RhaR, and in vivo whole cell 
assay with RhaS.  Results are the average of three independent experiments with two replicates 
each.  Analogues concentrations were between 1.1 to 2.0mM (except for E4: 0.65 mM).  Results 
were the average of three independent experiments with two replicates each.  
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the in vivo whole cell-based assays.  Analogue A21 was very similar to SE-1 in structure, but 
was uncharged and showed 2-fold less potent inhibition as compared to SE-1, suggesting that the 













RhaR is a member of the AraC family of bacterial transcription regulators, and activates 
transcription of the rhaSR operon of the E. coli L-rhamnose regulon in the presence of L-
rhamnose [10, 46, 53].  In order to better understand the properties of RhaR, and the mechanism 
of transcription activation by RhaR, we need to purify RhaR protein to perform biochemical 
assays.  Previously, untagged RhaR protein has been purified with L-rhamnose using DNA 
affinity chromatography, and the protein purified was active [53].  However, the yield of RhaR 
protein was quite low; only 0.1 mg protein was purified from 6.6 L of E. coli [53].  Our lab has 
constructed the chitin-binding domain-intein fusion protein, and the yield of RhaR protein was 
extremely low (10 µg protein was purified from 1 L of E. coli) despite that the protein was active.   
We later constructed GB1 fusion protein, and the His6-GB1
basic-RhaR was soluble and active.  
The yield of RhaR protein using this construct was relatively high (at least 1mg per 1 L E. coli).  
However, since the GB1 tag was at the N-terminus of the protein, it might interfere with the 
conformational change of the arm region in response to rhamnose and thus the fusion protein 
may not be as active as it supposed to be.  Here, I initially purified RhaR by using the chitin 
binding domain (CBD)-intein fusion.  In the process of working with that fusion protein, I 
discovered that there was an error in the annotation of rhaR.  Once the correct rhaR open reading 
frame was overexpressed, there was a dramatic increase in the overexpression and solubility of 
active RhaR protein.  For simplicity, we will refer to the native gene and protein as rhaR and 
RhaR, and the previously annotated, non-native gene and protein as +30rhaR and +30RhaR. 
Purification of RhaR using CBD-intein fusion.  RhaR protein was first expressed as the CBD-
intein-RhaR fusion protein, and loaded onto a chitin column for purification.  The chitin resin 
with CBD-intein-RhaR bound was mixed with buffer containing 100mM DTT to cleave the 
untagged RhaR (now shown to be +30RhaR) protein off the column, and untagged +30RhaR 
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protein was subsequently eluted (Fig. 21A).  Using this method, the +30RhaR protein I obtained 
was active based on its ability to bind to a DNA fragment carrying its specific DNA recognition 
sequence when assayed by EMSA in the presence of L-rhamnose (Fig. 21C).  However, the 
protein wasn’t pure as shown on the 12% SDS-PAGE that showed two bands at approximately 
the size of RhaR (Fig. 21B).  In order to determine which band was RhaR, western blots were 
performed using custom anti-RhaR antibody and a control sample of RhaR.  Surprisingly, we 
found that both of the bands reacted with the anti-RhaR antibody, (Fig. 21D), suggesting there 
might be two variants of RhaR in the purified RhaR protein (+30RhaR and RhaR).  A major 
difference between RhaR and RhaS, and indeed between RhaR and most of the other AraC 
family proteins, is that RhaR contains a 33 amino acid extension at the N-terminal end.  The 
calculated molecular mass of the extension was around 4 kDa, and the size difference between 
the two RhaR bands shown on the gel approximately matched the size of the extension.  In 
addition, earlier in our lab, we constructed and assayed various N-terminal deletions within this 
extension region, and found that RhaR ∆29 and ∆34 (deleting most or all of the extension region) 
migrated to the same position on SDS-PAGE as wild-type RhaR; only the RhaR ∆40 ran at a 
smaller size as compared to the wild-type RhaR in western blot (Fig. 22).  This result, combined 
with the western blot of the purified RhaR protein suggested that the wild-type RhaR may not 
include the extension.  Therefore, we hypothesized that the bottom band of RhaR might be a 
natural cleavage product of RhaR, likely removing residues from the N-terminal end.  The purity 





Fig. 21.  (A) Schematic showing the procedures of RhaR CBD-intein fusion purification.  (B) 12% 
SDS-PAGE gel showing purified RhaR protein with two sizes.  M, molecular mass marker; U, 
uninduced sample; S, supernatant; B, beads after DTT cleavage; E, concentrated protein elution.  
(C) The EMSA gel showing the DNA-binding by purified RhaR with L-rhamnose (+rha).  (D) 
Western Blot of purified RhaR protein.  E, concentrated RhaR protein elution; M, molecular 




Fig. 22. Western blot showing the protein levels and relative sizes of RhaR N-terminal deletion 
variants.  The culture samples were grown in the presence and absence of L-rhamnose [(+)rha 
and (-)rha, respectively].  Equivalent cell densities (based on OD600) of the culture samples were 
loaded in all of the lanes.  All RhaR N-terminal deletion variants were expressed from pHG165.  
Molecular mass marker (M) is in the last lane.   
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Purification of RhaR using His6 tagged fusion.  Because of the complications with the CBD-
intein-RhaR fusion, I attempted to purify RhaR using a different construct which was the C-
terminal His6-tagged RhaR fusion.  Since we hypothesized that there might be a cleavage near 
the N-terminal end of RhaR, we expected that we might be able to enrich for the smaller sized 
RhaR by using a C-terminally tagged fusion protein.  Using this construct, I was able to purify 
the RhaR protein (now shown to be +30RhaR), however, two different sized RhaR proteins 
(+30RhaR and RhaR) were also purified from this construct, as observed from the 12% SDS-
PAGE gel and western blot (Fig. 23A & B).  The purified protein was active, based on the 
evidence that it bound to the DNA in an EMSA, as shown in Fig. 23C.  In order to determine 
which form of the RhaR protein was active, I performed the DNA binding assay in EMSA by 
using protein from elution fraction 28 (F28) which is enriched for the larger sized RhaR 
(+30RhaR), and fraction 33 (F33) which is enriched for the smaller sized RhaR (RhaR) (Fig. 
23D). There was much more active RhaR protein in fraction F33 than in F28, suggesting that the 
smaller sized RhaR (RhaR) was the active form.  Additional support for this hypothesis that the 
smaller sized RhaR (RhaR) is the active form came from the first purified RhaR (RhaR) using 
DNA affinity purification as reported by Tobin and Schleif [53].  This purification was expected 
to purify only active protein, since it required that the protein bind to the DNA that had been 
linked to the resin.  The size of the active RhaR (RhaR) purified by Tobin and Schleif [53] was 
roughly the same size as the smaller sized RhaR (RhaR) (Fig. 24).  These results support the 





Fig. 23.  (A) 12%SDS-PAGE gel showing purified RhaR-His6 protein with two different sizes.  
Molecular mass marker (M) is in lane 1; lane 2 to 6 are elution fractions from 28 to 33.  Two 
bands that both react with anti-RhaR antibodies (part B) are indicated by arrows.  (B) Western 
blot showing the two bands in the partially purified RhaR-His6 that react with anti-RhaR 
antibodies. Molecular mass marker (M) is in lane 1; lane 2 to 6 are elution fractions from 28 to 
33.  (C) DNA-binding by purified RhaR-His6 protein fractions from 28 to 33 with L-rhamnose 
[(+)Rha] in EMSA.  (D)  EMSA showing DNA-binding activity of purified RhaR-His6 fraction 
28 (F28) enriched for larger sized RhaR, fraction 33 (F33) enriched for smaller sized RhaR and 
their dilutions in the presence of L-rhamnose [(+) rha].  Black triangles represent decreasing 




Fig. 24.  12% SDA-PAGE gel of purified RhaR.  The arrow indicates the location of RhaR 
protein.  M, molecular mass marker. From Tobin & Schleif (1990) [53]  
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Protein peptide mapping and N-terminal protein sequencing.  In order to test the hypothesis 
that the smaller and larger sized RhaR proteins (RhaR and +30RhaR) differed at their the N-
terminal ends, samples of the protein purified from the His6 RhaR fusion (RhaR and +30RhaR) 
were sent to the Mass Spectrometry and Analytical Proteomics Laboratory at the University of 
Kansas, where they performed protein in-gel digestion and analyzed the resulting peptides by 
mass spectrometer.  Several of the same RhaR peptides were not detected from both the longer 
and shorter bands, suggesting that these did not correspond to the difference between the 
proteins.  The only difference in the peptide maps was near the N-terminus, where the larger 
band included peptides corresponding to the previously annotated RhaR sequence minus only the 
N-terminal methionine (predicted 312 residues) (+30RhaR), while the smaller protein had no 
peptide coverage for the first 36 residues of the previously annotated RhaR sequence (RhaR, Fig. 
25).  This result supported the hypothesis that the difference between the two proteins was at the 
N-terminus.  To determine the precise N-terminal end of the smaller sized RhaR, it was sent for 
N-terminal sequencing by Edman degradation to the protein facility at Iowa State University.  
The result indicated that the smaller protein was missing the first 31 amino acids relative to the 
prior annotation, with the sequence Ala-His-Gln-Leu-Lys at the N-terminus (predicted 282 
residues).  This allowed us to identify the N-terminus of the RhaR that our assays indicated was 
the active form of RhaR.   
Identification of RhaR annotation error.  Examination of the sequence of the rhaR open 




25.  Peptide coverage of two different RhaR protein products determined by LC-MS/MS.  
Top, peptide sequence coverage of the larger sized RhaR protein.  Bottom, peptide sequence 
coverage of the smaller sized RhaR. Peptides detected by LC-MS/MS are highlighted in yellow.  
The N-terminal sequence of the smaller protein, determined by Edman degradation, is shown in 
red.    
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was GTG, which is used as a start codon in 14% of E. coli genes [137]. Additionally, a potential 
Shine-Dalgarno (SD) sequence (GAGG) was identified 8 bp upstream of the putative GTG start 
codon (Fig. 26).  Taken together with the finding that the smaller, 282-residue RhaR protein was 
more active in DNA binding, these results suggested that the true rhaR translational start codon 
might be GTG, and that the first methionine was removed after translation in vivo.  This was 
consistent with the sequence obtained by Edman degradation, and would produce a protein with 
281 residues and a molecular mass of 32 kDa.  These results also suggested that the 282-residue 
RhaR protein may not be a product of cleavage, but rather was the product of a start codon that 
was different from the original annotation.   
Additional support for the hypothesis that RhaR (282-residue) represented the native 
RhaR protein came from analysis of plasmids designed for in vivo RhaR transcription activation 
assays (rather than high-level overexpression).  In contrast to pET24b (and other “pET” vectors), 
which provide an optimally positioned, strong SD signal, plasmids for in vivo RhaR expression 
(on the pHG165 vector) relied on the SD sequence provided by the rhaR region.  Despite the 
presence of the upstream (originally annotated) ATG start codon and associated putative SD 
sequence, we found that pHG165-based +30rhaR clones expressed a protein the size of native 
RhaR (~282 residues), consistent with translation beginning at the downstream GTG codon (Fig. 
21D and Fig. 22).  Thus, it appears that the putative upstream SD sequence (positioned near the 
+30rhaR ATG start codon) directed little or no translation, as determined by little or no detection 
of +30RhaR protein by Western blot. However, upon correctly positioning the strong pET24b 




Fig. 26.  Portions of the rhaR open reading frames with upstream SD sequences.  The previously 
annotated SD sequence of RhaR (312 residues) is underlined in blue, and the corresponding 
protein sequence is also in blue. The upstream SD sequence for the true RhaR (282 residues) is 
underlined in red, and related protein sequence is also shown in red.  
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at the non-native, upstream, in-frame, ATG start codon.  RhaR expressed from pHG165 
activated transcription to a level that was six-fold higher than the activation by RhaR expressed 
from the native chromosomal locus, consistent with the modest overexpression of RhaR from 
pHG165, and suggesting that RhaR expressed from pHG165 was fully functional [10, 57].  
Importantly, these findings indicate that RhaR expressed from pHG165 was the native RhaR 
sequence, regardless of whether +30rhaR or rhaR was cloned.  Thus, in vivo experiments 
reported by our lab and the Schleif lab prior to this publication erred only in the numbering of 
RhaR residue positions, with an extra 30 residues at the N-terminus of RhaR relative to the 
native protein sequence.   
As an additional test of the hypothesis that the downstream GTG codon served as the 
native RhaR start codon, I have constructed a pHG165-based clone to express rhaR from the 
GTG start codon and corresponding SD sequence (pSE312).  A construct with one additional 
nucleotide introduced immediately after the ATG start codon was also made.  In this construct, 
the expression of +30rhaR, if any, from the upstream ATG will be out of frame (pSE313).  
However, if translation starts at the GTG codon, the amount of active RhaR protein expressed, 
and transcription activation by RhaR will not be effected.  A clone with the previously annotated 
start codon and its associated SD sequence (pSE302) was also included in this experiment.  The 
results showed that in vivo RhaR transcriptional activation activities, protein levels, and protein 
size were indistinguishable from the three plasmids (pSE302, pSE312, pSE313) (Fig.27).  These 
results support the hypothesis that RhaR translation initiates at the GTG codon, not the ATG 
codon, and that the previously annotated RhaR protein sequence had 30 extra amino acids at its 




Fig. 27.  (A) β-Galactosidase activity was assayed from a single-copy Φ(rhaS-lacZ)Δ85 fusion in 
a strain with Δ(rhaSR)::kan recA::cat and RhaR proteins were expressed from a plasmid 
pHG165.  Cultures were grown with or without L-rhamnose.  pSE302 contained the previously 
annotated ATG start codon and associated SD sequence; pSE312 contained the GTG start codon 
and corresponding SD; pSE313 contained an extra nucleotide after the upstream ATG start 
codon.  (B) Western blots showing the protein levels and sizes of RhaR protein expressed from 
each of the three plasmids.  The culture samples in all of the lanes were loaded at equivalent cell 
densities (based on OD600).  DnaK was used as a loading control.  Molecular mass marker is in 
the first lane.   
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Purification of His6 tagged RhaR having the newly identified start codon.  I constructed a 
new RhaR overexpression clone in pET24b (pSE308) to express the true RhaR protein sequence.  
This plasmid expressed a much larger amount of soluble RhaR protein, and only a single band 
corresponding to RhaR was detected by SDS-PAGE.  After purification of the protein by Ni+2-
affinity and size exclusion chromatography, we obtained roughly 10 mg of soluble RhaR protein 
per liter of E.coli cells grown in the absence of rhamnose, and the RhaR protein was at least 95% 
pure. No peak at the expected mass of RhaR monomer was detected, suggesting that the protein 
was in the form of a dimer. The protein was also active, as measured by its binding to the RhaR 
binding site DNA in an EMSA (Fig. 28).   
RhaR was slightly more stable and soluble when the overexpressing cells were grown 
and the protein was purified in the presence of rhamnose.  However, RhaR protein from cells 
grown in the absence of rhamnose and also purified in the absence of rhamnose was sufficiently 
stable and soluble for the purposes of this study, and allowed direct comparison of activity in the 




Fig. 28.  (A) 12%SDS-PAGE gel showing purified RhaR-His6 protein eluted from size 
exclusion chromatography.  Molecular mass marker (M) is in the first line.  (B) DNA-binding by 
purified RhaR-His6 with L-rhamnose [(+)Rha] in EMSA.  (C)  Size exclusion chromatography of 
RhaR-His6.  Y-axis: UV absorbance at 280 nm and X-axis shows elution volume.  The peak at 
38.79 ml retention represents aggregation.  The next peak at 66.34 ml retention eluted at the size 
of ~64 kDa, peaks at 106.22 ml and 128.8 ml retention eluted at the size of ~12 kDa and 0.12 








Structure of the Regulatory Domain of RhaR with and without  




Despite the large size and ubiquity of the AraC family, only a relatively few members 
have been well characterized, largely due to the tendency of family members to exhibit low 
protein solubility and difficulties in purification and crystallization.  Thus, available high 
resolution structures of AraC family proteins are limited in number.  Among the subset of AraC-
family proteins that share sequence similarity with the RhaR regulatory domain, available 
structures include: the NTD of AraC, the transcriptional activator of the E. coli arabinose regulon 
[33, 34]; the NTD of ExsA, a transcriptional activator of type three secretion system genes in P. 
aeruginosa [58, 129]; and the NTD from the structure of full-length ToxT, which regulates the 
expression of cholera toxin and other virulence factors of V. cholerae [22, 23, 38].  In order to 
identify the mechanism allosteric signaling by RhaR, and to provide structural information, I 
have purified RhaR-NTD-His6 protein, set up crystallization screens, optimized crystallization 
condition, and solved the structure of RhaR-NTD both with and without bound rhamnose.   
Purification and crystallization of RhaR-NTD-His6.  The protein was overexpressed as a C-
terminal His6 tagged fusion protein from pET24b vector in E.coli BL21 (DE3) cells grown in the 
absence of rhamnose for initial crystallization screening.  A two-step protocol was used to purify 
RhaR-NTD-His6 protein.  First, the protein was purified via Ni
2+-affinity chromatography, and 
the elution fractions showed that the protein was at least 90% pure.  Elution fractions containing 
RhaR-NTD-His6 were pooled and then further purified through size exclusion chromatography 
(SEC).  After the SEC, the RhaR-NTD-His6 protein was at least 95% pure (Fig 29).  The protein 
elution fractions from the SEC were combined and concentrated to ~6 mg/ml for crystallization 





Fig. 29.  12% SDS-PAGE gel stained with coomassie blue showing purified RhaR-NTD-His6 
protein eluted from size exclusion chromatography.  Molecular mass marker (M) is in the first 
lane.    
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 Crystallization trials were carried out using commercially available crystallization kits 
Wizard I and II (Rigaku, Bainbridge Island, WA) in 96 well MarC 2 Well crystallization plates 
(Hampton research, Aliso Viejo, CA).  For each condition, two sitting drops were set up; one 
drop with 0.2% L-rhamnose added to the protein, and the other with no added L-rhamnose.  
Among all 96 conditions tested, two conditions from the Wizard II kit produced RhaR-NTD-His6 
crystals without L- rhamnose.  No RhaR-NTD-His6 crystals were found in the presence of L-
rhamnose. Of the two conditions that resulted in formation of crystals, condition 28 contained 
20% (w/v) polyethylene glycol (PEG)-8000, 100 mM MES pH 6.0, and 200 mM Ca(OAc)2, and 
the other, condition 48, contained 1 M K/Na tartrate and 100 mM MES pH6.0.  Crystals from 
both conditions were small; therefore crystallization condition optimization was required to 
obtain larger crystals.    
 For each of the two conditions that resulted in crystal formation, condition optimization 
was performed.  Various length oligomers of PEG (PEG-8000, PEG3350), several 
concentrations of PEG (from 6% to 20%), Ca(OAc)2 (50 mM, 100mM, and 200 mM) and pH of 
MES (pH 5.5, 6.0, 6.5, 7.0) were tested in hanging drops using 24-well VDX plate (Hampton 
research, Aliso Viejo, CA).  Wells with 6%-10% PEG-3350, 100 mM MES pH 6.0, 200 mM 
KCl, 50 mM Ca(OAc)2, produced the largest crystals.  Surprisingly, solutions in which the 
concentration of K/Na tartrate and the pH of MES were varied did not yield any crystals, and 
even repeating the original condition did not produce any crystal.  It is unclear why obtaining 
crystals from condition 48 cannot be repeated.  The large crystals were then picked, transferred 
to cryo-protectant, flash frozen with liquid nitrogen, and then sent to the Advanced Photon 
Source (APS) at Argonne National Laboratory (Argonne, IL) for X-ray diffraction.  Crystal 
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diffraction data was collected and analyzed.  One of the crystal diffracted to 2 Å, however, due to 
the phase problem, structure solving was not successful. 
 In order to solve the structure of RhaR-NTD-His6 and the phase problem, seleno-
methionine incorporated protein was need.  Two protocols were used to overexpress seleno-
methionine labelled RhaR-NTD-His6.  One method utilized the feedback inhibition of 
methionine biosynthesis by adding an amino acid mix including lysine, threonine, phenylalanine, 
leucine, isoleucine, and valine prior to induction.  The advantage of this method is that the 
overexpression can be carried out in the standard BL21(DE3) strain. In order to confirm seleno-
methionine had been successfully incorporated into purified protein from cells grown using this 
method, the putative seleno-methionine-labeled purified protein sample as well as the native 
(unlabeled) protein were sent to the Mass Spectrometry and Analytical Proteomics Laboratory at 
the University of Kansas to measure the molecular mass of each sample of protein (Fig. 30).  The 
analysis showed that the molecular mass of the putative seleno-methionine-labeled RhaR-NTD-
His6 protein sample was 21,269 Da, which matched with the molecular mass of the native 
protein.  This result indicated that the protein was not labeled with seleno-methionine.  
 The second method of seleno-methionine incorporation used a protocol from New 
England Biolabs (Ipswich, MA), with modifications.  The RhaR-NTD protein was overexpressed 
in E.coli B834 cells (Novogen), a strain that is a methionine auxotroph.  The cells were grown in 
minimal medium with regular L-methionine until the cell density reached 0.6, then pelleted and 
re-suspended in a minimal medium without any methionine.  The cell culture was incubated for 
an additional 3 hours to deplete any residual methionine, and then seleno-methionine was added 




Fig. 30.  The molecular mass profile of RhaR-NTD protein (A) RhaR-NTD-His6 protein was 
overexpressed using feedback inhibition of methionine biosynthesis in an effort to incorporate 
seleno-methionine.  The most intense peak was at 21,269 Da, a mass that was identical to the 
unlabeled protein.  (B) Native RhaR-NTD-His6 without any seleno-methionine labeling.  The 
most intense peak was at 21,269 Da.   
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protein with a molecular mass of 21,457 Da, as measured by mass spectrometry (Fig. 31).  
RhaR-NTD-His6 protein contains four methionines, and if all four methionines were replaced by 
seleno-methionine, the molecular mass of the protein would be 21,457 Da, which precisely 
matched the mass of the purified protein, indicating that the seleno-methionine incorporation was 
successful.   
The seleno-methionine labeled RhaR-NTD protein was concentrated to ~5 mg/ml, and 
used for crystallization.  Crystals were obtained using the same conditions described above to 
obtain larger crystals, and were then soaked with L-rhamnose, transferred to cryoprotectant and 
sent to the Stanford Synchrotron Radiation Lightsource (SSRL) for X-ray diffraction.   
Structure of RhaR-NTD-His6 in complex with L-rhamonse.  We have solved the crystal 
structure of the RhaR-NTD-His6 in complex with L-rhamnose to 2.05 Å resolution (Fig. 32 and 
Table 11).  The structure contained two protomers of RhaR-NTD in the asymmetric unit, with 
residues 6 to 165 in protomer A and residues 5 to 165 in protomer B of the dimer. The C-
terminal His6 and the flexible linker region between RhaR-NTD and His6 tag were not visible, 
and protein residue numbers given here were numbering of RhaR-NTD only.  The binding 
pockets in both protomers were fully occupied with L-rhamnose.  The N- and C-terminal 
residues of the overexpression clone were not visible (residues 2-5 or 2-4 in protomers A and B, 
respectively, and 166-172 in both protomers), likely indicated that those regions were disordered.  
Each protomer of RhaR-NTD in the asymmetric unit was comprised of eight antiparallel β-
strands (β1 to β8), four -helices (1 to ), and a З10 helix.  The β-strands formed a cupin-
superfamily β-barrel [138] containing the L-rhamnose-binding pocket.  The pocket was enclosed 
by residues L7, F12, A23, R25, Q28, F31, H34, H36, F38, E40, H74, Y76, N86, and I88 (Fig. 





Fig. 31.  The molecular mass profile of RhaR-NTD.  Protein was overexpressed using a 
protocol modified form New England Biolabs (Ipswich, MA) to incorporate seleno-methionine.  




Fig. 32.  The structure of RhaR-NTD dimer in complex with L-rhamnose.  Protomer A is in 
magenta, protomer B is in cyan, L-rhamnose is in red stick, metal ion is in green sphere.  The N- 
and C-termini, as well as secondary-structure elements are indicated.  The arm region of each 
promotmer is colored blue.  Protein structure figure was generated by UCSF Chimera package 
[140].   
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Table 11   Data collection and refinement statistics for RhaR NTD structure  
Beamline SSRL 12-2 














RMSD, Bond lengths/Å  0.008 
RMSD, Bond angles/ 1.15 
Overall B value (Å2) 38.06 
















molecule of L-rhamnose and one metal ion in each protomer.  The metal ion was coordinated by 
residues H34, H36, E40, and H74 as well as two of the hydroxyl groups (-OH) of L-rhamnose.   
A search for proteins with related structures (DALI [141]) identified the various AraC-
NTD structures as the top hits, with PDB:1XJA as the best match among AraC-NTD structures 
(z=14, rmsd=2.5, 15% sequence identity).  The structure of ExsA-NTD and ToxT were the 
second and third best AraC family protein hits (PDB: 4ZUA, z=10.4, rmsd=2.9, 10% sequence 
identity; and PDB:3GBG, z=7.7, rmsd=4.0, 7% sequence identity, respectively).  The remaining 
structures related to RhaR-NTD were predominantly cupin β-barrel containing enzymes and seed 
storage proteins, including the bacilysin biosynthetic enzyme BacB structure (PDB: 3H7J), 
which was more closely related to the RhaR-NTD structure than ToxT.   
Despite low sequence similarity, the overall fold of RhaR-NTD closely resembled those 
of the regulatory domains of AraC [33], ExsA [58], and ToxT [38], which all share a cupin-
superfamily β-barrel.  Overlays of the RhaR-NTD with the regulatory domains of AraC, ExsA, 
and ToxT are shown in Fig. 34.  Structural alignments of the RhaR-NTD with AraC-NTD (PDB: 
2ARC) and ExsA-NTD (PDB: 4ZUA) produces an r.m.s.d. of  2.6 Å and 2.9 Å (DALI [141]) 
respectively, with only 18% sequence identity. Superimposing RhaR-NTD with ToxT-NTD 
(PDB: 3GBG) produces an r.m.s.d of 3.4 Å (DALI [141]) with only 11% identical residues.  The 
RhaR-NTD has one less β-strand than AraC, ExsA, and ToxT; the sequence that aligns with β2 
in AraC, ExsA, and ToxT is an unstructured loop in the RhaR-NTD structure.  The β-barrel 
structure of RhaR-NTD is aligned most closely with the AraC-NTD, with an r.m.s.d. of 1.84 Å 
(DALI [141]). The structural alignment of the ExsA and ToxT β-barrels, compared to the RhaR-
NTD, produce an r.m.s.d. of 2.01 Å and 2.37 Å (DALI [141]), respectively. Overall, the RhaR-




Fig. 33.  RhaR L-rhamnose-binding site in detail.  (A) Zoomed in view of the L-rhamnose 
binding pocket.  L-rhamnose is in in gray stick, the metal ion is in green sphere.  Residues 
enclose the rhamnose binding pocket are indicated.  Protein structure figure was generated by 
UCSF Chimera package [140]. (B) A two-dimensional diagram showing interactions between 
RhaR-NTD and L-rhamnose as calculated by LIGPLOT[142].  Hydrogen bonds and distances 
are indicated in green and hydrophobic interactions are represented by an arc with spokes 




Fig. 34.  RhaR-NTD overlays with AraC-NTD, ToxT-NTD, ExsA-NTD. RhaR-NTD is in 
cyan. (A)  RhaR-NTD (light blue) superimposed with AraC-NTD.  AraC-NTD: pink. (B)  RhaR-
NTD overlaid with ToxT-NTD.  ToxT-NTD: blue. (C)  RhaR-NTD structurally aligned with 
ExsA-NTD.  ExsA-NTD: Green. Protein structure figure was generated by UCSF Chimera 
package [140].   
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structure does.  Our results below suggest a biological rationale for the reduced structure in the 
region that aligns structurally with β2 in the other structures.  Despite that the RhaR-NTD has 1 
more helix than ExsA and 2 more than AraC; however, the helical contents of the RhaR-NTD 
aligns closely with those of the AraC-NTD and ExsA-NTD with an r.m.s.d. of 1.67 Å and 1.68 Å 
(DALI [141]), respectively.  This structural similarity is mostly due to the similarity of α3 and α4 
in RhaR-NTD to α2 and α3 in ExsA-NTD and in AraC-NTD.  However, the overlay of the 
RhaR-NTD helices and ToxT-NTD helices gave a relatively large r.m.s.d. of 2.68 Å (DALI 
[141]), which is mostly because ToxT only contain one analogous helix α3 with RhaR-NTD. 
The N-terminal 20 residues of AraC, prior to the first β-strand, are referred to as the arm.  
The AraC arm contains no secondary structure, however, conformational changes in this region 
are key to the mechanism that regulates AraC protein activity in response to arabinose [27, 29-
31, 33, 143, 144].  The N-terminal arm of RhaR in our structure, as defined by residues before 
the first β-strand, consists of residues L5-A19.  In contrast to the absence of secondary structure 
in the AraC arm, RhaR residues K9 to F12 formed a short α-helix (Fig. 35).   
RhaR-NTD dimerization.  In the presence of rhamnose, RhaR-NTD-His6 crystallized with a 
dimer in the asymmetric unit.  Similar to AraC and ExsA, the two protomers of RhaR-NTD in 
the crystals were in an antiparallel conformation, with an interface area of 890 Å2.  At each end 
of the dimerization interface, residues E136 and R161 (from helices α3 and α4, respectively) 
formed two hydrogen bonds, a salt bridge and multiple non-bonded interactions with each other 
(Fig. 36A).  R161 from chain A also forms two hydrogen bonds with P142 from chain B, and 
R161 from both chains forms multiple additional non-bonded interactions.  Near the center of the 




Fig. 35.  Zoomed in view of the RhaR-NTD arm region (residues L5 to A19).  The α helix region 
(residues K9 to F12) was highlighted in yellow. Protein structure figure was generated by UCSF 
Chimera package [140].   
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each to Q132 and Q154 from protomer A.  Residues Q132, E136, Q154 and R161 are each 
≥95% identical among RhaR protein sequences, consistent with the importance of these residues 
in RhaR dimerization.  In AraC, the dimerization interface is anchored at the ends by a triad of 
leucine residues, providing stability [33].  Although leucine triads aren’t found in RhaR-NTD, 
nine additional residues in chain A and eleven additional residues in chain B are predicted to 
participate in non-bonded interactions, contributing to dimerization strength.   A detailed 
schematic illustrating the interactions between the protomers is shown in Fig. 37. 
In addition to the contacts between residues in α3 and α4, residues K95, L96, N97 and 
L98 in the loop between α2 and the З10 helix from each protomer are positioned to make contacts 
that likely provide additional dimer stability (Fig. 36B); in AraC, residues R101 and Y103 in the 
analogous region are positioned to make similar interactions [33].  In RhaR-NTD, N97 in each 
chain can form two hydrogen bonds with N97 and one hydrogen bond with K95 in the opposite 
chain.  Further, the residues in these positions are identical (L96 and N97) or conserved as 
positively charged (K95) or hydrophobic (L98) in ≥89% of RhaR protein sequences.   
L-rhamnose binding pocket.  Each protomer of RhaR-NTD contained a molecule of L-
rhamnose and a metal ion within the open end of a small pocket formed by the cupin fold (Fig. 
30).  This rhamnose binding pocket is much smaller in volume (230.8 Å3 [139]) than the sugar 
binding pocket of AraC (401.8 Å3 [139]) or the fatty acid binding pocket of ToxT (789.9 Å3 
[139]), and there are no water molecules found within the RhaR-NTD pocket.  In AraC, an 
extensive network of bound water molecules in the arabinose-binding pocket mediates hydrogen 
bonding between the arabinose and AraC [33].  In RhaR, residues R25, Q28, and N86 are 
positioned to directly interact with rhamnose through hydrogen or electrostatic bonding; and F31 




Fig. 36.  (A) Hydrogen-bond (H-bond) interactions at the RhaR-NTD dimerization interface 
between protomer A and B. (B) H-bond interactions at the loop connecting α2 and the З10 helix 
between protomer A and B.  Protomer A is in magenta and protomer B is in cyan.  Helices 
α2,α3,α4, and 310 are labeled.  Residues involved in making H-bond interactions at the interface 
are indicated in the same color as each of the protomer backbone.  H-bonds are highlighted in 




Fig. 37.  Schematic diagram of interactions between RhaR protomers.  Residues are colored 
by their type.  Positively charged residues (His, Lys, Arg) are blue; negatively charged residues 
(Asp, Glu) are red; neutral residues (Ser, Thr, Asn, Gln) are green;  aliphatic residues (Ala, Val, 
Leu, Ile, Met) are grey; aromatic residues (Phe, Tyr, Trp) are purple; proline and glycine residues 
are orange.  Interactions are indicated by lines between residues.  The number of H-bond lines 
between any two residues indicates the number of potential hydrogen bonds between them.  For 
non-bonded contacts, the width of the striped line is proportional to the number of the atomic 
interactions.  Diagram generated by PDBsum [145-148].  
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substitutions at positions R25, Q28, and N86, and found that transcription activation by these 
variants were down by 25 to 30% in the presence of rhamnose [(+)rha] compared to wild-type 
RhaR (Fig. 38A), supporting the hypothesis that these residues contribute to the strength of 
rhamnose binding.  We would not have predicted that in the absence of rhamnose [(-)rha], Q28A 
and N86A both would showed slightly increased activity, and R25A would have approximately 
2-fold increased activity relative to wild-type RhaR.  An F31A variant of RhaR-NTD was also 
constructed.  Transcription activation by this variant was approximately the same as wild type 
(+)rha, however, the variant exhibited a 2.5-fold increase in activity (-)rha compared to wild type 
(Fig. 38A).  The wild-type activity of the F31A variant (+)rha suggests that rhamnose stacking 
with the aromatic ring of F31 does not contribute as much to rhamnose binding in RhaR as the 
stacking between arabinose and the aromatic ring of W95 in AraC [33, 149]. The finding that 
both R25A and F31A had 2- to 2.5-fold increased activity (-)rha compared with wild type 
suggests that these residues play roles in the (-)rha conformation, possibly by helping to maintain 
a (-)rha conformation that has reduced activity relative to the (+)rha conformation.  Lowden et al 
have proposed that interactions (bridged by the fatty acid effector) between ToxT residues K31 
within the effector binding pocket and K230 in the DBD function to hold ToxT in its non-
activating (reduced activity) conformation [38].  This suggests the hypothesis that one or both of 
RhaR R25 and F31 may contact RhaR DBD in the absence of rhamnose to hold RhaR in its 
lower activity (-)rha conformation.  Results below provide evidence that a region including these 
residues undergoes a rhamnose-dependent conformational change, consistent with this 
hypothesis.   
Interestingly, the bound rhamnose also interacts with a metal ion that is positioned deep 




Fig. 38.  (A) Transcription activation by RhaR variants.  Plasmids expressing wild-type RhaR or 
variants were transformed into strain SME2525 [Ф(rhaS-lacZ)∆128 ΔrhaSR::kan recA::cat], the 
cells were grown with or without L-rhamnose, as indicated, and β-galactosidase activity was 
measured in Miller units. (B) Western blots showing the protein levels of the RhaR variants. The 
culture samples in all of the lanes were loaded at equivalent cell densities (based on OD600).
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binding.  The metal ion is located in the center of the cupin barrel of each domain.  The metal ion 
is coordinated by four residues: H34 and H36, which are on a loop connecting β1 and β2; E40 on 
β2; and H74 on β6.  These four residues are all highly conserved among proteins in the cupin 
superfamily of proteins, function to coordinate metal ions [150].  These residues are 100% 
conserved among RhaR protein sequences, suggesting that metal binding are conserved among 
RhaR proteins.  The total coordination number of the metal ion is six: the three His residues each 
coordinate via their NE2 atoms, the Glu residue via OE2, and rhamnose via O3 and O4. The 
metal ion-ligand distances are between 1.99 and 2.27 Å (Fig.39).   
To further examine the role of the His residues within the sugar-binding pocket, we 
constructed individual alanine substitutions at H34 and H74. In both of these variants, 
transcription activation was substantially decreased both in the presence [(+)rha] and the absence 
of rhamnose [(-)rha] as compared to the wild type, and both of these variants showed no 
increasein activation (+)rha relative to (-)rha (Fig. 38A).  Western blot data (Fig. 38B) showed 
that the protein levels of H34A and H74A were decreased by 75% and 60%, respectively, 
relative to wild-type RhaR both (-) and (+)rha, suggesting a decrease in protein stability.  It is 
likely that the instability of the H34A and H74A variants was at least largely the result of the loss 
of metal binding; however, conformational changes in the binding pocket due to the alanine 
substitutions may also contribute.   
Structure of rhamnose-free RhaR-NTD-His6.  In order to obtain rhamnose-free RhaR-NTD 
crystals, RhaR-NTD-His6 protein was over-expressed in a M9 salt minimal media [151], purified, 
and crystallized without addition of rhamnose.  Two structures of the rhamnose-free RhaR-NTD 




Fig. 39.  Metal ion coordination in detail. The protein ligands are His34, H36, H74, and E40.  A 
L-rhamnose molecule completes the coordination sphere.  The metal ion is drawn in green sphere, 
and the metal ion-ligand distances are indicated.  Protein structure figure and analysis were 
performed with UCSF Chimera package [140].   
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molecule within the sugar binding pocket of each protomer (RhaR-NTD-EG) (Fig. 40A, Table 
12).  The other structure was diffracted to 1.9 Å resolution, and a glycerol molecule was found 
within the sugar binding pocket of each protomer (RhaR-NTD-GLY) (Fig. 40B, Table 12).  
Overall, the two rhamnose-free RhaR-NTD structures are nearly identical with an RMSD of 0.33 
Å between Cα atoms following superposition of the dimers with GESAMT (General Efficient 
Structural Alignment of Macromolecular Targets) [152].  
A metal ion was also present within the sugar-binding pocket in each protomer.  Given 
that the crystallization solution contains 50 mM Ca(OAc)2, RhaR-NTD could acquire the Ca
2+ 
from the crystallization solution since it was most abundant.  However, refinement of the RhaR-
NTD structure with Ca2+ ion resulted in a large amount of residual positive electron density 
around the ion, which suggested that a larger metal was bound within the sugar-binding pocket.  
Furthermore, the metal ion-ligand distant was approximately 2.0 Å to 2.1 Å, which was much 
shorter than the expected distance of ~2.4 Å for a Ca2+ ion [153].  The phased anomalous 
difference map calculated using data collected at a wavelength of 1.0000 Å yielded peaks with 
heights 38σ and 30σ at the rhamnose-bind pocket in protomers A and B, respectively.  This 
indicated that a larger ion (for instance, Zn2+) that would give a strong anomalous signal at 
λ=1.0000 Å occupied these sites.  However, an X-ray fluorescence scan of the RhaR-NTD 
crystals revealed that Ni2+ ions were present (Fig. 41A).  An additional X-ray fluorescence scan 
was carried out to determine whether Zn2+ could also be present.  However, no zinc signal was 
detected (Figure 41B).  Additional X-ray diffraction data were collect for RhaR-NTD at 
wavelengths of 1.4848 Å (8,350 eV) and 1.4938 Å (8,300 eV) which corresponded to the 




Fig. 40.  Structures of rhamnose-free RhaR-NTD-EG and RhaR-GLY.  (A) 1.73 Å RhaR-
NTD-EG structure.  Ethylene glycol molecules are in sticks, Ni2+ ions are in dark blue sphere.  
(B) 1.90 Å RhaR-NTD-GLY structure.  Glycerol molecules are in sticks, Ni2+ ions are in light 




Table 12.  Crystallographic data for apo RhaR-NTD. 
 RhaR-NTD-EG RhaR-NTD-GLY 
Data Collection   
Unit-cell parameters (Å, o) a=b=101.82, c=96.14  a=b=101.64, c=96.84  
Space group P43212 P43212 
Resolution (Å)1 48.07-1.73 (1.76-1.73) 48.42-1.90 (1.94-1.90) 
Wavelength (Å) 1.0000 1.0000 
Temperature (K) 100 100 
Observed reflections 703,229 529,996 
Unique reflections 53,302 40,601 
<I/(I)>1 19.3 (1.7) 19.4 (1.8) 
Completeness (%)1 100 (100) 100 (100) 
Multiplicity1 13.2 (13.6) 13.1 (13.1) 
Rmerge (%)
1, 2 7.6 (177.9) 8.1 (164.4) 
Rmeas (%)
1, 4 7.9 (184.9) 8.4 (170.9) 
Rpim (%)
1, 4 2.2 (50.0) 2.3 (47.0) 
CC1/2 
1, 5 0.999 (0.634) 0.999 (0.669) 
Refinement   
Resolution (Å) 1 36.00-1.73 35.94-1.90 
Reflections (working/test)1 50,538/2,687 38,573/1,956 
Rfactor / Rfree (%)
1,3 17.5/20.0 17.9/20.1 
No. of atoms (Protein/ 
Ni2+/Ethylene glycol or 
glycerol/Water) 
2,500/2/12/188 2,527/2/18/144 
Model Quality   
R.m.s deviations    
Bond lengths (Å) 0.010 0.011 
Bond angles (o) 0.974 1.011 
Average B-factor (Å2)   
All Atoms 40.1 49.6 
Protein 39.7 49.4 
Ni2+ 32.2 38.5 
Ethylene glycol or glycerol 42.3 60.8 




Ramachandran Plot    
Most favored (%) 98.4 97.4 
Additionally allowed (%) 1.6 2.3 
1) Values in parenthesis are for the highest resolution shell. 
2) Rmerge = hkli |Ii(hkl) - <I(hkl)>| / hkli Ii(hkl), where Ii(hkl) is the intensity 
measured for the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl.  
3) Rfactor = hkl ||Fobs (hkl) | - |Fcalc (hkl) || / hkl |Fobs (hkl)|; Rfree is calculated in an  
identical manner using 5% of randomly selected reflections that were not included in the refinement. 
4) Rmeas = redundancy-independent (multiplicity-weighted) Rmerge [92, 122].  Rpim = precision-indicating (multiplicity-weighted) Rmerge 
[123, 124]. 




Fig.41.  X-ray fluorescence spectra from a rhamnose-free RhaR-NTD crystal.  (A) 




calculated using the peak and low energy data sets yielded peaks in protomers A/B of 44σ/35σ 
(peak wavelength) and 5.6σ/5.7σ (low energy wavelength) thus confirming the Ni2+ was the 
metal ion bound to RhaR-NTD.  Since the RhaR-NTD protein was purified through Ni2+ affinity 
chromatography, it is likely that the Ni2+ was acquired during the purification.  Throughout all 
the purification steps, the Ni2+ was the only divalent metal the protein was exposed to.  It was 
interesting that RhaR-NTD retained the bound Ni2+ through the size exclusion chromatography 
purification step, and the high concentration of Ca2+ in the crystallization solution did not replace 
the Ni2+.  These all suggested that the metal binding to the protein was tight.  Although X-ray 
fluorescence scan was not performed on the rhamnose-bound RhaR-NTD crystals, it is 
reasonable to believe that the metal ion present in the rhamnose-bound RhaR-NTD structure 
were also Ni2+ because the protein used to produce these crystals was also purified through the 
Ni2+ affinity chromatography.  The refinement of the rhamnose-bound RhaR-NTD structure with 
Ni2+ did not yield any large amount of residual positive electron density around the ion, which 
suggested that Ni2+ fitted well within the sugar-binding pocket.  In addition, the metal-ion 
distance was approximately 1.99 Å to 2.27 Å, which was also the expected distance of a Ni2+ ion 
(1.99 Å to 2.30 Å) [154].   
The Ni2+ ion is coordinated by residues H34, H36, H74 and E40, same as the rhamnose-
bound RhaR-NTD structure mentioned above.  Following refinement with the Ni2+ ions placed in 
each protomer, large difference electron density peaks were present near the “open” coordination 
site of the metal ions.  For the RhaR-NTD-GLY structure, the electron density was consistent 
with glycerol molecules coordinating the Ni2+ ions (Fig. 42A).  The glycerol was likely acquired 
from the protein storage buffer (5%, v/v).  However for the RhaR-NTD-EG structure, the 
glycerol at the metal coordination site was displaced by ethylene glycol during cryoprotection 
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(Fig. 42B).  It should be noted that data collected using crystals cryoprotected with PEG 200 and 
PEG 400 displayed electron density consistent with a glycerol molecule, similar to RhaR-NTD-
GLY, at the metal coordination site.   
Overall, the rhamnose-free RhaR NTD-EG structure is similar to the rhamnose-bound 
structure with RMSD of 0.7 Å for the backbone Cα trace (Fig. 43A).  In particular, two of the 
helices α4 and α5 that are involved in dimerization are well aligned in the two structures, 
suggesting that the dimerization is likely unaffected by rhamnose binding.  However, there are 
also several differences between the two structures, with the largest difference being the 
positions of the backbones in the region from residue V22 to residue T35 (Fig 43B).  Within this 
region, residues D24 to Q28 in protomer A, and residues R25 to V30 in protomer B of the 
rhamnose-free structure are completely disordered.  It is clear that the position of the backbone in 
the region from D29 to T35 (in protomer A, F31 to T35 in protomer B) in the rhamnose-free 
structure has changed as compared to the rhamnose-bound structure (Fig. 43B).  Residues R25, 
Q28, F31, and H34 are positioned to contact rhamnose, thus the lack of these interactions when 
rhamnose isn’t bound has caused region D24 to Q28 (in protomer A, R25 to V30 in protomer B) 
became more flexible in the isolated RhaR-NTD structure.  The V22 to T35 region in RhaR 
aligns with a region in ToxT that contacts the ToxT DBD, suggesting this region’s potential 
involvement in transmitting the rhamnose binding signal to the DBD.  It is likely that this region 
contacts the DBD in the absence of rhamnose, and changes conformation so that several residues 
(R25, Q28, F31 and H34) are in position to interact with the rhamnose when rhamnose becomes 
available, transmitting the allosteric signal from the NTD to the DBD.  In addition, a region of β6 




Fig. 42.  Fo-Fc omit map (green mesh) and phased anomalous difference map (orange mesh) 
contoured at 3σ.  (A) RhaR-NTD-EG and (B) RhaR-NTD-GLY.  The anomalous difference 
maps were calculated using data collected at 1.0000 Å and 1.4848 Å for RhaR-NTD-EG and 
RhaR-NTD-GLY respectively.  The Ni2+ ions are drawn as green spheres. 
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movement (Fig. 43C). Residue S75 to N80 forms a loop connecting β6 and β7 when rhamnose is 
bound; however, in the rhamnose-free structure, these residues became part of the β6.  The 
conformational changes of the region from residue S75 to V83 suggests that this region may also 
involve in transmitting the rhamnose binding signal from the NTD to the DBD.  
The N-terminal arm regions (residues L4-A19) of the rhamnose-free RhaR-NTD are well 
aligned with the rhamnose-bound structure, suggesting a lack of conformational change between 
the (+)rha and (-)rha states.  In AraC, the analogous N-terminal arm region is key to allosteric 
arabinose signalling: the arm contacts the DBD in the absence of arabinose, constraining AraC in 
its non-activating state; in the presence of arabinose, the arm adopts an alternative conformation 
and releases the DBD, thus allowing AraC to activate transcription of araBAD (the ‘light-switch’ 
mechanism) [35].  Our previous N-terminal deletions of the arm region of RhaR [52] did not 
have rhamnose-dependent effects on RhaR activity, arguing that RhaR likely does not use 
amechanism analogous to the AraC ‘light-switch’ mechanism.  Instead, deletions of the RhaR 
arm had similar effects on the (+)rha and (-)rha states, consistent with the lack of conformational 
differences in the structures [52].  The arm region in AraC folds over the sugar-binding pocket in 
the presence of arabinose but lays on one edge of the sugar-binding pocket rim in the absence of 
arabinose.  The RhaR arm region, on the other hand, stays on one edge of the rhamnose-binding 
pocket rim regardless weather rhamnose is bound or not.  This rim of the pocket is the opposite 
edge of the pocket rim that shows the conformational change in RhaR.   
Overall, the conformational changes between the (+) and (-)rha conformations are 
relatively small; however, prior studies suggest that this is reasonable.  It has previously been 
shown that in vivo and in vitro RhaR activity increases by approximately 10-fold (+)rha relative 




Fig. 43.  (A) The superimposition of the rhamnose-free RhaR-NTD-EG protomer to the 
rhamnose-bound structure protomer.  Cyan, rhamnose-bound RhaR-NTD structure; magenta, 
rhamnose-free RhaR-NTD-EG structure.  The rhamnose, ethylene glycol, and Ni2+ are not shown.  
(B) Zoomed in view of the V22 to T35 region and (C) the region of S75 to V83 showing 
structure differences of these regions between rhamnose-bound and free RhaR-NTD structures.  
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activity increases by 1000x upon addition of rhamnose, for example) might be achieved through 
relatively modest conformational changes upon rhamnose binding.  The finding that four 
residues in the V22-T35 loop, R25, Q28, F31, and H34, are positioned to contact rhamnose 
provides a potential mechanism for the conformational change in this region.  Further, our 
finding that alanine substitutions at R25 and F31 in this loop had increased activity in the 
absence of rhamnose suggests that these residues promote the non-activating, lower activity state 
of RhaR in the absence of rhamnose.  By analogy with ToxT, in which K31 interacts with K230 
to stabilize the non-activating state of ToxT, R25 and F31 and potentially other residues in the 
V22-H34 loop may contact RhaR-DBD to stabilize the non-activating (-)rha state of RhaR. 
Partially rhamnose-occupied RhaR-NTD structure.  Prior to obtaining the structure of RhaR-
NTD in the absence of rhamnose, we had made a prior effort to obtain a rhamnose-free RhaR-
NTD structure.  We carried out all of the steps to obtain purified protein (cell growth, protein 
purification, crystallization) in the absence of rhamnose. We solved the structure of RhaR-NTD 
from protein crystals grown from this protein at 2.02 Å resolution, however, the structure had 
electron density within the rhamnose-binding pocket.  The finding that the electron density in the 
pocket had a higher average B factor than the surrounding protein atoms (Table 13) suggested 
the possibility that the pocket was only partially occupied with the ligand.  Thus, we hypothesize 
that the density in the pocket was due to rhamnose binding to some, but not all, of the protein in 
the crystal.  This partial occupancy is suggested by comparison of the 2Fo – Fc electron-density 
maps for the two structures (Fig. 44).  The source of the rhamnose bound to RhaR-NTD in this 
structure is unknown, however the yeast extract that was a component of the growth medium 




Table 13   Data collection and refinement statistics for RhaR NTD structure with partial 
 L-rhamnose occupancy  
Beamline APS 














RMSD, Bond lengths/Å  0.008 
RMSD, Bond angles/ 1.15 
Overall B value (Å2) 42.90 
















through multiple chromatographic purification steps suggests that the binding was tight, with a 
low dissociation constant or at least a slow off rate for the rhamnose.   
Overall, the partially rhamnose-occupied structure is similar to the fully rhamnose-
occupied structure and the rhamnose-free structure, with an r.m.s.d of 0.7 Å, and 0.5 Å 
respectively for the backbone Cα trace (45A).  The N-terminal arm region as well as the two α 
helices α4 and α5 involved in dimerization are well aligned both in backbone and side chains in 
the three structures.  Similar to the rhamnose-free RhaR-NTD structure, residues R25 to D29 in 
protomer B of the partially rhamnose-occupied structure were completely disordered, but in 
protomer A, the backbone electron density could be traced although the side chain electron 
density was poor.   Comparison of the three RhaR-NTD structures shows that two regions (V22 
to H34 and S75 to V83) have the largest difference.  The partial rhamnose-occupied structure 
region V22 to T35 (specifically V22 to A23, and V30 to T35) aligned well with the same region 
in the rhamnose-free structure.  In the region of S75 to V83 in the partial rhamnose-occupied 
structure, S75 to A77 aligned with the same region in the rhamnose-free structure, and S78 to 
V83 aligned with the same region in the full rhamnose-bound structure (Fig. 45B & C).  These 
observations support the idea that partially rhamnose-occupied structure represents an average of 




Fig. 44.  2Fo – Fc electron-density maps of rhamnose with full and partial occupancy (contoured 




Fig. 45.  (A) The structure overlay of the full rhamno Structures of RhaR-NTD se-bound 
RhaR-NTD, partial rhamnose-occupied RhaR-NTD, and rhamnose-free RhaR-NTD. Cyan, full 
rhamnose-bound RhaR-NTD structure; magenta, rhamnose-free RhaR-NTD-EG structure; brown, 
partial rhamnose-occupied RhaR-NTD.  The rhamnose, ethylene glycol, and Ni2+ ions are not 
shown.  (B) Zoomed in view of the V22 to T35 region and (C) the region of S75 to V83 showing 












In the presence of L-rhamnose, the AraC family transcriptional activator RhaR increases 
transcription activation of the rhaSR operon by 10-fold relative to the absence of rhamnose [13] 
[10-12].  The mechanism of the increase in RhaR activity when it has L-rhamnose bound isn’t 
fully understood.  Prior studies have provided evidence that L- rhamnose binding to RhaR results 
in a 25-fold increase in DNA binding affinity, and (even if DNA binding is saturated) is required 
post-DNA binding for transcription activation (presumably through increasing contacts with the 
RNA polymerase sigma subunit) [48, 53, 54].  Although RhaR DNA-binding affinity isn’t the 
only property that is affected by L-rhamnose binding, measurements of L-rhamnose-dependent 
effects on DNA binding by RhaR are expected to provide information about the mechanisms of 
allosteric L-rhamnose signalling in RhaR.  Here, by using Electrophoretic mobility shift (EMSA) 
assays, I have measured the dissociation constants, a measurement of DNA-binding affinity, for 
the interactions between RhaR and the isolated RhaR-DBD with RhaR DNA binding sites.   
Equilibrium binding measurements.  Tobin and Schleif previously performed equilibrium 
DNA binding assays of RhaR binding to the full RhaR binding site upstream of the rhaSR 
promoter in the absence and presence of rhamnose and to one of the RhaR half-sites in the 
presence of rhamnose [53].  Our goal was to expand these studies to identify functional 
consequences of rhamnose allosteric signaling in RhaR.  We reasoned that rhamnose binding to 
RhaR might affect the DNA binding affinity of each RhaR protomer in a dimer, and/or the 
ability of the two DBDs in each RhaR dimer to bind cooperatively to the full RhaR DNA site.  
Although other mechanisms are certainly possible, based on findings with other AraC family 
proteins, we hypothesize the following mechanisms.  We propose that changes in the DNA-
binding affinity of each protomer might involve backbone movement resulting in HTH 
repositioning, as has been proposed from comparison of AraC family DBD structures in 
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activating or non-activating conformations [34, 38].  We further propose that changes in the 
ability of the two DBDs in a RhaR dimer to bind cooperatively to DNA might involve effector-
dependent rigid body movement of the DBDs relative to the regulatory domains, similar to the 
domain movements proposed in the AraC protein light-switch model [35].  EMSAs were used to 
determine the equilibrium DNA binding affinity of RhaR to its full (dimer binding) and half 
(protomer binding) DNA binding sites in the presence and absence of L-rhamnose, and the 
affinity of the RhaR-DBD to the half-site DNA in the absence of L- rhamnose.   
To determine whether rhamnose binding affected the DNA binding affinity of each RhaR 
protomer, we assayed binding of RhaR to a DNA fragment that included a single 17 bp DNA 
half-site (one protomer binds each half-site) with 4 bp of flanking DNA on either end.  This 
method was used to measure binding by each protomer of dimeric RhaR rather than attempting 
to assay DNA binding by RhaR monomers based on our finding that there was no detectable 
RhaR monomer peak following size exclusion chromatography with protein at a concentration of 
28 uM (0.9 mg/mL).  The short flanking DNA on either end of the half-site sequence in the DNA 
fragments was expected to preclude binding by both RhaR DBDs of a dimer to a single DNA 
fragment.  Thus, this assay was expected to report the DNA binding affinity of each RhaR 
protomer of a RhaR dimer.  To identify the effect of the RhaR NTD on the function of the RhaR 
DBD, we also assayed equilibrium DNA binding by the isolated RhaR-DBD to the same half-
site DNA fragment.  4 show that RhaR bound 350-fold more tightly to the half-site DNA than 
the isolated RhaR-DBD, suggesting that the presence of the RhaR NTD in the full-length protein 
had a large impact on DNA binding affinity.  The binding affinity we measured for RhaR 
binding to half-site DNA was approximately 30-fold tighter than that previously measured by 
Tobin and Schleif [53], however, they reported fitting a single data point to a Michaelis-Menton 
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binding curve, and did not report which RhaR half-site was used.  We measured half-site DNA 
binding over RhaR concentrations that yielded 0% (undetectable) to 100% binding of the DNA 
fragment in both the absence and presence of rhamnose (Fig. 46), suggesting that the current 
measurements are likely to be more accurate.  We were surprised to find that rhamnose did not 
appreciably alter the binding of RhaR to half-site DNA.  Thus, we conclude that the RhaR NTD 
increased the binding affinity of each RhaR protomer by a mechanism that was independent of 
rhamnose, and that rhamnose binding caused no further change in protomer binding affinity.   
We also assayed the effect of rhamnose on RhaR binding to the full RhaR DNA site 
(Table 14).  RhaR bound to the full DNA site approximately 10-fold more tightly in the presence 
of rhamnose compared to the absence of rhamnose.  This fold difference in binding is consistent 
with previous findings [53].  Comparison of RhaR binding to half-site DNA with binding to full 
site DNA showed that binding to the full site was stronger in both the absence and presence of 
rhamnose.  However, examination of the Hill slopes for evidence of cooperative binding (Hill 
slopes significantly greater than 1), suggested that only the RhaR binding to the full site in the 
presence of rhamnose exhibited significant cooperativity (data not shown).   
Our finding that the strength of RhaR binding to half-site DNA was not rhamnose 
dependent suggests that the affinity of each protomer for DNA was not increased in the presence 
of rhamnose.  Thus, an alternative mechanism must explain the increase in the strength of RhaR 
binding to full-site DNA.  Based on this, we hypothesized that the cooperative binding in the 









Full-Site 4.6 × 10-12 M 4.2 × 10-11 M 
Gapped 1.3 × 10-10 M 2.7 × 10-10 M 
Half-Site 2.5 × 10-9 M 3.1 × 10-9 M 
RhaR-DBD Half-Site N.Aa 1.1 × 10-6 M 
* Standard errors were no greater than 11% of the value. 
a The Kd measurement for RhaR-DBD binding to half-site DNA was measured only in the 




Fig. 46.  Representative EMSA gels showing the binding of RhaR-His6 to half site DNA. Top, 
RhaR-His6 binding to half site DNA in the absence of L-rhamnose [(-)rha].  Bottom, RhaR-His6 
binding to half site DNA in the presence of L-rhamonse [(+)rha].  Free DNA (F) is in the first 
lane on each gel. The black triangles represent decreasing concentrations of proteins, with serial 
two-fold dilutions. The highest protein concentration added was at 6 × 10-8 M.   
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positioning or the flexibility/dynamics of the positioning of the two DBDs in the dimer.  More 
specifically, we hypothesized that in the absence of rhamnose, the two DBDs in a RhaR dimer 
were somewhat constrained such that their binding to the full RhaR binding site was not 
significantly cooperative; but in the presence of rhamnose, the two DBDs were either more 
optimally positioned, or more flexible/dynamic in their positioning, such that binding to the full 
site DNA was cooperative.   
To test the hypothesis that rhamnose binding to RhaR might alter the ability of the DBDs 
in a RhaR dimer to bind cooperatively to full-site DNA, we tested RhaR binding to “gapped” 
full-site DNA.  This DNA fragment had double-stranded half-sites but had 17 bp of single 
stranded DNA between the half-sites – a region of DNA that is not contacted by RhaR.  The 
rationale, as previously proposed by Harmer et. al [29], was that the single stranded spacer DNA 
would provide much greater flexibility than the double stranded spacer, and thus would be better 
able to accommodate binding to two RhaR DBDs that might be sub-optimally positioned in the 
absence of rhamnose to bind to the fully double stranded full site DNA.  RhaR binding to the 
gapped DNA differed by only two-fold in the absence versus the presence of rhamnose, which is 
a significantly smaller difference than the 10-fold difference measured for fully double stranded 
full site DNA.  This finding supports the hypothesis that at least the majority of the effect of 
rhamnose binding to RhaR is a change in the relative positioning or the flexibility/dynamics of 
the two DBDs in the dimer such that they are better able to bind cooperatively to the full RhaR 
DNA binding site.   
RhaR DNA bending.  The hypothesis that the primary consequence of rhamnose binding to 
dimeric RhaR may involve the repositioning of the two DBDs relative to one another suggests 
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that there might be a measurable rhamnose-dependent difference in the degree of DNA bending 
by RhaR when bound to its full DNA site.  Tobin and Schleif previously estimated the degree of 
RhaR bending in the presence of rhamnose to be approximately 160°, but did not measure 
bending in the absence of rhamnose [53].  We used the gel electrophoresis assay developed by 
Wu & Crothers [103] to estimate the bending angle of RhaR binding to full site DNA in the 
absence and presence of rhamnose.  We designed five 292 bp DNA fragments with the 50 bp 
RhaR DNA binding site at different positions (Fig.47A), and otherwise identical DNA sequences.  
Figure 47B shows that the equivalent length DNA fragments had a faster mobility when the 
RhaR-bound DNA binding sequence was located at one or the other end of the DNA fragment 
than when the site was located at or nearer to the center of the fragment.  The gel also shows that 
there were differences in the migration of the identical RhaR-bound DNA fragments in the 
absence versus the presence of rhamnose.  Using the method described by Thompson & Landy 
[104], we estimated the bending angle with RhaR bound to its full DNA site to be 141° in the 
absence of rhamnose and 150° in the presence of rhamnose, comparable to the prior 
measurement in the presence of rhamnose.  The large difference in the length of the DNA 
fragments used for the bending experiments (Tobin, 787 bp; this work, 292 bp) may account for 
at least some of the difference in the bending estimates in the presence of rhamnose between 
these two studies.  The difference between the bend angles in our experiments in the absence and 
presence of rhamnose was found to be statistically significant, with a P value of <0.005.  
Although this difference in bend angles was modest, this is consistent with the relatively small 
(~10x) difference in binding affinity of RhaR for its full DNA site in the absence and presence of 
rhamnose.  Interestingly, despite the AraC protein’s switch from looping in the absence of 
arabinose to binding adjacent DNA sites in the presence of arabinose, and the use of a phase-
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sensitive DNA bending assay, no arabinose dependent change in the angle of DNA bending by 





Fig. 47.  RhaR DNA bending as measured by EMSA. (A) Maps of DNA fragments to estimate 
DNA bending by RhaR.  Each DNA fragment was labeled with a fluorescent tag at the 5’.  RhaR 
binding site positions were included, and different shades of blue blocks represent the same 
length but different sequences of the flank region. (B) EMSA showing RhaR-His6 protein 















The AraC family transcriptional activator RhaS regulates the expression of genes 
involved in the L-rhamnose regulon.  RhaS activates transcription of both the rhaBAD operon, 
which contains genes encoding L-rhamnose catabolic enzymes, and the rhaT operon, which 
contains a gene encoding L-rhamnose transporter [10, 49].  RhaS also negatively auto-regulates 
its own expression, and the expression of RhaR, at the rhaSR operon.  In the presence of 
rhamnose, RhaS activates transcription approximately 1000-fold higher than in the absence of 
rhamnose [51].  This increase in transcription activation suggests that there must be an allosteric 
signal that is transmitted from the regulatory domain where the rhamnose binds to the DNA-
binding domain between its (-)rha and (+)rha states.  Although RhaS DNA-binding affinity isn’t 
the only property that is affected by L-rhamnose binding, measurements of L-rhamnose-
dependent effects on DNA binding by RhaS are expected to provide information about the 
mechanisms of allosteric L-rhamnose signalling in RhaR.  Here, by using EMSA assays, I have 
measured the dissociation constants for the interactions between RhaS and the isolated RhaS-
DBD with RhaS DNA binding sites.   
Purification of RhaS-His6 in the presence of rhamnose.  To overproduce soluble RhaS protein, 
0.2% rhamnose (final concentration) was added before induction.  RhaS protein was first 
purified as C-terminal Hi6 fusion protein by Ni
2+ affinity chromatography.  During the 
purification, 0.2% rhamnose was also included in the purification buffer (binding, wash, elution 
buffers).  After eluting RhaS-His6 protein from the Ni
2+ column, the protein sample was quickly 
loaded onto a a HiPrep 16/60 Sephacryl S-300 HR column (GE healthcare) and eluted with 
buffer without the rhamnose.  By using this method, I was able to purify 4 mg of RhaS-His6 
protein from 1L of cultured bacterial cells (Fig. 48A).  The purified RhaS was active, based on 





Fig. 48.  (A) 12% SDS-PAGE gel stained with coomassie blue showing purified RhaS-His6 
protein eluted from Ni2+-affinity chromatography.  Molecular mass marker (M) is in the first lane.  




Equilibrium binding measurements.  EMSAs were used to determine the equilibrium DNA 
binding affinity of RhaS to its full (dimer binding) and half (protomer binding) DNA binding 
sites in the presence of rhamnose.  Because we were unable to purify RhaS in the absence of 
rhamnose due to insolubility of the protein, the equilibrium binding assays for the full length 
RhaS were carried out in the presence of rhamnose.  To determine the effect of rhamnose 
binding on the DNA binding affinity of each RhaS protomer, I have assayed full length RhaS 
binding to a DNA fragment that included a single 17 bp DNA half-site (one protomer binds each 
half-site) with 4 bp of flanking DNA on either end.  Because the short flanking DNA on either 
end of the half-site sequence in the DNA fragments was expected to preclude binding by both 
RhaS DBDs of a dimer to a single DNA fragment, this assay was expected to report the DNA 
binding affinity of each RhaS protomer of a RhaS dimer.  To identify the effect of the RhaS 
NTD on the function of the RhaS DBD, the affinity of the RhaS-DBD to the same half-site DNA 
in the absence of L- rhamnose was also measured.   
The results in Table 15 show that in the presence of rhamnose full length RhaS bound 40-
fold more weakly to the half-site DNA than the isolated RhaS-DBD, suggesting that the presence 
of the RhaS NTD in the full-length protein decreased the RhaS-DBD DNA binding affinity to 
the half site in the presence of rhamnose.  We also found that RhaS bound to the full DNA site 
approximately 10-fold more tightly than to the half site in the presence of rhamnose, suggesting 
that the two DBDs in the RhaS dimer bind cooperatively.  The finding that the full length RhaS 
binding to the full-site DNA was about 3-fold weaker than the isolated RhaS-DBD binding to the 
half-site indicated that despite the increased cooperativity in full site RhaS DNA binding, the 
RhaS-NTD decreased DNA binding.  Although we have not measured the binding affinity of the 
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full length RhaS to the full site in the absence of rhamnose, our in vivo transcription activation 
assay predicted that it will be approximately 1000-fold weaker relative to (+)rha.   
RhaS DNA bending.  Since we do not have RhaS protein purified in the absence of rhamnose, 
we can only measure the DNA bending by RhaS in the present of rhamnose.  I have designed 
five 292 bp DNA fragments with the 51 bp RhaS DNA binding site at different positions.  These 
DNA fragments are similar to those used in the RhaR bending assay.  The flanking sequences are 
identical DNA sequences.  Using gel electrophoresis assays and the method described by 
Thompson & Landy [104], we estimated the bending angle with RhaS bound to its full DNA site 
to be 105° in the absence of rhamnose (Fig. 49A).  Each DNA-protein band on the gel smeared 
during gel running, which made the measuring quite difficult.  In order to confirm the bend angle 
induced by RhaS, I have purified a variant of RhaS protein, RhaSL201R-His6 [52] which binds 
DNA more tightly than the wild-type RhaS protein, and performed bending assay with this 
variant protein.  I found that RhaSL201R-His6 also produced an estimated 105° bend when binding 
to the DNA (Fig. 49B), which was consistent with the bend angle produced by the wild-type 
RhaS protein.  The RhaR DNA contains a natural bend with an estimated 58° bend angle in the 
absence of RhaR protein bound (Fig. 50A).  The RhaS DNA, on the other hand, does not contain 
a natural bend (Fig. 50B).     
 Prior data indicated that RhaS can bind to the RhaR binding site, but with decreased 
rhaSR expression [156].  Therefore, we previously hypothesized that RhaS decreases rhaSR 
expression by not bending the DNA sufficiently for αCTD to contact CRP.  To test this 
hypothesis, we measured the DNA bending by RhaS at the RhaR DNA binding site.  We found 
that RhaS produced a 148° bend (Fig. 51).  This bend angle was 43° greater than the bend angle 
RhaS produced at the RhaS binding site, supporting the hypothesis for strong auto-regulation.  
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However, in our assays, RhaR bent RhaR binding site to 150° in the presence of rhamnose, 
which was approximately the same as the bend angle produced by RhaS at the RhaR binding site 
(within the error of our measurements).  This result indicated that DNA bending cannot explain 









Full-Site 3.8 × 10-9 M N.A.b 
Half-Site 4.5 × 10-8 M N.A.b 
RhaS-DBD Half-Site N.A.a 1.2 × 10-9 M 
a The Kd measurement for RhaS-DBD binding to half-site DNA was measured only in the 
absence of L-rhamnose.    
b The Kd measurement for RhaS binding to full-site and half-site DNA were measured only in the 




Fig. 49.  EMSA showing (A) wild-type RhaS-His6 and (B) RhaS
L201R-His6 binding to different 





Fig. 50.  EMSA showing (A) RhaR DNA fragments produced a 58° natural bend in the absence 






Fig. 51.  EMSA showing RhaS-His6 and RhaR-His6 bind to the RhaR DNA fragments, 














I have investigated of residues in the regions of RhaS DBD that were predicted to contact 
the NTD in allosteric signalling based on alignment with AraC: HTH1, HTH2, and allosteric site 
in subdomain 2 (AS2).  In total, 18 positions within these three regions of RhaS DBD were 
subjected to site-directed random mutagenesis, and assayed their transcription activation 
activities in the rhaB-lacZ fusion.  Table 16, 17, and 18 summarized the transcription activation 


















WT 100 ± 6 100 ± 3 100 ± 5 100 ± 2 
L208M 1204 ± 20 97 ± 3 126 ± 6 98 ± 3 
L208I 313 ± 8 95 ± 3 119 ± 4 99  ± 2 
Q210R 83 ± 6 102 ± 1 103 ± 10 104 ± 5 
Q210S 115 ± 11 98 ± 2 110 ± 12 103 ± 1 
Q210G 42 ± 4 86 ± 3 103 ± 13 88 ± 4 
Q210N 72 ± 7 97 ± 7 96 ± 10 92 ± 4 
Q210K 875 ± 17 98 ± 8 132 ± 14 97 ± 1 
Q211G 81 ± 11 91 ± 8 139 ± 13 87 ± 5 
Q211V 120 ± 12 95 ± 6 153 ± 13 86 ± 2 
Q211I 92 ± 13  62  ± 4 58 ± 6 68 ± 4 
T212C 19 ± 3 85 ± 3 71 ± 5 89 ± 6 
T212M 9 ± 2 89 ± 9 9 ± 0.4 97 ± 9 
T212A 8 ± 1 71 ± 6 45 ± 2 94 ± 2 
L214V 16 ± 2 114 ± 5 90 ± 8 86 ± 4 
L214I 41 ± 8 103 ± 5 136 ± 14 94 ± 3 
L214M 70 ± 6 106 ± 9 86 ± 8 86 ± 8 
L214G 4 ± 1 95 ± 9 19 ± 1 92 ± 5 
R218V 12 ± 2 99 ± 2 90 ± 7 88 ± 5 
R218L 6 ± 1 79 ± 7 11 ± 1 94 ± 2 
R218G 7 ± 1 87 ± 3 32 ± 2 81 ± 4 
Y219F 20 ± 2 96 ± 5 115 ± 7 82 ± 3 
Y219L 9 ± 1 84 ± 3 36 ± 3 88 ± 6 
Y219M 6 ± 1 94  ±9 12 ± 1 92 ± 4 
a. Variants were assayed in groups with a wild type RhaS activity range of 0.3-0.4 Miller Units  
(-)rha and 208-217 Miller Units (+)rha.  Values are the average of at least two independent 
assays with two replicates each and are shown as the percent of the corresponding (-)rha or 
(+)rha wild type values.  Error is shown as the standard deviation converted to percent of the 
Miller Unit values. 
b. Quantification of variant protein levels compared to wild-type RhaS.  Total protein was 
separated by 12% SDS-PAGE.  Proteins were transferred to nitrocellulose, probed with anti-
RhaS and anti-DnaK antibodies and quantified using densitometry analysis.  RhaS values were 
normalized to DnaK levels, are the average from two replicates and are shown as the percent of 
protein relative to the corresponding (-)rha or (+)rha wild type values. Error is shown as the 
standard deviation converted to percent of the normalized protein values. 
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WT 100 ± 6 100 ± 3 100 ± 5 100 ± 2 
R229I 69 ± 5  79 ± 6 58 ± 1 100 ± 7 
R229G 14 ± 1 79 ± 7 3 ±0.2 88 ± 4 
R229D 20 ± 1 74  ± 8 7 ± 0.3 94 ± 3 
R229T 29 ± 2 72 ± 6 22 ± 1 66 ± 1 
R229P 28 ± 2 72 ± 3 2 ± 0.2 65 ± 3 
H230E 393 ± 27 93 ± 7 67 ± 2 90 ± 6 
H230V 31 ± 2 70 ± 2 22 ± 1 91 ± 3 
H230I 27 ± 3 114 ± 1 3 ± 0.5 120 ± 6 
H230Q 69 ± 6 78 ± 4 57 ± 2 76 ± 4 
H230L 25 ± 2 66 ± 6 14 ± 0.5 68 ± 5 
H230G 20 ± 1 65 ± 3 21 ± 1 77 ± 3 
H230R 21 ± 2 73 ± 6 11 ± 0.5 67 ± 9 
L232M 9 ± 1 70 ± 5 11 ± 0.4 63 ± 3 
L232V 16 ± 2 66 ± 3 40 ± 1 59 ± 2 
L232I 32 ± 3 71 ± 8 76 ± 2 60 ± 4 
R233L 72 ± 3 99 ± 1 25 ± 1 103 ± 2 
R233P 8 ± 1 85 ± 8 1 ± 0.1 85 ± 6 
R233A 23 ± 1 80 ± 3 15 ± 1 89 ± 6 
R233W 13 ± 0.3 82 ± 6 7 ±0.2 93 ± 7 
R233D 12 ± 1 79 ± 2 5 ± 0.2 94 ± 3 
R233G 14 ± 1 74 ± 5 7 ± 0.2 92 ± 3 
H234T 295 ± 15 86 ± 6 131 ± 7 85 ± 4 
H234I 70 ± 11 102 ± 9 123 ± 7 93 ± 4 
H234K 65 ± 16 90 ± 7 106 ± 5 91 ± 7 
H234G 39 ± 5 91 ± 8 49 ± 3 92 ± 6 
H234Y 83 ± 4 89 ± 7 94 ± 6 84 ± 6 
H234V 72 ± 9 84 ± 5 104 ± 6 80 ± 4 
H234D 30 ± 1 94 ± 1 42 ± 2 85 ± 4 
H234E 57 ± 4 97 ± 3 56 ± 3 88 ± 1 
a. Variants were assayed in groups with a wild type RhaS activity range of 0.3-0.4 Miller Units  
(-)rha and 208-217 Miller Units (+)rha.  Values are the average of at least two independent 
assays with two replicates each and are shown as the percent of the corresponding (-)rha or 
(+)rha wild type values.  Error is shown as the standard deviation converted to percent of the 
Miller Unit values. 
b. Quantification of variant protein levels compared to wild-type RhaS.  Total protein was 
separated by 12% SDS-PAGE.  Proteins were transferred to nitrocellulose, probed with anti-
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RhaS and anti-DnaK antibodies and quantified using densitometry analysis.  RhaS values were 
normalized to DnaK levels, are the average from two replicates and are shown as the percent of 
protein relative to the corresponding (-)rha or (+)rha wild type values. Error is shown as the 


















WT 100 ± 6 100 ± 3 100 ± 5 100 ± 2 
E261N 74 ± 5 102 ± 1 101 ± 6 97 ± 3 
E261G 15 ± 1 91 ± 8 11 ± 1 89 ± 8 
E261S 1163 ± 92 128 ± 7 229 ± 7 127 ± 6 
E261M 482 ± 39 92 ± 3 176 ± 6 118 ± 3 
E261F 640 ± 56 95 ± 8 224 ± 4 107 ± 6 
F262Y 48 ± 4 95 ± 4 100 ± 5 103 ±8 
F262L 11 ± 1 96 ± 2 3 ± 1 92 ± 8 
N263Y 22 ± 1 100 ± 8 45 ± 3 104 ± 6 
N263E 33 ± 2 108 ± 7 72 ± 4 92 ± 1 
N263R 46 ± 4 100 ± 5 85 ± 3 99 ± 5 
N263L 19 ± 1 128 ± 8 13 ± 2 99 ± 4 
N263W 14 ± 1 93 ± 2 26 ± 3 96 ± 7 
W264H 95 ± 6 90 ± 5 77 ± 4 105 ± 7 
W264M 377 ± 42 80 ± 5 69 ± 4 93 ± 7 
W264E 56 ± 2 90 ± 5 28 ± 2 100 ± 5 
     
a. Variants were assayed in groups with a wild type RhaS activity range of 0.3-0.4 Miller Units  
(-)rha and 208-217 Miller Units (+)rha.  Values are the average of at least two independent 
assays with two replicates each and are shown as the percent of the corresponding (-)rha or 
(+)rha wild type values.  Error is shown as the standard deviation converted to percent of the 
Miller Unit values. 
b. Quantification of variant protein levels compared to wild-type RhaS.  Total protein was 
separated by 12% SDS-PAGE.  Proteins were transferred to nitrocellulose, probed with anti-
RhaS and anti-DnaK antibodies and quantified using densitometry analysis.  RhaS values were 
normalized to DnaK levels, are the average from two replicates and are shown as the percent of 
protein relative to the corresponding (-)rha or (+)rha wild type values. Error is shown as the 














Identifying Small Molecule Inhibitor Binding Site in RhaS.  In this study, we have 
demonstrated that SE-1 directly bound to VirF and RhaS-DBD using florescence-based thermal 
melt assay and intrinsic tryptophan florescence assay.  Mutagenesis studies suggested that 
residues D191, S249, and L257 were at or near the SE-1 binding site on RhaS-DBD, which 
supports the prediction of docking that SE-1 is likely bound to a small pocket between the two 
HTH motifs, and these residues also contribute to the binding of SE-1.  Identification of the 
binding site of SE-1 in RhaS allows us to postulate the possible mechanism of action of SE-1.  It 
is likely that upon binding to the small pocket between the two HTH motifs, SE-1 contacts 
residues D191, S249, and L257.  Because of the binding of SE-1, RhaS is predicted to be unable 
to contact DNA, and therefore, will be unable to activate transcription of the rhaBAD and rhaT 
operons.  AraC family proteins are defined by the presence of a structurally conserved DBD.  A 
small molecule inhibitor targeting this domain could potentially target many protein members of 
the family.  To target multiple members of the AraC family, the small molecule must bind to a 
pocket with a conserved shape to accommodate the shape of the DNA across family members.  
Additionally, sequence alignment and analysis of 200 AraC family members indicate that 
residues which possibly contribute to SE-1 binding are fairly conserved.  Position D191, S239, 
L247 shared 50%, 36%, and 53% sequence similarity with the 200 AraC members analyzed.  In 
our lab, we have found that SE-1 inhibited the activities of multiple AraC family members: 
RhaS, RhaR, VirF, Rns, and ToxT.  Our docking studies indicated that SE-1 could fit in the 
small pocket between the two HTH motifs in all the proteins tested, including MarA, RhaS, VirF, 
and Rns. Therefore, it is likely that SE-1 inhibits these proteins by binding to the same pocket 
between the HTH motifs.  Since the HTH motifs are fairly well conserved across the AraC 
family, and docking studies suggest that the binding pocket that SE-1 binds to is present in all 
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AraC family proteins tested, it is possible that SE-1 could target quite a large number of AraC 
family proteins including those regulate expression of virulence genes.  Traditional antibiotics 
act by inhibiting bacterial functions (such as cell wall synthesis, DNA replication, RNA 
transcription and protein synthesis) that are essential for cell growth.  Targeting the expression of 
virulence factors does not affect the cellular viability.  It has several advantages including 
exerting less selective pressure, which may result in decreased resistance.  Therefore, small 
molecule inhibitor SE-1 that target AraC family virulence activators potentially can be developed 
into a “broad spectrum” antimicrobial agent.   
Higher resolution structure of ToxT and SE-1-ToxT crystallization trial.  In an effort to 
obtain crystals of ToxT in a complex with the inhibitor SE-1 with the goal of more directly 
identifying the SE-1 binding site, we first started with crystalizing ToxT.  Despite following the 
protocol used by Lowden et al. as closely as possible, we were unable to obtain ToxT crystals 
using the published crystallization conditions [38].  This wasn’t entirely surprising giving that 
poor reproducibility has been a notorious problem in the protein crystallization field [157, 158], 
and it is common that crystallization results differ even under the “same conditions” [159].  
Many parameters, such as the precise protein concentration, temperature, buffer composition and 
pH, among other factors, can affect protein crystallization [160, 161].  After screening over 480 
different crystallization conditions, we obtained crystals of ToxT with a condition that is 
completely different from the published one.  The structure was solved to 1.65Å resolution (PDB 
code 4MLO) which is a higher resolution than the previously determined ToxT structure.  Many 
structural quality parameters of the current ToxT structure (Rfree, clashscore, etc.) were in the 
high percentile range, suggesting the overall high quality of the structure, and the higher quality 




Fig. 52. Percentile scores (ranging between 0-100) for global validation metrics of (A) 
previously determined ToxT structure (PDB:3GBG), and (B) current ToxT structure 




In addition to the improved overall quality of the current structure, a previously 
disordered region of ToxT between α1 and β9 from residues D101 to E110, could be fully traced 
in the current structure.  Many residues in this region have previously been shown important for 
ToxT activity in respond to its fatty acid effectors and Virstatin, an inhibitor of ToxT activity 
[41, 79, 164], thus solving the structure of this region provided significant new information for 
understanding the role of individual residues within and around this region.  For instance, alanine 
substitutions of residues M103, R105 and N106 within this region have shown activity at the 
ctxA promotor that is three-fold higher than wild-type ToxT, suggesting that these residues have 
a negative effect on the activity of wild-type ToxT [164].  The analysis of the current ToxT 
structure reveals that R105 forms a salt bridge with E156.   This observation combined with the 
alanine substitution results suggests the possibility that R105 holds E156 in a position that 
somewhat attenuates ToxT activity.  E156 is located in helix α3, which is likely involved in 
dimerization to facilitate transcriptional activation [38].  Thus, R105 may maintain the activity of 
ToxT at its wild-type level by somewhat supressing dimerization (relative to the R105A 
substitution).  Of course, protein structure does not always provide explanations for the 
phenotypes of protein variants.  For example, other than their potential effects on R105, the 
structure does not provide obvious explanations for how alanine substitutions at residues M103 
or N106 also increased ToxT activity.  Virstatin, a small molecule inhibitor of ToxT identified 
by Hung et al (2005) [79], blocks ToxT dimerization and thus its ability to activate transcription 
of the tcp and ctx promoters [165].  Shaknovich et al. [165] also have demonstrated that a ToxT 
variant, L114P, is resistant to virstatin and suggested that L114P may result in a conformational 
change in ToxT that allows the protein to dimerize more efficiently [165].  Lowden et al. [38] 
suggested that the previously disordered region from D101 to E110 might be involved in the 
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virstatin resistance of the L114P variant due to their proximity; however, there are no obvious 
interactions between L114 and any of the residues in the 101-110 region that would suggest that 
region’s involvement in the mechanism of virstatin resistance of ToxT L114P. 
 Once we obtain the ToxT crystal, we attempted to crystalize ToxT in a complex with the 
inhibitor SE-1.  However, obtaining SE-1-ToxT crystals either by soaking or direct 
crystallization was not successful.  One explanation for failing to obtain SE-1-ToxT crystals was 
that SE-1 bound to ToxT with a much weaker affinity than the other proteins we identified as 
inhibited by SE-1.  Therefore, it might require ToxT crystals to be soaked in higher 
concentration of SE-1 than those used, or increased SE-1 concentration while mixing with ToxT 
protein, but, the limited solubility of SE-1 made it impossible to test these possibilities.  Another 
possibility is that the current ToxT structure contains the effector PMA, and thus the protein was 
in its non-activating state which is unable to bind to DNA [38].  Since the switch from the 
activating to the non-activating state of ToxT is predicted to involve a shift in the positioning of 
the two HTH motifs relative to one another, it’s possible that the binding pocket that SE-1 binds 
to is not present in the non-activating state of ToxT [34, 38].  However, it’s likely that at least 
some portion of the protein used to set up crystallization trays was in an activating state initially, 
as we showed that adding oleic acid, which is predicted to act as a ToxT effector in the same way 
that PMA does, inhibited DNA binding.  The finding that SE-1 inhibited DNA binding by ToxT 
suggested that SE-1 can at least bind to the activating conformation of ToxT, but we don’t know 
whether it can bind to the non-activating conformation.  Therefore, one hypothesis is that SE-1 
can only bind to the activating conformation of ToxT, and we either haven’t been able to find a 
condition to obtain crystals of the activating ToxT conformation, or that the activating 
conformation of ToxT has too much inherent flexibility to readily form crystals.  Alternatively, 
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SE-1 might be able to bind both conformations of ToxT, but with weak affinity, thus it cannot 
easily be crystalized with any forms of ToxT.   
SE-1 optimization.  Typically, in the process of drug discovery, small molecule hits from a high 
throughput screen require several rounds of optimization to improve the specificity and potency 
before being considered lead compounds that have the potential to enter the clinical drug 
development process [166-169].  Hence, in collaboration with Dr. Jeff Aubé, we have carried out 
optimization studies on the small molecule inhibitor SE-1 to improve its potency and specificity.  
Unfortunately, none of the analogues tested had increased inhibition potency or specificity.  Our 
results indicated that the biquinolinium core of SE-1 is important for the inhibition activity 
against the AraC family activator VirF.  Replacing the quinolinium core resulted in inactivity of 
the analogues (entries 6, 7, 12, 13, 15, Table 9).  To maintain activity, the N-substitution of the 
n-butyl group had to be limited to linear alkyls (entries 2, 19-23, Table 9); and any bulky groups 
(i.e. chlorobenzyl group) resulted in analogues that were less active than SE-1 (entry 3 & 5, 
Table 9).  However, the n-nonyl substitution showed loss of selectively (entry 22, Table 9), while 
the n-hexyl substituted analogue showed similar inhibition activity and specificity as compared 
to SE-1 (entry 21, Table 9).  The above findings suggested that only short length of the alkyls 
(maybe up to six-carbon alkyl) can be tolerated at this position to maintain the selectivity of the 
analogues, although it was unclear that how n-heptyl, and n-octyl would behave in the inhibition 
assay.  The reason for this phenomenon was not known.   
During the optimization, it was discovered that SE-1 and several analogues converted to 
quinolinium salts when dissolved in aqueous solution, and further, that the quinolinium salt was 
responsible for the observed inhibitory activity.  The quinolinium salt is positively charged, and 
can accept an electron pair in order to bond to a nucleophile [133].  When this reaction occurs in 
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cell, it could cause undesired disposition (including absorption, distribution, metabolism, and 
excretion), and even cell damage [170-172], therefore, quaternary ammonium salts such as this 
have limited pharmaceutical relevance.  Based on this finding, the Aubé lab was no longer 
interested in continuing our collaboration.  However, our previous study of SE-1 has shown that 
SE-1 had no detectable effects on the metabolic activity of mammalian tissue culture cells (L-
929 cells) at concentrations as high as 40 µM [80].  This suggested that SE-1 might still have the 
potential to be developed into novel antimicrobial agent despite being a quinolinium salt.   
In the current optimization study, we explored the SAR of SE-1 with the goals of 
improving the potency and specificity of SE-1.  However, efforts were not directed specifically 
at the goal of optimizing the solubility of SE-1.  Our preliminary study shows that SE-1 is quite 
hydrophobic and dissolves poorly in aqueous solution or buffer.  Improving the solubility of SE-
1 could allow us to further characterize the binding of SE-1 to AraC family proteins.  For 
instance, we might be able to measure the binding affinity of SE-1 for purified VirF protein 
using fluorescence-based thermal melting assays, for which concentrations of SE-1 that are 
higher than those currently possible are required.  Therefore, optimization of the solubility of SE-
1 might enable further studies.  
RhaR purification and annotation error.  As is the case with many of the AraC family 
transcriptional activators, many aspects of RhaR function have been difficult to characterize due 
to the protein’s low solubility.  During our efforts to optimize RhaR purification, we discovered 
that the true start site of rhaR was a GTG codon located 30 codons downstream of the previously 
annotated, in-frame +30rhaR ATG start codon.  Despite cloning the incorrectly annotated open 
reading frame, prior published purifications yielded only the correct, 282 residue native RhaR 
protein, likely with the following explanations.  Tobin and Schleif [53] used DNA affinity 
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chromatography in their RhaR purification, thereby selecting for the active 282 residue species.  
In addition, the Shine-Dalgarno sequence in their clone was not as strong as that in newer vectors 
such as pET24b, and consequently was unlikely to drive expression of much +30RhaR.  Our 
previously published in vitro RhaR studies used protein expressed with an intein-chitin binding 
domain fused at the C-terminus of RhaR [173].  In retrospect, it appears that RhaR and +30RhaR 
bound to the chitin column, but that the intein self-cleavage of the RhaR fusion was much more 
efficient than for the +30RhaR fusion (perhaps due to the higher propensity of +30RhaR to 
aggregate), again resulting in the purification of predominantly the native RhaR species.  Thus, 
the selection of methods that yielded active protein enabled studies of the native RhaR protein 
prior to recognition of the incorrect annotation.  After identifying the correct rhaR translation 
start site, it was found that both the yield and the solubility of RhaR were dramatically increased. 
Structures of RhaR-NTD.  After many years of effort, we have finally obtained a crystal 
structure for a domain of the RhaS or RhaR proteins.  The structures of rhamnose-bound [(+) 
rha] and rhamnose-free [(-) rha] RhaR-NTD were determined at 2.05 Å and 1.73 Å, respectively.    
The structures of RhaR-NTD reveal that a metal ion was present deep within the 
rhamnose-binding pocket, and using X-ray fluorescence and ICP-OES, we determined that the 
metal was Ni2+.  Given that the protein was purified by Ni2+-affinity chromatography, it is likely 
that the Ni2+ displaced the native metal or there was no metal bound to the purified RhaR-NTD, 
and that Ni2+ is not likely the native metal in RhaR.  Although metal binding is very common 
among cupin superfamily proteins [138, 150], among AraC family proteins with a cupin 
superfamily regulatory domain, RhaR-NTD is the only one that has thusfar been demonstrated to 
bind a metal ion within the effector-binding pocket.  Typical cupin domains contain two 
conserved motifs with the first motif contributing two His residues and one Glu residue and the 
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second motif contributing the third His residue to the overall metal binding motif [150].  As in 
RhaR-NTD, these four residues coordinate a metal ion, that in enzymatic cupin family proteins, 
is frequently bound at the active site [150].  There are structures available for three AraC family 
protein cupin superfamily domains, none of which contains a metal.  Alignment of the sequences 
of these three AraC-family cupin superfamily domains, AraC, ToxT, and ExsA, shows that these 
proteins contain at most one of the four conserved His and Glu residues that comprise the metal-
binding site (Fig. 53).  In addition to RhaR, out of 100 sequences that we analysed, 10 additional 
AraC family members share the conserved metal-binding residues of the cupin motif, including 
RhaS (Fig. 53, and not shown).  RhaS, a second rhamnose-responsive AraC family 
transcriptional activator protein, shares 35% sequence identity and 67% sequence similarity with 
RhaR [10] (sequence alignment was performed using Clustal Omega[174]). Given that all four of 
the metal binding residues are conserved in RhaS,  it is reasonable to predict that RhaS may also 
contain a metal ion within its rhamnose-binding pocket.  Additionally, it is likely that other 
AraC-family proteins with the conserved cupin superfamily metal-binding residues also bind 
metal ions in their cupin binding pockets.   
The Ni2+ ion that was present in the RhaR-NTD crystal structures was likely acquired 
during the Ni2+ affinity chromatography protein purification step since the protein was exposed 
to Ni (but not any other divalent metal ions) during the purification.  However in vivo it was not 
clear whether Ni2+ was the native metal for RhaR.  The ionic radius of Ni2+ is 0.083 Å [175]; 
since there are a number of divalent metal ions with similar size that are physiologically relevant 
and commonly found in E. coli cells, it is possible that other metal cations with similar sizes and 
the same coordination number could be accommodated within the pocket in vivo.  For instance, 
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Zn2+, which is a six-coordination metal with ionic radius of 0.089 Å, is one possible candidate.  







Fig. 53.  Sequence alignment of RhaR, AraC, ToxT, ExsA, and ToxT.  Conserved His and Glu 
are highlighted in gray.  
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cofactor at the active site.  The Zn2+ that is bound to L‐rhamnulose-1-phosphate aldolase is also 
coordinated by three His residues and one Glu residue.  It would be very interesting if the 
regulator protein and the protein whose expression was regulated bind to the same metal ion.  If 
this were true, Zn2+ could be a factor that affects both the transcription activation of the rhaSR 
operon and the enzymatic activity of L‐rhamnulose-1-phosphate aldolase.  Thus, limited access 
to Zn2+, even when rhamnose is around, could potentailly result in E.coli being unable to 
effectively use rhamnose as a carbon source.   
 The comparison of the (+)rha and (-)rha RhaR-NTD structures showed that the N-
terminal arm regions did not change conformation in response to rhamnose.  However, two loop 
regions (residues V22 to T35 and residues S75 to V83) did undergo conformational changes 
upon rhamnose binding, suggesting that these regions may be involved in transmitting the 
rhamnose binding signal from the RhaR NTD to the DBD.  Interestingly, the two analogous loop 
regions in AraC, I26 to D37 and R84 to E90, did not show any structural changes in response to 
arabinose.  The arm region in AraC, on the other hand, upon the binding of arabinose changes its 
conformation.  This structural change is hypothesized to release the constraint on the AraC dimer 
in such a way that allows the AraC dimer to bind to two adjacent half sites and activate 
transcription [35].  The comparison of the regions that showed structural changes in AraC and 
RhaR upon effector binding suggested that AraC and RhaR utilize different regions of the 
protein to transmit effector binding signal from one domain (NTD) to the other (DBD).  
Therefore, we propose that RhaR rhamnose-dependent allosteric signaling shares some features 
with the ‘light switch’ model of AraC, but differs in other features.   
Model for RhaR allosteric effector response.  We propose that in RhaR, there might be within-
protomer changes in DNA binding affinity as well as changes in the relative positions of the 
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DBDs within the dimer.  By comparing RhaR binding to half site and full site DNA, we could 
separately test the effect of rhamnose on binding by one protomer of the RhaR dimer and on 
binding of the full dimer, and thereby provide information about the possible mechanism.  We 
utilized RhaR protein that was purified in the absence of rhamnose to perform in vitro 
biochemical assays, including equilibrium measurements of RhaR and RhaR-DBD binding to the 
full-site or half-site RhaR DNA binding sites.   
One goal of our studies was to determine the effect of rhamnose on the affinity of one 
protomer of the RhaR dimer for its specific half-site DNA.  We chose to assay this by using 
DNA fragments that consisted of a single half-site of the RhaR binding site, and therefore that 
were long enough to bind one RhaR protomer but not long enough to bind the full RhaR dimer, 
for several reasons.  First, at the protein concentrations necessary for these experiments there was 
little to no monomeric wild-type RhaR detectable by gel filtration chromatography, thus isolation 
of monomeric wild-type RhaR wasn’t possible.  Second, disruption of AraC dimerization 
required four residue substitutions [176], and our structures showed that the RhaR dimerization 
interface is at least as large as that of AraC, suggesting that multiple mutations would be required 
to disrupt RhaR dimerization, and raising concerns that protein folding might be effected in 
addition to dimerization.  Finally, although it would be of interest to determine whether 
dimerization alters the DNA binding affinity of RhaR protomers within a dimer relative to free 
RhaR monomers, in the event that it does, measurement of DNA binding by each protomer 
within a dimer was a more relevant comparison with RhaR dimer binding to its full DNA 
binding site for our analysis.  
In addition to testing the effect of rhamnose on RhaR binding to half-site DNA, we also 
tested binding by the isolated RhaR-DBD to half-site DNA to identify the effect of the RhaR-
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NTD on binding by each protomer.  Our assays showed that deletion of the RhaR-NTD reduced 
DBD binding to half-site DNA by 350-fold.  However, assays in the absence and presence of 
rhamnose indicated that rhamnose did not appreciably change the KD for full-length RhaR 
binding to the half-site.  Lowden et al. [38] found that the two HTH motifs in the DBD in the 
effector–bound ToxT (which is the non-activating ToxT state) were in a conformation that is 
quite different from those in the DNA-bound MarA, and unlikely to be able to binding DNA.  
They predicted that the HTH motifs of ToxT in the absence of effector would be positioned 
similarly to those in the DNA-bound MarA structure, thus increasing ToxT DNA binding.   If 
HTH repositioning is important in RhaR function, the HTH repositioning would be predicted to 
affect the strength of DNA binding by each RhaR protomer. Our data suggests that, although 
HTH positioning may be important in RhaR, it does not occur in response to rhamnose binding.  
The 350-fold increase in half-site DNA binding by full-length RhaR relative to RhaR-DBD 
could potentially be a result of constitutive HTH positioning by the RhaR NTD.  Thus, while 
effector-dependent HTH positioning may be a feature of allosteric signaling in other AraC 
family proteins, in RhaR this effect on DBD activity appears to occur constitutively and does not 
appear to be effector-dependent.   
We next measured the effect of rhamnose on RhaR binding to its full DNA site and found 
that rhamnose increased this binding strength by 10-fold.  This value is consistent with the fold-
activation measured in prior in vivo and in vitro transcription activation studies [53, 173] (using 
chromosomally-expressed RhaR and purified RhaR, respectively), as well as prior in vitro 
measurements of DNA binding by RhaR [53].  Interestingly, the affinity of full length RhaR for 
binding to its full DNA site even in the absence of rhamnose is relatively strong (Kd = 4 × 10
-11 
M).  If the intracellular RhaR concentration is not dramatically different than that of AraC [177, 
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178] (approximately 10-8 to 10-9 M), RhaR would be predicted to be bound to DNA at the rhaSR 
promoter even in the absence of rhamnose.  None-the-less, and consistent with in vitro 
transcription assays (where RhaR concentration was 50-fold higher than its Kd in the absence of 
rhamnose [48]), there is also a 10-fold increase in transcriptional activation by RhaR upon 
addition of rhamnose [51].  Our previous work showed that transcriptional activation by RhaR 
involves protein-protein contacts with the RNA polymerase 70 subunit [54].  The current 
findings suggest that, in the absence of rhamnose, even RhaR that is bound at the rhaSR 
promoter region is not in the optimal conformation to contact RNA polymerase, and thereby 
does not activate transcription.  Given that DNA bending can influence transcription activation 
[103, 179-181], the change in DNA bending that we measured upon addition of rhamnose to 
RhaR could contribute to the increase in both DNA binding and transcription activation.  Thus, 
although two independent changes could separately effect DNA binding and transcription 
activation, the simplest hypothesis is that the same change in RhaR structure or dynamics 
increases both DNA binding and transcription activation by approximately 10-fold.   
Although the binding affinity of RhaR for full site DNA increased by 10-fold upon 
addition of rhamnose, the binding affinity of RhaR for half-site DNA did not vary upon 
rhamnose addition.  Thus, the affinity of the dimer increased despite no increase in affinity of 
each protomer.  The simplest hypothesis to explain these findings is that the increased affinity of 
the dimer involves an increase in cooperativity of DNA binding by the two DBDs.  The 
rhamnose-dependent change in cooperativity could indicate that the RhaR DBDs are not 
optimally positioned to contact the two half-sites in the RhaR binding site in the absence of 
rhamnose, and that a rhamnose-dependent rigid body movement improves the positioning of the 
DBDs for cooperative binding to the full RhaR binding site.  An analogous rigid body movement 
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is proposed in the AraC light-switch mechanism as AraC toggles from its non-activating, DNA-
looped state to its activating state, bound to adjacent half-sites [35].  Further support for our 
hypothesis that rhamnose binding induced a rigid body movement that increased the 
cooperativity of binding by the two RhaR DBDs came from testing the effect of rhamnose on 
RhaR binding to a gapped DNA fragment.  Use of the gapped DNA fragment in which the two 
double stranded RhaR half-sites were flexibly connected by single stranded DNA, similar to a 
previous assay with AraC [29], allowed us to test the prediction that the RhaR DBDs are not 
optimally positioned in the absence of rhamnose RhaR to bind cooperatively to the full dsDNA 
RhaR binding site.  Addition of rhamnose increased RhaR binding to the gapped DNA by only 
2-fold (compared with the 10-fold increase on fully double stranded DNA), supporting the model 
that the primary effect of rhamnose binding to RhaR is an increase in cooperative binding by 
repositioning of the DBDs in the RhaR dimer.  Our finding that there is a significant difference 
in the angle of DNA bending by RhaR in the absence and presence of rhamnose is also 
consistent with a rigid body movement of the RhaR DBDs within the dimer.  Thus, we 
hypothesize that the majority of the RhaR rhamnose allostery is due to rigid-body movement of 
the RhaR DBDs.   
Although the mechanism of effector signaling in RhaR bears some notable similarities 
with that of AraC, there are also differences in the molecular details of RhaR and AraC function.  
One notable difference is that the isolated AraC DBD bound to half-site DNA with the same 
apparent equilibrium binding constant as full-length AraC in the presence of arabinose (although 
the DBD dissociated from half-site DNA 150-fold more slowly than AraC plus arabinose).  Thus, 
the AraC NTD altered the kinetics of DNA binding by the DBD, but it did not alter the 
equilibrium binding, and therefore had a neutral effect on net DNA binding by the DBD.  In 
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contrast, the RhaR NTD had a very large (350-fold tighter equilibrium binding constant) positive 
effect on equilibrium half-site DNA binding by its DBD (compare RhaR-DBD and RhaR, each 
binding to half-site DNA).   
Another difference in the results obtained with RhaR and AraC involves the effector 
dependence of their DNA bend angles.  Our results show a small, but significant increase of 9 
degrees in the bend angle when RhaR binds to its full DNA site in the presence of rhamnose 
relative to the absence of rhamnose.  In contrast, no change in the bend angle was detected for 
AraC binding to several variants of its full DNA site in the absence versus the presence of 
arabinose [155].  
A final difference between our findings with RhaR and those with AraC involves the role 
of the arm region.  The N-terminal arm region of AraC plays a central role in the rigid body 
movement of the AraC DBDs in response to binding arabinose to the NTD [35].  Unlike the 
structures of the AraC NTD with and without arabinose bound [27], there was no significant 
change in the structure of the RhaR N-terminal arm between the structures with and without 
rhamnose bound, suggesting that the arm may not play a significant role in transmitting the 
rhamnose binding signalling from the RhaR NTD to the DBD.  Instead, the RhaR NTD 
structures show structural changes in a RhaR region that aligns with 2 of AraC and ToxT.  The 
AraC NTD structures do not show effector-dependent structural changes in the aligned region, 
although molecular dynamics simulations predicted that substitutions in the AraC arm would 
result in the aligned AraC region differing in structure from wild type [32, 33, 182, 183].  
Nonetheless, it appears that AraC and RhaR utilize different region(s) of the protein to transmit 
effector binding signal from the NTD to another DBD.   
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Overall, we propose the following model for the role of the RhaR NTD in DNA binding 
and the allosteric rhamnose response.  Our data supports the conclusion that the RhaR NTD 
constitutively promotes a DBD conformation that has a much higher affinity for DNA than the 
DBD without the NTD.  Results from other AraC family activators [38] suggests that this 
conformation may involve the NTD promoting a DBD conformation with the two HTH motifs in 
each protomer well-positioned to bind to the adjacent major grooves of the RhaR half-sites.  The 
constitutive HTH positioning results in a much higher basal level of transcription activation than 
RhaR would have if HTH positioning was rhamnose dependent.  The high basal level would 
allow RhaR to quickly activate transcription of the rhaSR operon as soon as rhamnose became 
available.  The constitutive HTH positioning fits the role of RhaR.  Prior [51, 53] and current 
results indicate that the addition of rhamnose increases RhaR DNA binding, transcription 
activation (even when DNA binding is saturated) and DNA bending.  We propose that rhamnose 
binding to RhaR NTD induces a rigid body movement of the RhaR DBDs relative to the NTDs 
that increases cooperative binding to the two half-sites of the full RhaR binding site; likely 
explaining the increases in DNA binding and bending.  We hypothesize that the same rigid body 
movement may also increase transcription activation by increasing RhaR contacts with RNAP 
and/or DNA bending.  
Allosteric control of transcription activation is common in the AraC family, therefore, 
investigating how effector binding impacts protein conformation at an atomic level may provide 
us with insight into the functions and mechanisms of allosteric control in the broader AraC 
family [4].  Our data indicates that rigid body movement is likely involved in RhaR rhamnose 
allosteric signalling mechanism.  In RhaS, our data currently suggests that HTH positioning is 
involved in the mechanism by which RhaS responds to rhamnose signalling.  In AraC, rigid body 
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movement seems to be the major conformational change the protein undergoes in respond to 
arabinose.  We thus further propose that the rigid body movement and HTH positioning 
mechanisms are somewhat common as mechanisms to respond to effector molecules among 
AraC family proteins.  Additionally, the data suggesting that HTH positioning occurs in response 
to the presence of RhaR-NTD could potentially explain why many virulence activators within 
this family require the presence of NTD to activate transcription but do not dimerize or need an 
effector.  This study is a step forward in both the characterization of RhaR and in attempting to 
develop a family-wide model of the mechanism of allosteric regulation.  As many AraC family 
members are regulated by allosteric interactions, including some that mediate virulence factor 
expression in pathogenic bacteria, elucidating a family-wide mechanism that they use to respond 
to allosteric interactions would represent significant progress towards characterizing hundreds of 
currently uninvestigated proteins, as well as providing potential targets for novel antimicrobial 
compounds designed to stop, stimulate, or imitate allosteric signalling in AraC family proteins. 
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